data_2mld_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mld _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.75 0.309 . . . . 0.0 110.769 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 114.46 130.8 5.04 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.4 pt -103.21 177.11 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-O 121.177 0.513 . . . . 0.0 111.658 -170.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -101.32 70.48 1.32 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.255 -175.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.441 HG12 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -131.44 179.53 4.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.324 -176.5 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.441 ' N ' HG12 ' A' ' 5' ' ' VAL . 7.2 p-10 -128.33 111.28 13.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.56 0.695 . . . . 0.0 109.966 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.437 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.8 p -92.9 132.07 37.36 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.969 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 mtmt -87.6 -18.45 29.64 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 163.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.446 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.2 p-80 -167.49 167.39 13.72 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.616 -1.175 . . . . 0.0 110.329 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.428 ' HB3' ' H ' ' A' ' 27' ' ' CYS . 4.9 p -72.27 -31.26 65.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -176.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.27 -27.87 66.04 Favored Glycine 0 CA--C 1.517 0.212 0 C-N-CA 121.11 -0.567 . . . . 0.0 113.408 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.446 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -89.0 3.65 50.94 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 122.597 -0.355 . . . . 0.0 110.721 -178.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 88.9 m -86.86 -16.12 37.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.829 0.347 . . . . 0.0 110.483 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.9 mt -62.67 -62.78 1.5 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.913 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.453 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 54.5 tttm -55.23 -58.44 15.04 Favored Pre-proline 0 N--CA 1.446 -0.633 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.453 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 37.2 Cg_endo -66.5 -28.1 45.94 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 121.403 1.402 . . . . 0.0 112.922 -173.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.426 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 4.2 t -82.76 -26.65 31.69 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.19 0.519 . . . . 0.0 109.897 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -72.33 -36.31 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.8 tptm -72.14 -32.7 67.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.825 173.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.8 -48.1 80.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.586 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 144.95 8.78 0.35 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.887 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.426 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.78 178.36 4.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.71 0.255 . . . . 0.0 110.326 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.6 mtm180 -96.84 -54.18 3.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.864 0.364 . . . . 0.0 111.241 -173.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.445 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.4 OUTLIER -112.48 -153.15 0.52 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.886 -176.633 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.35 139.06 3.18 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.725 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -133.03 151.47 52.05 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 177.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.428 ' H ' ' HB3' ' A' ' 10' ' ' SER . 42.6 t -88.01 131.87 34.48 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.605 HG23 ' N ' ' A' ' 29' ' ' ASN . 6.4 mt -122.89 -112.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.207 -177.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.605 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.22 46.73 1.27 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.417 0.627 . . . . 0.0 110.586 -179.579 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.28 -5.71 65.54 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.662 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -109.1 154.57 22.09 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 120.729 0.299 . . . . 0.0 110.262 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 35.9 m -96.73 90.55 5.32 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.807 172.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.443 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -86.0 135.13 33.77 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.857 175.276 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.445 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 3.2 m -135.39 178.62 6.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.893 0.378 . . . . 0.0 111.063 -170.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.443 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 57.9 m -113.64 127.42 26.84 Favored Pre-proline 0 N--CA 1.443 -0.787 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 171.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -84.87 -161.37 0.13 Allowed 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.894 2.396 . . . . 0.0 112.102 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.512 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.947 0 CA-C-O 118.595 -0.716 . . . . 0.0 110.035 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.9 m . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.655 0.264 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.617 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 110.96 109.51 3.14 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.903 178.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.517 HG12 ' CB ' ' A' ' 32' ' ' CYS . 1.1 pt -98.24 175.66 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.666 0.27 . . . . 0.0 110.314 -177.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -103.76 109.63 21.42 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.587 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.7 p -156.53 -175.95 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -172.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.587 ' H ' HG23 ' A' ' 5' ' ' VAL . 7.1 m-20 -127.77 97.28 4.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.449 0.642 . . . . 0.0 111.041 -176.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 5.8 p -94.36 134.18 37.14 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.223 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -88.93 -14.64 36.24 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 166.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -171.34 161.66 6.54 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 114.643 -1.162 . . . . 0.0 110.445 174.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.5 p -58.61 -40.44 83.3 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -176.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.61 -41.69 50.24 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 114.112 0.405 . . . . 0.0 114.112 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -83.52 -2.72 56.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.031 0.415 . . . . 0.0 111.467 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.29 -11.95 57.19 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.233 0.54 . . . . 0.0 110.159 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.8 mp -63.44 -42.88 98.67 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.55 -178.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -56.8 -58.33 18.17 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.339 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.69 -24.04 22.16 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 121.47 1.447 . . . . 0.0 112.062 -178.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 46.3 t -69.33 -38.96 78.42 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 178.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -71.47 -35.18 70.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.42 178.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.3 tmtm? -61.6 -38.12 86.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.289 -0.868 . . . . 0.0 109.539 175.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.15 -44.1 76.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.54 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.25 8.14 0.75 Allowed Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.912 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.433 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.2 mpp? -108.1 -173.83 2.38 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 117.594 0.697 . . . . 0.0 111.208 -179.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 64.1 mtm180 -93.21 -60.69 1.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.451 -174.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -130.75 161.14 32.37 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.567 -176.279 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.481 ' HA2' ' HA ' ' A' ' 34' ' ' CYS . . . -131.22 140.02 11.43 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.858 -175.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -101.55 170.08 8.42 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 173.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.7 t -107.56 107.85 18.88 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.187 0.518 . . . . 0.0 111.187 -176.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.418 ' CD1' ' HB2' ' A' ' 33' ' ' ASP . 3.2 mt -104.56 162.27 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.19 -38.57 0.78 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.09 13.68 1.29 Allowed Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.054 175.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.9 148.82 45.01 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 120.961 0.41 . . . . 0.0 110.618 -173.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.617 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -94.55 87.92 5.27 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 167.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.418 ' HB2' ' CD1' ' A' ' 28' ' ' ILE . 32.1 t70 -74.52 96.73 2.98 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 122.019 0.914 . . . . 0.0 109.38 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.481 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 69.7 m -86.45 167.85 14.31 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.12 -1.4 . . . . 0.0 112.968 -171.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 30.4 m -129.23 119.92 19.83 Favored Pre-proline 0 N--CA 1.434 -1.264 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 168.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.433 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 72.0 Cg_endo -84.4 -157.98 0.09 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.303 0 C-N-CA 122.16 1.907 . . . . 0.0 111.609 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.572 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.776 -0.63 . . . . 0.0 110.601 -179.522 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.653 0.263 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.624 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 103.84 104.65 2.92 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.886 -0.674 . . . . 0.0 111.769 -179.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.493 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.7 pt -91.88 178.51 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.698 0.285 . . . . 0.0 110.452 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -104.24 110.79 23.14 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 177.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.562 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -160.82 -178.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -173.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.562 ' H ' HG23 ' A' ' 5' ' ' VAL . 26.3 m-20 -128.6 107.77 9.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.366 0.603 . . . . 0.0 110.069 -178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 p -91.63 135.69 33.69 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.204 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -82.8 -20.72 35.22 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.413 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 22.3 p-80 -177.93 159.06 1.32 Allowed 'General case' 0 CA--C 1.522 -0.114 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.272 175.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 p -52.72 -44.88 66.65 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.428 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -54.49 -34.32 54.89 Favored Glycine 0 C--O 1.228 -0.273 0 CA-C-N 115.908 -0.587 . . . . 0.0 114.002 -177.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -91.48 3.12 55.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 117.744 0.772 . . . . 0.0 111.99 -177.432 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -84.09 -2.51 56.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.62 0.724 . . . . 0.0 109.543 -177.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 72.3 mt -61.09 -55.93 26.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.829 -1.078 . . . . 0.0 111.404 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -52.03 -54.86 36.24 Favored Pre-proline 0 CA--C 1.542 0.664 0 N-CA-C 113.341 0.867 . . . . 0.0 113.341 -172.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.18 -31.58 22.81 Favored 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 121.276 1.318 . . . . 0.0 112.406 -176.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 7.8 t -81.59 -22.09 37.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.21 0.528 . . . . 0.0 110.198 -178.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -65.41 -38.79 90.99 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 174.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -62.3 -43.94 97.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.98 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.35 -40.45 90.75 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.759 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 129.22 17.51 1.78 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.969 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.54 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -109.8 -178.02 3.42 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.748 179.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.3 mtm180 -103.8 -63.58 1.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.891 0.377 . . . . 0.0 111.589 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.61 157.43 25.36 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 -177.411 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.9 144.47 16.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.988 -174.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttp -110.12 167.55 10.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 110.229 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 36.3 t -108.54 110.72 22.27 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.437 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.463 HG23 ' N ' ' A' ' 29' ' ' ASN . 10.1 mt -117.15 176.03 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 28' ' ' ILE . 9.6 p30 -38.4 -43.97 0.87 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -169.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -155.83 17.07 0.47 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.784 173.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -124.54 148.85 47.52 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.665 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.624 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -92.83 89.17 6.49 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 173.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -77.12 107.69 9.67 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.615 0.721 . . . . 0.0 109.388 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.449 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.9 m -111.06 171.49 7.44 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.841 -171.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.427 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 75.4 m -122.18 122.9 27.39 Favored Pre-proline 0 N--CA 1.436 -1.13 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 168.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.498 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 95.8 Cg_endo -84.55 -162.95 0.17 Allowed 'Trans proline' 0 N--CA 1.445 -1.332 0 C-N-CA 122.197 1.931 . . . . 0.0 112.474 -177.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.624 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.03 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 120.624 0.249 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.486 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.87 127.24 5.85 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -174.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.4 pt -100.74 172.71 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.419 0.628 . . . . 0.0 111.732 -169.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -102.64 95.29 6.12 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.815 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.452 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -155.67 -177.39 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.948 -0.569 . . . . 0.0 109.734 -172.799 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.452 ' H ' HG23 ' A' ' 5' ' ' VAL . 16.4 m-20 -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.817 0.341 . . . . 0.0 110.42 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.531 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 2.4 p -92.83 128.97 38.88 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 62.5 tttm -81.73 -19.53 41.24 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 167.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.449 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 6.5 p-80 -166.28 151.19 8.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.804 -177.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 t -74.3 73.8 1.83 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.68 177.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.14 -28.84 0.03 OUTLIER Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.105 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 9.8 pt20 -87.98 3.39 48.91 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 121.142 -0.223 . . . . 0.0 111.146 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.568 ' O ' ' HB2' ' A' ' 17' ' ' CYS . 73.5 m -77.17 -11.52 59.83 Favored 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.355 -175.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.4 mt -62.19 -54.52 39.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.844 -0.617 . . . . 0.0 111.846 -174.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -53.51 -54.92 40.35 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.403 -178.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.95 -23.62 25.16 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 121.786 1.657 . . . . 0.0 112.538 178.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 19.4 t -69.72 -35.53 75.12 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.447 0.641 . . . . 0.0 109.629 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -70.47 -30.66 67.54 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.924 177.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 52.9 tttm -68.56 -41.43 79.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.705 173.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.42 -40.38 93.29 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.741 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 119.76 17.6 4.62 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.479 177.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.534 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 61.3 mtt -116.12 177.68 4.59 Favored 'General case' 0 C--N 1.32 -0.699 0 O-C-N 122.6 -0.353 . . . . 0.0 110.432 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 -91.76 -74.09 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 120.458 -0.497 . . . . 0.0 111.983 -169.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.493 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -110.23 158.95 17.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.886 -174.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.7 161.41 22.88 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.46 -175.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 0.4 OUTLIER -145.83 144.84 30.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -177.21 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 39.2 t -89.05 121.45 31.4 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.413 -178.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.421 HG23 ' N ' ' A' ' 29' ' ' ASN . 6.5 mt -114.96 167.69 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.421 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -67.2 53.1 0.05 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -175.015 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 155.1 -36.77 0.65 Allowed Glycine 0 N--CA 1.438 -1.176 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.309 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.561 ' HZ3' ' HB3' ' A' ' 31' ' ' LYS . 0.4 OUTLIER -124.45 174.1 8.0 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 117.505 0.652 . . . . 0.0 111.663 -172.623 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.531 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -108.08 98.16 7.76 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 166.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.486 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.7 t70 -76.19 117.85 18.31 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.592 0.711 . . . . 0.0 110.367 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.403 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 48.3 m -106.83 160.68 15.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.443 -175.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.493 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 48.2 m -112.24 125.75 29.6 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 169.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -79.9 -159.83 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.673 2.249 . . . . 0.0 111.688 -176.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.3 mptt . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.705 -0.664 . . . . 0.0 109.794 178.977 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 121.015 0.436 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.469 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 107.77 114.66 3.84 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.862 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.447 HG12 ' CB ' ' A' ' 32' ' ' CYS . 10.3 pt -100.51 -179.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.126 0.489 . . . . 0.0 111.155 -173.261 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -108.16 118.51 36.94 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.373 -0.83 . . . . 0.0 108.993 175.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.569 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.4 p -167.32 -174.97 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -172.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.569 ' H ' HG23 ' A' ' 5' ' ' VAL . 7.3 p-10 -126.94 110.88 13.48 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.673 0.749 . . . . 0.0 110.395 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -92.84 127.45 38.36 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.476 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -73.97 -25.88 60.17 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 165.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -174.75 163.76 3.47 Favored 'General case' 0 C--O 1.226 -0.165 0 CA-C-N 114.511 -1.222 . . . . 0.0 109.459 -179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 p -59.21 -37.07 76.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.692 0.282 . . . . 0.0 111.72 -177.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.56 -33.45 66.85 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 116.269 -0.423 . . . . 0.0 114.065 -176.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 6.34 44.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.413 0.607 . . . . 0.0 111.185 -178.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.537 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 46.0 t -84.47 -15.25 46.71 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.253 0.549 . . . . 0.0 109.744 179.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.8 mt -58.18 -50.76 72.39 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.816 -175.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.57 ' HZ3' ' HB2' ' A' ' 15' ' ' LYS . 3.5 ttmp? -59.96 -56.25 37.46 Favored Pre-proline 0 N--CA 1.445 -0.709 0 CA-C-N 115.453 -0.794 . . . . 0.0 113.063 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.8 -26.17 32.66 Favored 'Trans proline' 0 C--N 1.356 0.934 0 C-N-CA 121.024 1.149 . . . . 0.0 111.45 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.541 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 42.0 t -68.07 -37.02 80.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.783 175.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.407 ' HB2' ' NZ ' ' A' ' 18' ' ' LYS . 2.7 ttmp? -68.64 -39.94 80.51 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.733 176.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -59.16 -33.14 70.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.231 175.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.08 -36.85 55.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.739 177.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.06 2.18 5.18 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.354 -0.926 . . . . 0.0 114.29 172.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.541 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.0 mpp? -96.03 -169.01 1.85 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 117.705 0.753 . . . . 0.0 111.051 -177.081 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 -99.87 -59.61 1.68 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.02 0.438 . . . . 0.0 111.45 -175.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.442 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -128.99 158.98 37.33 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.345 -175.973 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.537 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -135.27 155.02 21.89 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.813 -177.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -117.86 166.73 12.12 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 48.7 t -103.81 106.29 16.75 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.913 -178.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 30' ' ' GLY . 12.8 mt -116.03 171.71 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.467 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.3 OUTLIER -58.48 65.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.493 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 95.94 6.41 59.22 Favored Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 31.1 ttmt -123.73 133.57 53.84 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -176.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.469 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.3 OUTLIER -97.07 87.78 4.31 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 172.434 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.86 113.08 15.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.49 0.662 . . . . 0.0 109.566 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.456 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 99.0 m -101.66 173.42 6.43 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.17 -172.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.442 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 87.9 m -126.09 124.97 24.7 Favored Pre-proline 0 N--CA 1.44 -0.958 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 168.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.92 -156.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 122.744 2.296 . . . . 0.0 111.868 -176.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 5.5 mptp? . . . . . 0 C--O 1.247 0.954 0 CA-C-O 118.603 -0.713 . . . . 0.0 110.672 178.265 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.447 HG11 ' O ' ' A' ' 34' ' ' CYS . 76.3 t . . . . . 0 N--CA 1.479 1.016 0 CA-C-O 120.813 0.34 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.569 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 102.53 97.97 2.4 Favored Glycine 0 N--CA 1.443 -0.893 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.183 179.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' A' ' 32' ' ' CYS . 2.1 pt -94.77 -179.55 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -106.49 106.45 16.97 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.555 HG23 ' H ' ' A' ' 6' ' ' ASP . 3.6 p -154.0 -177.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -172.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.555 ' H ' HG23 ' A' ' 5' ' ' VAL . 12.0 m-20 -128.92 102.97 6.76 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 120.96 0.41 . . . . 0.0 110.787 -178.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.1 p -94.33 131.36 40.04 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.345 176.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -85.26 -18.0 35.29 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 165.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.419 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 8.6 p-80 -167.68 162.63 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.775 -176.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.3 p -66.88 -37.73 84.97 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -174.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.71 -26.28 59.92 Favored Glycine 0 CA--C 1.519 0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 113.897 -174.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.419 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 17.5 pt20 -88.39 -4.67 58.61 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 117.384 0.592 . . . . 0.0 110.908 -177.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -88.42 -2.36 58.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.534 0.683 . . . . 0.0 109.85 -175.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.3 mt -62.58 -57.16 12.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.169 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.435 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.2 tmmm? -50.76 -57.86 12.06 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 114.695 -1.138 . . . . 0.0 112.811 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.445 ' HB2' HD13 ' A' ' 3' ' ' ILE . 37.1 Cg_endo -64.94 -33.55 51.43 Favored 'Trans proline' 0 C--N 1.352 0.724 0 C-N-CA 121.628 1.552 . . . . 0.0 113.356 -173.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -83.5 -21.72 32.72 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.084 0.468 . . . . 0.0 110.463 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -72.78 -36.26 67.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -68.15 -36.32 79.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.783 173.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.69 -45.94 84.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.442 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.89 21.23 0.56 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.842 176.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.462 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 2.1 mpt? -109.7 -175.42 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 O-C-N 122.669 -0.312 . . . . 0.0 110.493 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.0 mtm180 -96.37 -61.44 1.43 Allowed 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.183 -0.607 . . . . 0.0 111.958 -176.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.456 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -108.06 -158.11 0.64 Allowed 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.074 -173.42 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.21 141.63 6.93 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.328 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -130.36 166.9 19.45 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 177.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.4 t -107.15 110.68 22.82 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.959 -175.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.478 HG23 ' N ' ' A' ' 29' ' ' ASN . 8.3 mt -113.37 171.46 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 174.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.478 ' N ' HG23 ' A' ' 28' ' ' ILE . 12.6 m-80 -38.6 -53.71 1.59 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.908 0.483 . . . . 0.0 111.869 -171.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.71 21.82 2.17 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 173.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.41 ' O ' ' HB ' ' A' ' 28' ' ' ILE . 30.1 ttmt -122.67 132.79 54.43 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 110.305 -0.258 . . . . 0.0 110.305 -171.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.569 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.4 t -87.84 90.52 8.41 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -77.13 104.81 7.84 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.465 0.65 . . . . 0.0 109.753 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.447 ' O ' HG11 ' A' ' 1' ' ' VAL . 4.3 p -128.47 141.11 51.49 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.253 -173.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.456 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 38.4 m -92.91 127.87 45.86 Favored Pre-proline 0 N--CA 1.441 -0.915 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.462 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 46.4 Cg_endo -84.03 -154.09 0.05 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 122.521 2.147 . . . . 0.0 111.714 -176.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 37' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.567 178.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 34' ' ' CYS . 27.2 m . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.847 0.356 . . . . 0.0 110.306 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.517 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 100.65 118.11 4.23 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -176.157 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.8 pt -102.55 170.61 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.43 0.634 . . . . 0.0 111.082 -174.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -104.79 92.09 4.11 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.255 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.462 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.7 OUTLIER -147.69 -179.2 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.498 -173.385 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.462 ' H ' HG23 ' A' ' 5' ' ' VAL . 10.9 m-20 -128.4 102.69 6.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.163 0.506 . . . . 0.0 110.298 -178.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.578 ' HA ' ' NE2' ' A' ' 12' ' ' GLN . 1.9 p -92.91 133.57 35.97 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.337 -176.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -84.68 -21.84 30.03 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 164.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.456 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 14.1 p-80 -168.63 163.99 12.23 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.759 -176.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.6 p -65.09 -41.4 95.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.724 0.297 . . . . 0.0 111.577 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.85 -18.27 46.03 Favored Glycine 0 C--O 1.228 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 114.61 -172.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.578 ' NE2' ' HA ' ' A' ' 7' ' ' CYS . 9.7 pt20 -89.12 -17.48 29.14 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 117.73 0.765 . . . . 0.0 110.634 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.4 m -90.83 24.39 2.75 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-O 121.009 0.433 . . . . 0.0 111.432 -175.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.65 -41.58 19.24 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 169.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.5 ttpt -62.31 -58.25 18.44 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.599 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.87 -27.05 21.65 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.318 1.345 . . . . 0.0 112.17 -177.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 40.7 t -74.12 -30.94 62.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.374 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 11.3 tppt? -67.86 -36.92 81.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 177.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.4 tttp -73.56 -28.86 62.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.903 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.49 -36.82 85.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.34 176.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.63 10.79 5.26 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.95 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.533 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.2 mpt? -107.88 -175.4 2.77 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.576 -0.367 . . . . 0.0 110.344 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 -93.61 -62.48 1.35 Allowed 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.473 -0.491 . . . . 0.0 111.268 -177.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.49 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.8 160.27 22.94 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.978 -175.961 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.87 146.22 17.61 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.402 -176.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 61.6 mtpt -134.97 167.15 21.45 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.1 t -104.81 121.55 43.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.867 -174.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 29' ' ' ASN . 8.9 mt -117.41 178.5 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.816 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.477 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -64.67 56.23 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -174.722 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 134.65 -23.03 3.62 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 121.354 -0.451 . . . . 0.0 112.661 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -123.06 169.16 11.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.832 0.316 . . . . 0.0 110.236 -173.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.545 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 5.2 m -114.39 100.79 8.59 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.538 0.685 . . . . 0.0 109.289 167.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.517 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.6 t70 -77.96 149.14 34.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.033 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.451 ' O ' HG22 ' A' ' 1' ' ' VAL . 98.4 m -137.43 160.16 39.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -170.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.49 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 89.0 m -116.28 123.12 31.15 Favored Pre-proline 0 N--CA 1.437 -1.076 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 167.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -79.72 -163.24 0.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.555 2.17 . . . . 0.0 112.215 -174.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.425 -0.798 . . . . 0.0 110.234 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.48 1.067 0 CA-C-O 120.55 0.214 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 104.8 130.52 6.83 Favored Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 5' ' ' VAL . 15.5 pt -108.48 178.72 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.187 0.518 . . . . 0.0 111.486 -171.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -105.04 37.8 2.09 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.001 -175.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.64 HG11 ' SG ' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -98.43 158.33 3.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.21 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -102.84 112.52 25.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.922 0.391 . . . . 0.0 110.407 -174.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.623 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 6.0 p -91.5 131.94 36.61 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.9 mmtp -82.03 -19.58 40.09 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 164.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 -170.2 164.7 9.11 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.093 177.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.0 p -57.99 -38.94 77.05 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.887 0.375 . . . . 0.0 111.568 -176.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.58 -36.56 54.43 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.771 -176.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -91.71 14.6 14.8 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.265 0.533 . . . . 0.0 112.415 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.623 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 58.6 m -90.13 -21.89 22.03 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 171.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.6 -46.8 83.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.223 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.4 ttpp -62.24 -58.61 16.49 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -176.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' CG ' HG12 ' A' ' 5' ' ' VAL . 32.8 Cg_endo -69.92 -29.1 23.64 Favored 'Trans proline' 0 C--N 1.354 0.844 0 C-N-CA 121.237 1.291 . . . . 0.0 112.695 -177.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 13.9 m -74.06 -27.15 60.77 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 120.748 0.309 . . . . 0.0 110.801 176.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -70.69 -37.66 73.61 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.8 ttpp -67.93 -32.75 73.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.577 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.66 -46.79 71.38 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.019 176.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.85 14.15 1.9 Allowed Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.69 -0.687 . . . . 0.0 112.914 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -99.89 173.89 6.46 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.108 0.454 . . . . 0.0 111.002 -178.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -94.78 -53.56 3.81 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.961 0.41 . . . . 0.0 111.859 -170.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.483 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.6 OUTLIER -110.19 -157.29 0.61 Allowed 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.044 -175.447 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.671 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.0 132.04 2.26 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.575 -0.822 . . . . 0.0 112.921 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -131.89 152.43 51.06 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 35.7 t -95.52 119.16 33.54 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.118 0.485 . . . . 0.0 110.806 -174.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mt -109.49 164.0 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.171 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.95 -38.69 1.01 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -145.53 11.25 1.73 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.067 175.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.2 mttm -123.9 146.63 48.3 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 -174.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.64 ' SG ' HG11 ' A' ' 5' ' ' VAL . 5.7 m -96.8 89.66 4.98 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 163.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -77.99 115.19 17.54 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.747 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.671 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 35.1 m -132.86 141.27 48.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.868 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.467 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 34.9 m -91.84 132.4 33.02 Favored Pre-proline 0 N--CA 1.447 -0.588 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -176.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -81.21 -159.7 0.11 Allowed 'Trans proline' 0 N--CA 1.46 -0.444 0 C-N-CA 123.13 2.553 . . . . 0.0 112.166 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 mptt . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.352 178.502 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.479 1.004 0 CA-C-O 120.638 0.256 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 98.35 126.24 5.48 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.182 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.7 pt -106.42 177.81 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.049 0.452 . . . . 0.0 111.35 -172.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -101.17 94.91 6.21 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.284 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.454 HG12 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -156.97 -179.1 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -175.773 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.454 ' N ' HG12 ' A' ' 5' ' ' VAL . 5.6 m-20 -137.15 110.99 8.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.448 0.642 . . . . 0.0 110.479 177.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.523 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 7.3 p -93.01 140.36 29.56 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.186 -178.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -85.32 -21.75 28.8 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 164.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.558 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 10.0 p-80 -164.45 162.67 22.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.893 -176.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 12.7 p -68.51 -32.17 71.95 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -175.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.05 -28.75 64.27 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.506 -176.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.558 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 21.1 pt20 -84.94 -11.08 56.32 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.894 0.347 . . . . 0.0 111.04 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -72.3 -23.99 61.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.816 0.341 . . . . 0.0 110.212 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 -44.99 80.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.099 -174.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.482 ' HA ' ' HE3' ' A' ' 15' ' ' LYS . 1.1 tpmt? -65.32 -59.04 10.5 Favored Pre-proline 0 N--CA 1.444 -0.736 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -176.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.86 -24.46 46.45 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.629 1.552 . . . . 0.0 112.505 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.67 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 45.6 t -74.81 -33.14 62.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.27 0.557 . . . . 0.0 110.219 176.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.8 tttp -71.51 -35.75 70.85 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.671 0.748 . . . . 0.0 109.403 177.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -70.43 -27.0 63.92 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.838 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.685 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 133.62 11.16 1.73 Allowed Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.716 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.67 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -108.96 -171.14 1.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 117.399 0.6 . . . . 0.0 110.784 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -97.75 -66.34 0.91 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.884 0.373 . . . . 0.0 111.537 -174.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.457 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.19 160.33 22.36 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.902 -176.567 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.0 141.25 12.38 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.353 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -117.14 156.58 27.39 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.2 t -97.24 115.78 28.24 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.06 0.457 . . . . 0.0 110.714 -175.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.7 mt -114.92 163.61 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -39.61 -42.39 1.17 Allowed 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 -172.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -141.46 12.21 2.73 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.025 175.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.4 mttm -124.94 140.47 52.89 Favored 'General case' 0 N--CA 1.445 -0.72 0 O-C-N 122.901 -0.176 . . . . 0.0 110.836 -175.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.523 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.2 m -92.11 82.31 5.05 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 160.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.499 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -76.84 128.81 35.28 Favored 'General case' 0 CA--C 1.514 -0.412 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.895 -176.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 77.7 m -109.31 171.99 7.12 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.115 -169.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.457 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.2 m -120.54 124.48 27.6 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 166.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -81.32 -161.07 0.14 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.446 2.097 . . . . 0.0 111.786 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 119.026 -0.512 . . . . 0.0 110.809 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.8 m . . . . . 0 N--CA 1.479 0.993 0 CA-C-O 121.066 0.46 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.595 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 117.37 113.11 2.65 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.365 -176.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.505 HG12 ' CB ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -97.03 175.85 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.163 0.506 . . . . 0.0 111.076 -172.723 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -99.34 113.65 26.08 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.11 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.564 HG23 ' H ' ' A' ' 6' ' ' ASP . 3.0 p -162.34 -177.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.564 ' H ' HG23 ' A' ' 5' ' ' VAL . 9.6 m-20 -132.92 100.2 4.83 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.535 0.683 . . . . 0.0 110.795 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.5 p -93.91 141.78 28.12 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 114.777 -1.101 . . . . 0.0 111.477 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -90.13 -17.93 26.76 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 164.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.534 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 11.0 p-80 -172.7 155.07 3.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.935 -175.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.3 p -68.51 -21.7 64.57 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -174.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.0 -34.72 88.97 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.113 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.534 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -85.7 -4.5 59.18 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.897 0.379 . . . . 0.0 110.232 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.47 -10.94 58.82 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.258 0.551 . . . . 0.0 109.734 -172.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -62.31 -53.53 53.73 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.903 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.482 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 23.5 ttpp -50.52 -55.04 29.06 Favored Pre-proline 0 CA--C 1.541 0.625 0 CA-C-N 115.139 -0.937 . . . . 0.0 113.03 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.482 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.9 Cg_endo -72.63 -26.44 16.38 Favored 'Trans proline' 0 C--N 1.357 0.999 0 C-N-CA 121.397 1.398 . . . . 0.0 112.367 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 38.8 t -70.14 -34.2 72.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.229 0.538 . . . . 0.0 110.288 178.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.56 ' HZ1' ' HB3' ' A' ' 18' ' ' LYS . 3.8 mmmp? -72.6 -31.93 65.56 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.333 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.5 tptt -67.63 -30.74 70.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.808 174.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.28 -43.41 28.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.162 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.46 8.06 2.06 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.181 -1.009 . . . . 0.0 114.057 174.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 3.9 mpp? -106.02 -178.42 3.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 117.765 0.782 . . . . 0.0 110.914 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.445 ' NE ' ' HA ' ' A' ' 37' ' ' LYS . 70.6 mtm180 -91.67 -63.59 1.23 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.885 0.374 . . . . 0.0 111.686 -176.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.441 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -118.04 157.87 26.02 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.361 -175.287 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.12 157.68 21.27 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.112 -177.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -128.91 153.69 47.26 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 21.0 t -92.54 109.62 21.03 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.011 0.434 . . . . 0.0 110.893 -173.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mt -112.24 164.23 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -43.44 -37.64 2.46 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -173.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.23 17.91 1.04 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.002 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -123.48 147.07 47.56 Favored 'General case' 0 CA--C 1.513 -0.444 0 O-C-N 122.527 -0.396 . . . . 0.0 110.827 -176.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.595 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 6.4 t -96.77 87.45 4.32 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 166.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -75.62 95.42 3.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 122.062 0.934 . . . . 0.0 109.653 -176.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 68.7 m -92.5 175.71 6.73 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.522 -1.217 . . . . 0.0 113.129 -169.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.441 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 33.3 m -136.61 126.72 16.08 Favored Pre-proline 0 N--CA 1.439 -1.008 0 CA-C-N 114.541 -1.209 . . . . 0.0 107.89 168.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.418 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 83.0 Cg_endo -80.0 -158.44 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.301 2.001 . . . . 0.0 112.049 -179.244 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.483 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.101 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.443 177.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.479 1.012 0 CA-C-O 120.67 0.271 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.559 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 109.43 118.56 4.08 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.491 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.6 OUTLIER -104.9 175.03 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 117.001 0.401 . . . . 0.0 110.369 -176.418 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -106.62 107.38 18.37 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.575 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.2 p -155.64 -176.86 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.408 -170.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.575 ' H ' HG23 ' A' ' 5' ' ' VAL . 9.9 m-20 -122.6 105.77 10.39 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -91.93 150.06 21.22 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-O 121.39 0.614 . . . . 0.0 111.174 178.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.9 mtpt -91.29 -33.9 15.15 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 115.003 -0.999 . . . . 0.0 108.843 170.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -149.11 166.24 29.36 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.304 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 t -82.34 64.31 6.93 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.831 175.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.668 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -177.38 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.065 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.98 9.59 5.24 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.956 0.408 . . . . 0.0 111.933 -178.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.1 t -85.45 13.65 6.49 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.9 0.857 . . . . 0.0 109.075 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.668 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 80.9 mt -60.47 -48.87 79.86 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.02 -178.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -54.55 -55.68 35.07 Favored Pre-proline 0 CA--C 1.541 0.596 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -175.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -71.64 -27.61 18.28 Favored 'Trans proline' 0 C--N 1.354 0.835 0 C-N-CA 121.177 1.252 . . . . 0.0 111.767 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.571 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 44.0 t -69.6 -34.28 73.9 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.018 178.109 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -72.17 -36.07 69.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.883 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -65.3 -32.44 74.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.714 176.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.13 -42.12 47.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.056 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 124.2 25.21 1.69 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.726 172.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.571 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -114.67 178.47 4.27 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.35 0.575 . . . . 0.0 111.072 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 73.8 mtm180 -83.61 -71.73 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 111.729 -173.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.501 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -115.29 159.11 21.43 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -175.45 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.62 124.79 3.76 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.577 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -100.57 168.33 9.78 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.928 0.394 . . . . 0.0 110.219 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 22.4 t -108.34 116.84 32.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.161 0.505 . . . . 0.0 110.895 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.484 ' O ' ' N ' ' A' ' 30' ' ' GLY . 9.0 mt -124.14 172.75 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 176.128 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.512 ' N ' HD21 ' A' ' 29' ' ' ASN . 0.0 OUTLIER -59.52 63.85 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -172.266 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 100.55 5.87 53.55 Favored Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 ttmm -122.68 129.66 52.07 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -173.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.559 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 7.1 t -89.85 89.97 7.98 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 172.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -77.35 105.0 8.19 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.665 0.745 . . . . 0.0 109.283 178.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 93.2 m -101.51 169.22 8.99 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.822 -1.081 . . . . 0.0 111.79 -175.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.501 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 59.6 m -115.52 125.2 29.03 Favored Pre-proline 0 N--CA 1.441 -0.906 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 167.445 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.55 -160.66 0.13 Allowed 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.555 2.17 . . . . 0.0 111.813 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.297 -0.859 . . . . 0.0 110.166 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.645 0.259 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.572 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 113.66 110.89 2.96 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.45 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.6 pt -87.22 178.05 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.082 0.468 . . . . 0.0 110.896 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -103.27 92.75 4.64 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.031 -177.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.56 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.1 p -145.4 -178.17 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.56 ' H ' HG23 ' A' ' 5' ' ' VAL . 7.0 m-20 -131.48 101.52 5.55 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.339 0.59 . . . . 0.0 110.541 -176.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 p -93.07 132.49 37.13 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.641 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -90.13 -18.37 25.95 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 166.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 m80 -151.05 167.72 26.81 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.8 179.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.408 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 22.2 p -80.93 -21.6 40.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.876 0.369 . . . . 0.0 110.764 177.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.18 -39.55 72.17 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 121.203 -0.523 . . . . 0.0 112.746 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -79.62 2.9 20.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.995 0.426 . . . . 0.0 110.54 178.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.408 ' HB3' ' O ' ' A' ' 10' ' ' SER . 42.6 t -85.04 -16.33 41.07 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.583 0.706 . . . . 0.0 109.566 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.7 mt -65.04 -57.78 7.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.209 -178.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.7 tppp? -49.42 -53.97 34.99 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.129 -0.941 . . . . 0.0 113.493 -174.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.96 -27.87 20.21 Favored 'Trans proline' 0 C--N 1.355 0.911 0 C-N-CA 121.374 1.383 . . . . 0.0 112.873 -177.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.527 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 3.3 m -78.45 -25.78 46.0 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 120.819 0.343 . . . . 0.0 110.903 178.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.03 -23.65 55.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 173.27 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -72.83 -36.81 67.57 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.245 -0.888 . . . . 0.0 109.14 172.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.61 -49.96 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.789 178.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.36 20.22 0.57 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.1 177.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.509 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 1.8 mpt? -103.18 178.23 4.61 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 122.737 -0.272 . . . . 0.0 111.367 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.5 mtm180 -97.39 -57.87 2.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.206 0.526 . . . . 0.0 111.805 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.516 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.5 OUTLIER -105.88 -161.44 0.8 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.819 -174.195 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.727 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -160.41 138.21 5.41 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.481 178.113 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -132.23 143.97 50.3 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 t -95.78 112.59 24.28 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-O 120.929 0.395 . . . . 0.0 110.672 -174.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.9 mt -110.01 163.22 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 176.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -44.73 -36.99 3.44 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -172.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -142.73 12.25 2.42 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.855 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -123.84 158.21 32.38 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 117.231 0.516 . . . . 0.0 111.55 -175.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.572 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -105.6 88.47 2.84 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 162.786 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -77.64 90.28 3.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.739 0.781 . . . . 0.0 110.032 -178.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.727 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 34.9 m -111.28 142.54 43.37 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.75 -174.253 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.5 m -96.34 128.67 35.81 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.509 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 88.1 Cg_endo -83.81 -162.06 0.16 Allowed 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.55 2.167 . . . . 0.0 112.581 -177.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.411 -0.805 . . . . 0.0 110.367 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.629 0.252 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.449 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.78 124.87 5.41 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -178.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.2 pt -103.5 -174.37 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -177.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.481 ' O ' HG13 ' A' ' 5' ' ' VAL . 24.2 t-20 -87.68 -87.2 0.15 Allowed 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.506 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER 50.78 -172.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 124.05 0.844 . . . . 0.0 112.078 175.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.506 ' H ' HG23 ' A' ' 5' ' ' VAL . 3.6 p30 -141.07 115.55 9.48 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 174.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.1 p -93.53 130.54 39.36 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.373 0.606 . . . . 0.0 112.036 177.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . 0.563 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 64.5 tttm -84.66 -21.43 30.22 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 163.286 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.435 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.7 p-80 -175.96 159.34 2.17 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.135 -177.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.9 p -67.5 -26.81 66.54 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -174.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.02 -34.49 79.31 Favored Glycine 0 CA--C 1.517 0.184 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.812 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.563 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 10.3 pt20 -90.66 5.56 47.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.029 0.443 . . . . 0.0 110.393 -178.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.577 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 42.2 t -88.11 -14.45 38.76 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.193 0.521 . . . . 0.0 110.316 -175.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -64.79 -51.72 60.68 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.033 -177.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.46 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 59.7 tttp -50.88 -56.89 15.9 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -177.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.46 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 58.7 Cg_endo -71.27 -26.79 20.48 Favored 'Trans proline' 0 C--N 1.355 0.913 0 C-N-CA 121.335 1.357 . . . . 0.0 111.702 -177.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.1 t -74.15 -30.49 62.3 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.053 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 tppt? -74.16 -30.83 62.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.83 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.485 ' HZ2' ' HB2' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -70.95 -28.32 64.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.454 174.82 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.5 -36.0 65.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.845 174.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.05 19.95 5.78 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.294 173.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.602 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -103.88 -174.61 2.58 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 122.714 -0.286 . . . . 0.0 111.0 -178.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -90.87 -57.95 2.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.885 0.374 . . . . 0.0 110.719 -175.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.484 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -136.11 161.09 36.69 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.186 -176.893 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.577 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -122.56 163.86 15.79 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.386 178.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 35.4 tptt -138.01 145.41 41.85 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.5 t -91.27 106.16 18.31 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.14 0.495 . . . . 0.0 110.057 -177.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.604 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 9.1 mt -96.3 -161.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.604 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 0.1 OUTLIER -65.19 44.87 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 120.294 1.407 . . . . 0.0 113.267 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 118.59 -2.4 15.6 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.111 -0.566 . . . . 0.0 113.39 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -120.89 159.72 24.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 117.555 0.678 . . . . 0.0 111.121 -175.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.2 m -100.51 87.87 3.49 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.042 174.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.449 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.2 t70 -78.98 124.43 28.24 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 171.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.0 m -107.58 168.12 9.47 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.112 -0.495 . . . . 0.0 112.183 -171.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.484 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 92.9 m -119.9 122.53 28.99 Favored Pre-proline 0 N--CA 1.441 -0.905 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 168.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -85.64 -159.27 0.1 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.704 2.269 . . . . 0.0 111.431 -177.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.812 -0.613 . . . . 0.0 110.194 178.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.781 0.324 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.59 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 108.77 125.9 5.26 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.482 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.4 pt -110.21 176.32 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.0 0.428 . . . . 0.0 110.827 -175.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -107.72 97.24 6.99 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -178.162 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.573 HG23 ' H ' ' A' ' 6' ' ' ASP . 3.7 p -141.87 -177.73 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.927 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.573 ' H ' HG23 ' A' ' 5' ' ' VAL . 11.8 m-20 -126.35 92.57 3.59 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-O 121.609 0.718 . . . . 0.0 110.964 -177.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.9 p -94.55 135.16 36.32 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.473 -1.24 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.0 tptp -85.42 -17.57 36.23 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 166.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.473 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 7.9 p-80 -169.17 155.1 6.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.801 -176.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.69 ' OG ' ' HA ' ' A' ' 26' ' ' LYS . 39.2 t -60.91 -30.23 70.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.852 -175.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.08 -33.23 68.78 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.187 -0.53 . . . . 0.0 113.447 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.473 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 19.1 pt20 -90.78 1.8 56.6 Favored 'General case' 0 C--N 1.326 -0.425 0 O-C-N 122.488 -0.419 . . . . 0.0 110.959 -177.106 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.28 -11.03 57.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.193 0.52 . . . . 0.0 110.011 -175.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 64.0 mt -63.88 -53.39 51.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.454 -176.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.441 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 8.6 tmtt? -51.61 -57.12 15.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.368 -177.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 54.7 Cg_endo -68.86 -26.02 32.41 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 121.477 1.451 . . . . 0.0 111.948 -178.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.689 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.7 t -70.27 -35.76 73.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.928 177.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.8 mmmt -72.71 -32.01 65.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.183 177.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -70.98 -31.74 68.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.701 176.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.56 -52.3 16.13 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.483 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 143.77 12.43 0.33 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.536 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.689 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -106.26 -174.72 2.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 117.316 0.558 . . . . 0.0 110.511 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 76.6 mtm180 -98.98 -58.5 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 111.004 -176.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.454 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -123.45 156.41 35.6 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.022 -176.801 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.7 150.82 20.2 Favored Glycine 0 N--CA 1.448 -0.562 0 O-C-N 123.615 0.572 . . . . 0.0 111.969 -176.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.69 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 59.1 tttm -130.24 149.74 51.8 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -94.21 116.82 29.27 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.687 -178.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.626 HG23 ' N ' ' A' ' 29' ' ' ASN . 6.8 mt -120.07 -122.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.061 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.626 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -91.37 49.55 1.62 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 118.862 0.755 . . . . 0.0 111.243 -175.962 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 89.44 10.81 65.16 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.893 -0.67 . . . . 0.0 111.515 -177.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 22.8 ptmt -120.14 150.02 41.28 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.59 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.3 t -93.53 83.93 4.6 Favored 'General case' 0 C--N 1.315 -0.919 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 172.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.407 ' CB ' HD11 ' A' ' 28' ' ' ILE . 16.0 t70 -76.39 107.38 8.61 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 63.6 m -105.99 173.44 6.31 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.999 -1.001 . . . . 0.0 112.351 -170.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.454 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 90.0 m -122.29 124.6 26.81 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 167.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -82.07 -157.9 0.09 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.978 2.452 . . . . 0.0 112.122 -175.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.6 mppt? . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.491 -0.766 . . . . 0.0 109.747 178.195 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.481 1.095 0 CA-C-O 120.986 0.422 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.74 113.89 3.87 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.1 pt -87.98 175.66 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.166 0.508 . . . . 0.0 111.693 -166.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -106.68 89.68 3.09 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.024 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.484 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -146.81 -175.48 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.492 -171.288 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.484 ' H ' HG23 ' A' ' 5' ' ' VAL . 10.2 p-10 -129.9 107.6 9.5 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.749 0.785 . . . . 0.0 110.408 176.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 4.2 p -92.45 135.18 34.26 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.805 -177.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -83.52 -23.99 31.87 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 164.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -173.17 167.42 4.87 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 115.045 -0.98 . . . . 0.0 109.624 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' CYS . 25.6 p -65.7 -30.07 70.7 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.67 0.272 . . . . 0.0 111.682 -175.756 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.58 -39.52 66.74 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 121.175 -0.536 . . . . 0.0 112.495 178.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.67 14.82 14.07 Favored 'General case' 0 C--N 1.33 -0.277 0 O-C-N 122.577 -0.367 . . . . 0.0 111.905 178.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 10' ' ' SER . 35.0 m -90.26 -21.46 22.09 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.876 0.369 . . . . 0.0 110.156 173.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.5 mt -61.12 -56.29 22.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.831 -173.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.522 ' HZ2' ' HB2' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -57.08 -56.6 31.9 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.491 -177.113 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -66.63 -23.77 48.95 Favored 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 121.328 1.352 . . . . 0.0 112.31 -178.597 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.5 t -72.13 -37.25 69.5 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.234 0.54 . . . . 0.0 110.109 176.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -78.41 -26.81 46.5 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.857 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -71.0 -29.48 65.45 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.32 172.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.92 -51.76 17.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.433 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.53 9.93 0.62 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.113 177.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.65 -174.4 2.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.975 0.388 . . . . 0.0 110.242 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -99.93 -75.5 0.57 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.999 0.428 . . . . 0.0 111.504 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.432 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -101.68 157.95 16.45 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.92 -175.144 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 141.73 11.54 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.391 -175.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 87.6 tttt -126.85 152.94 46.33 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.6 t -97.84 118.49 34.51 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.636 HG23 ' N ' ' A' ' 29' ' ' ASN . 8.8 mt -118.36 -119.24 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.55 -172.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.636 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.77 45.77 1.28 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.313 0.578 . . . . 0.0 110.824 -175.693 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.96 1.95 58.37 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.519 -177.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -117.32 143.76 45.6 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 23.1 m -86.68 86.43 7.33 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 167.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.489 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.7 t70 -77.24 135.7 38.48 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.16 -178.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 85.7 m -126.49 168.11 14.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.33 -168.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.432 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 97.7 m -119.75 127.58 26.33 Favored Pre-proline 0 N--CA 1.444 -0.734 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 165.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.51 -159.88 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.601 2.201 . . . . 0.0 112.22 -175.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.546 -0.74 . . . . 0.0 110.195 -178.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.768 0.318 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 113.9 127.46 4.53 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -175.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.514 HD11 ' SG ' ' A' ' 17' ' ' CYS . 19.1 pt -103.77 -178.53 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.006 0.431 . . . . 0.0 111.249 -172.215 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -99.51 2.55 44.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.565 0.697 . . . . 0.0 110.292 -173.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.555 HG11 ' SG ' ' A' ' 32' ' ' CYS . 1.2 t -69.36 152.51 9.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.418 176.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.411 ' N ' HG13 ' A' ' 5' ' ' VAL . 5.8 p-10 -106.52 128.41 54.08 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.386 -176.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.713 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 2.7 p -91.43 139.64 30.52 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -177.07 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 35.1 ttpt -88.16 -22.68 23.93 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 163.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.553 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 16.1 p-80 -172.47 164.1 5.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.35 179.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 p -61.39 -42.89 99.44 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -174.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.63 -30.6 59.46 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 116.079 -0.51 . . . . 0.0 113.805 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.553 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.73 6.0 45.88 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 117.099 0.449 . . . . 0.0 111.554 -177.306 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.713 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 54.7 m -84.79 -21.52 29.91 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.077 0.465 . . . . 0.0 109.882 175.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.424 HD11 ' N ' ' A' ' 14' ' ' LEU . 10.0 mp -57.49 -49.26 76.88 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.492 178.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.574 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.3 tmtp? -53.48 -59.47 9.33 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.316 -175.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.574 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 47.5 Cg_endo -73.13 -29.16 11.99 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 121.25 1.3 . . . . 0.0 113.309 -178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.514 ' SG ' HD11 ' A' ' 3' ' ' ILE . 11.9 m -71.7 -29.73 64.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 120.635 0.255 . . . . 0.0 111.129 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.33 -27.99 62.77 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.242 0.544 . . . . 0.0 109.955 175.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -73.51 -37.87 65.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.567 172.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.77 -44.15 86.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.883 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.05 18.5 0.84 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.766 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.54 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -107.61 -173.16 2.22 Favored 'General case' 0 C--N 1.322 -0.622 0 O-C-N 122.588 -0.36 . . . . 0.0 110.85 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.9 mtm180 -108.29 -58.29 2.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.067 0.46 . . . . 0.0 111.745 -175.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.452 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -105.02 -153.83 0.5 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.77 -174.655 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.73 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.02 136.28 3.65 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.703 179.462 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -134.81 150.6 50.53 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 43.9 t -102.55 111.32 23.57 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -177.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.639 HG23 ' N ' ' A' ' 29' ' ' ASN . 9.4 mt -105.41 -115.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.22 -174.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.639 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.99 43.23 1.14 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 118.709 0.686 . . . . 0.0 110.588 -177.29 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.39 2.39 60.35 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.761 -176.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.526 ' HG2' ' ND2' ' A' ' 29' ' ' ASN . 16.8 ptpt -114.49 150.9 34.12 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.555 ' SG ' HG11 ' A' ' 5' ' ' VAL . 59.0 m -91.16 90.17 7.68 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.334 173.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.5 t70 -79.22 118.98 21.67 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 172.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.73 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 33.9 m -133.85 139.97 46.57 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 -173.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.452 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 88.3 m -86.32 131.93 44.69 Favored Pre-proline 0 N--CA 1.447 -0.595 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 67.5 Cg_endo -82.22 -161.57 0.15 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.657 2.238 . . . . 0.0 112.547 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.297 -0.859 . . . . 0.0 109.875 -179.158 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.482 1.138 0 CA-C-O 120.794 0.331 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 101.81 112.81 3.62 Favored Glycine 0 N--CA 1.443 -0.851 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -175.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.413 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.4 pt -92.12 177.48 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.328 0.585 . . . . 0.0 111.314 -171.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -103.08 86.63 2.73 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.304 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.499 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -145.0 -179.87 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.674 -173.41 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.499 ' H ' HG23 ' A' ' 5' ' ' VAL . 19.7 m-20 -132.58 106.74 8.0 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.916 0.389 . . . . 0.0 109.955 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -91.78 136.93 32.77 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.398 0.618 . . . . 0.0 111.309 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -83.86 -19.8 34.24 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 168.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.7 p-80 -170.89 167.3 7.49 Favored 'General case' 0 N--CA 1.461 0.083 0 CA-C-N 115.111 -0.95 . . . . 0.0 110.442 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.7 p -65.61 -40.4 92.58 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -176.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.85 -32.96 59.52 Favored Glycine 0 CA--C 1.52 0.376 0 CA-C-N 116.247 -0.433 . . . . 0.0 114.172 -175.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -90.4 -1.39 57.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.251 0.525 . . . . 0.0 111.287 -177.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 48.1 t -74.69 -23.12 58.57 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.656 0.741 . . . . 0.0 110.0 -178.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -60.01 -42.57 94.61 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.211 -179.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 75.9 tttt -56.09 -61.57 6.27 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.806 -176.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -78.51 -33.52 1.77 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 121.527 1.485 . . . . 0.0 113.965 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 6.0 t -74.91 -25.26 58.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.011 0.434 . . . . 0.0 110.734 -173.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -75.07 -35.61 61.82 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.039 0.447 . . . . 0.0 110.046 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -71.74 -25.8 62.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.981 177.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.15 -52.64 53.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.173 175.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.5 3.66 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.334 -0.936 . . . . 0.0 113.532 178.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -103.53 -178.74 3.75 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.346 0.573 . . . . 0.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -100.07 -56.61 2.33 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.353 -174.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.501 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.8 OUTLIER -107.25 -159.26 0.69 Allowed 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.698 -175.895 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.58 136.68 3.44 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.491 179.075 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -127.29 167.0 16.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.744 0.307 . . . . 0.0 110.352 177.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.8 t -110.1 100.13 9.1 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.511 HG23 ' N ' ' A' ' 29' ' ' ASN . 2.4 mp -95.78 -92.83 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.646 -172.427 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.511 ' N ' HG23 ' A' ' 28' ' ' ILE . 1.4 m120 -93.36 45.06 1.15 Allowed 'General case' 0 CA--C 1.505 -0.755 0 CA-C-O 121.88 0.848 . . . . 0.0 109.899 174.657 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.9 6.37 72.77 Favored Glycine 0 C--N 1.314 -0.654 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.282 -171.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.402 ' HD3' ' C ' ' A' ' 31' ' ' LYS . 0.0 OUTLIER -112.84 159.1 19.36 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.714 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.466 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 1.4 m -93.82 92.59 7.51 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.328 -176.244 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.505 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 19.3 t70 -86.92 124.24 32.91 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 167.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.438 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 7.5 m -135.11 158.47 44.27 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 121.056 -0.258 . . . . 0.0 110.846 -171.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.501 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 33.0 m -96.22 128.74 35.77 Favored Pre-proline 0 N--CA 1.446 -0.632 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 175.702 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -82.23 -160.03 0.12 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.572 2.181 . . . . 0.0 112.308 -178.016 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.206 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.863 0.363 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 121.14 126.35 3.29 Favored Glycine 0 N--CA 1.443 -0.891 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.226 -174.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -104.04 -178.01 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.329 0.585 . . . . 0.0 111.533 -173.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -105.3 109.07 20.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.893 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.5 HG23 ' H ' ' A' ' 6' ' ' ASP . 1.4 p -163.03 -178.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -173.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.5 ' H ' HG23 ' A' ' 5' ' ' VAL . 10.5 m-20 -127.74 110.47 12.66 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.535 ' HA ' ' OE1' ' A' ' 12' ' ' GLN . 2.0 p -91.04 123.91 34.86 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.415 0.626 . . . . 0.0 111.702 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -74.98 -25.48 58.87 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 167.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 28.4 p-80 -177.38 163.26 1.99 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.734 177.303 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.4 p -63.48 -36.35 83.47 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -175.561 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.49 -39.32 65.48 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.176 -0.535 . . . . 0.0 113.067 -178.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.535 ' OE1' ' HA ' ' A' ' 7' ' ' CYS . 0.0 OUTLIER -90.55 -0.12 57.56 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 122.66 -0.317 . . . . 0.0 110.959 -177.718 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.625 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 32.6 t -76.02 -22.07 56.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.587 0.708 . . . . 0.0 109.625 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.413 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 10.9 mp -57.43 -43.01 83.5 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.792 -1.095 . . . . 0.0 111.065 177.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -59.51 -61.05 8.63 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 115.597 -0.728 . . . . 0.0 112.843 -174.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.68 -31.34 13.37 Favored 'Trans proline' 0 C--N 1.354 0.823 0 C-N-CA 121.453 1.435 . . . . 0.0 112.622 -175.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 8.8 t -77.63 -23.46 49.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.173 -176.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 22' ' ' MET . 27.2 ttpp -68.35 -38.46 81.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 175.143 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -68.71 -28.25 66.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.504 176.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.0 -10.94 59.84 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.866 177.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.0 -26.12 6.56 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.501 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.585 ' O ' ' HA ' ' A' ' 18' ' ' LYS . 1.9 mpt? -83.47 175.98 9.4 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 117.261 0.531 . . . . 0.0 111.391 -174.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.7 mtm180 -94.29 -61.43 1.52 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.566 -175.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.56 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -121.81 158.57 28.58 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.044 -176.4 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.625 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -133.86 157.55 22.87 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.524 -177.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.8 tptt -127.18 157.57 39.41 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 176.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.4 t -104.61 97.87 7.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.602 . . . . 0.0 109.875 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.648 HG23 ' N ' ' A' ' 29' ' ' ASN . 3.5 mp -90.06 -110.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.738 -175.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.648 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.53 47.11 1.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 121.628 -0.67 . . . . 0.0 110.391 179.367 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 79.42 19.83 70.65 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -172.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.426 ' HE2' ' HA3' ' A' ' 2' ' ' GLY . 32.1 tttt -120.1 138.53 53.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.929 -0.635 . . . . 0.0 109.536 -179.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.452 ' SG ' HG11 ' A' ' 5' ' ' VAL . 1.3 m -87.56 83.02 7.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.718 173.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.553 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 16.3 t70 -79.13 124.43 28.31 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 168.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.56 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.7 m -124.11 178.17 5.45 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.105 0.479 . . . . 0.0 112.069 -167.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.434 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 95.2 m -125.12 125.53 25.28 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 170.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.401 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 86.1 Cg_endo -82.51 -159.64 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.745 2.297 . . . . 0.0 112.199 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 11.3 mptt . . . . . 0 C--O 1.247 0.949 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.322 177.713 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.435 0.16 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.564 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 97.38 138.9 10.37 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -174.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 10.1 pt -109.51 176.76 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-O 121.362 0.601 . . . . 0.0 111.872 -170.096 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -100.74 100.23 10.88 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.858 178.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.44 HG12 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -162.92 179.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -174.281 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.44 ' N ' HG12 ' A' ' 5' ' ' VAL . 6.4 m-20 -128.02 112.82 15.05 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.032 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.655 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.2 p -88.8 129.76 35.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.608 0.718 . . . . 0.0 111.663 -177.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -87.15 -15.08 39.45 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 167.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . 0.469 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 26.7 p-80 178.41 158.15 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.493 178.071 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.5 p -58.32 -35.45 71.9 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 111.648 -175.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.78 -32.64 70.31 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 115.99 -0.55 . . . . 0.0 113.641 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.83 7.78 38.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.576 0.688 . . . . 0.0 111.446 -177.486 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 74.8 m -82.05 -15.6 53.02 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.143 176.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.85 -56.59 19.34 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.186 -171.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -57.12 -54.15 57.69 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.55 -27.58 39.04 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 121.265 1.31 . . . . 0.0 112.557 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.417 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.6 t -73.01 -33.95 66.09 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.26 0.552 . . . . 0.0 110.209 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -73.13 -39.16 65.97 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.914 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.2 ttmm -69.17 -28.85 66.78 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.916 176.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.06 -43.54 78.4 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.891 175.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 125.72 15.04 3.0 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.849 176.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.518 ' SD ' ' HB2' ' A' ' 34' ' ' CYS . 60.9 mtt -116.13 -179.17 3.59 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 122.649 -0.324 . . . . 0.0 110.611 -178.164 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtm180 -92.77 -79.1 0.4 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.046 -170.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.504 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -107.17 158.9 16.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -175.584 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.98 137.15 9.21 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.328 -176.015 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -117.73 154.16 32.17 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.1 t -96.77 107.74 20.27 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.251 0.548 . . . . 0.0 110.354 -176.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.608 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 1.9 mp -94.49 -169.97 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 179.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.608 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 9.8 p30 -39.67 -43.17 1.32 Allowed 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 118.889 0.768 . . . . 0.0 112.244 -174.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 6' ' ' ASP . . . -152.41 2.63 0.33 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.201 -1.0 . . . . 0.0 112.305 172.68 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.25 152.01 40.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.997 0.427 . . . . 0.0 111.807 -169.548 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.655 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 65.2 m -91.59 92.91 8.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.509 176.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.564 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 22.3 t70 -80.82 135.94 36.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.605 175.228 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.518 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 81.1 m -123.84 157.51 33.99 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.268 -0.424 . . . . 0.0 112.121 -169.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.3 m -103.27 128.57 27.27 Favored Pre-proline 0 N--CA 1.442 -0.857 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 169.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -83.51 -163.63 0.22 Allowed 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.339 2.026 . . . . 0.0 112.167 -175.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm . . . . . 0 C--O 1.246 0.87 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.14 179.805 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.477 0.913 0 CA-C-O 120.928 0.394 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 111.93 106.13 2.84 Favored Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -176.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.1 pt -89.87 178.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.413 0.625 . . . . 0.0 111.639 -170.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -103.86 105.84 16.17 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.652 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.54 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -157.98 -175.91 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.364 -172.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.54 ' H ' HG23 ' A' ' 5' ' ' VAL . 4.9 m-20 -132.92 106.1 7.49 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.253 0.549 . . . . 0.0 110.236 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -92.94 125.6 37.62 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.187 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . 0.428 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 56.7 tptt -74.88 -22.14 58.82 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 167.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 13.5 p-80 -171.74 163.7 6.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 114.636 -1.165 . . . . 0.0 109.794 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 p -66.35 -33.4 75.65 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.787 0.291 . . . . 0.0 111.787 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.14 -34.38 62.39 Favored Glycine 0 CA--C 1.519 0.308 0 C-N-CA 121.273 -0.489 . . . . 0.0 113.353 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.428 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 6.5 pt20 -90.7 -1.73 57.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.836 0.351 . . . . 0.0 110.63 -177.389 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.1 t -79.86 -16.72 54.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.412 0.625 . . . . 0.0 110.258 -173.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.417 HD11 ' N ' ' A' ' 14' ' ' LEU . 9.6 mp -64.96 -48.74 72.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.864 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.448 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 73.2 tttt -53.81 -57.52 17.26 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -174.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.448 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.7 Cg_endo -67.97 -29.57 34.03 Favored 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 121.81 1.674 . . . . 0.0 112.397 -175.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 2.2 m -78.32 -29.07 47.49 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.46 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 13.7 tmtt? -67.59 -38.4 83.96 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.9 ttmm -68.01 -35.28 78.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.747 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.24 -12.99 60.72 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.28 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 108.23 14.21 17.23 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.783 -0.723 . . . . 0.0 113.358 175.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' MET . . . . . 0.504 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -104.32 179.67 4.2 Favored 'General case' 0 C--N 1.319 -0.738 0 O-C-N 122.333 -0.51 . . . . 0.0 110.758 178.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.45 -57.11 2.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.03 0.443 . . . . 0.0 111.658 -175.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.514 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.7 OUTLIER -105.5 -159.21 0.7 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.79 -174.681 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.638 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -170.6 133.14 2.69 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.271 -0.966 . . . . 0.0 112.9 178.371 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.49 147.09 50.31 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.9 t -96.7 112.02 23.94 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.837 0.351 . . . . 0.0 110.508 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.454 HG23 ' N ' ' A' ' 29' ' ' ASN . 7.0 mt -104.85 170.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.454 ' N ' HG23 ' A' ' 28' ' ' ILE . 9.2 p30 -45.09 -34.88 2.79 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -171.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.35 -1.76 1.03 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 119.365 -1.397 . . . . 0.0 113.931 174.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -124.02 153.7 40.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 118.184 0.992 . . . . 0.0 111.53 -172.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.5 OUTLIER -92.79 92.5 7.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 169.772 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -78.87 103.4 8.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.478 175.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.638 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 20.0 m -125.03 142.53 51.43 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.293 -174.422 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 41.2 m -88.42 129.83 47.87 Favored Pre-proline 0 N--CA 1.448 -0.574 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 90.2 Cg_endo -81.36 -158.73 0.1 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.798 2.332 . . . . 0.0 112.261 -177.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.498 -0.763 . . . . 0.0 110.771 -177.784 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.75 0.309 . . . . 0.0 110.769 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 114.46 130.8 5.04 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.4 pt -103.21 177.11 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-O 121.177 0.513 . . . . 0.0 111.658 -170.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -101.32 70.48 1.32 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.255 -175.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.441 HG12 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -131.44 179.53 4.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.324 -176.5 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.441 ' N ' HG12 ' A' ' 5' ' ' VAL . 7.2 p-10 -128.33 111.28 13.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.56 0.695 . . . . 0.0 109.966 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.437 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.8 p -92.9 132.07 37.36 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.969 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 mtmt -87.6 -18.45 29.64 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 163.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.446 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.2 p-80 -167.49 167.39 13.72 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.616 -1.175 . . . . 0.0 110.329 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.428 ' HB3' ' H ' ' A' ' 27' ' ' CYS . 4.9 p -72.27 -31.26 65.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -176.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.27 -27.87 66.04 Favored Glycine 0 CA--C 1.517 0.212 0 C-N-CA 121.11 -0.567 . . . . 0.0 113.408 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.446 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -89.0 3.65 50.94 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 122.597 -0.355 . . . . 0.0 110.721 -178.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 88.9 m -86.86 -16.12 37.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.829 0.347 . . . . 0.0 110.483 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.9 mt -62.67 -62.78 1.5 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.913 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.453 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 54.5 tttm -55.23 -58.44 15.04 Favored Pre-proline 0 N--CA 1.446 -0.633 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.453 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 37.2 Cg_endo -66.5 -28.1 45.94 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 121.403 1.402 . . . . 0.0 112.922 -173.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.426 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 4.2 t -82.76 -26.65 31.69 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.19 0.519 . . . . 0.0 109.897 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -72.33 -36.31 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.8 tptm -72.14 -32.7 67.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.825 173.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.8 -48.1 80.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.586 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 144.95 8.78 0.35 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.887 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.426 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.78 178.36 4.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.71 0.255 . . . . 0.0 110.326 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.6 mtm180 -96.84 -54.18 3.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.864 0.364 . . . . 0.0 111.241 -173.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.445 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.4 OUTLIER -112.48 -153.15 0.52 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.886 -176.633 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.35 139.06 3.18 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.725 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -133.03 151.47 52.05 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 177.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.428 ' H ' ' HB3' ' A' ' 10' ' ' SER . 42.6 t -88.01 131.87 34.48 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.605 HG23 ' N ' ' A' ' 29' ' ' ASN . 6.4 mt -122.89 -112.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.207 -177.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.605 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.22 46.73 1.27 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.417 0.627 . . . . 0.0 110.586 -179.579 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.28 -5.71 65.54 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.662 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -109.1 154.57 22.09 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 120.729 0.299 . . . . 0.0 110.262 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 35.9 m -96.73 90.55 5.32 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.807 172.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.443 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -86.0 135.13 33.77 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.857 175.276 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.445 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 3.2 m -135.39 178.62 6.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.893 0.378 . . . . 0.0 111.063 -170.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.443 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 57.9 m -113.64 127.42 26.84 Favored Pre-proline 0 N--CA 1.443 -0.787 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 171.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -84.87 -161.37 0.13 Allowed 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.894 2.396 . . . . 0.0 112.102 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.512 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.947 0 CA-C-O 118.595 -0.716 . . . . 0.0 110.035 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.9 m . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.655 0.264 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.617 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 110.96 109.51 3.14 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.903 178.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.517 HG12 ' CB ' ' A' ' 32' ' ' CYS . 1.1 pt -98.24 175.66 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.666 0.27 . . . . 0.0 110.314 -177.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -103.76 109.63 21.42 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.587 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.7 p -156.53 -175.95 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -172.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.587 ' H ' HG23 ' A' ' 5' ' ' VAL . 7.1 m-20 -127.77 97.28 4.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.449 0.642 . . . . 0.0 111.041 -176.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 5.8 p -94.36 134.18 37.14 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.223 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -88.93 -14.64 36.24 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 166.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -171.34 161.66 6.54 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 114.643 -1.162 . . . . 0.0 110.445 174.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.5 p -58.61 -40.44 83.3 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -176.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.61 -41.69 50.24 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 114.112 0.405 . . . . 0.0 114.112 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -83.52 -2.72 56.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.031 0.415 . . . . 0.0 111.467 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.29 -11.95 57.19 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.233 0.54 . . . . 0.0 110.159 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.8 mp -63.44 -42.88 98.67 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.55 -178.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -56.8 -58.33 18.17 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.339 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.69 -24.04 22.16 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 121.47 1.447 . . . . 0.0 112.062 -178.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 46.3 t -69.33 -38.96 78.42 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 178.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -71.47 -35.18 70.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.42 178.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.3 tmtm? -61.6 -38.12 86.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.289 -0.868 . . . . 0.0 109.539 175.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.15 -44.1 76.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.54 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.25 8.14 0.75 Allowed Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.912 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.433 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.2 mpp? -108.1 -173.83 2.38 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 117.594 0.697 . . . . 0.0 111.208 -179.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 64.1 mtm180 -93.21 -60.69 1.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.451 -174.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -130.75 161.14 32.37 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.567 -176.279 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.481 ' HA2' ' HA ' ' A' ' 34' ' ' CYS . . . -131.22 140.02 11.43 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.858 -175.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -101.55 170.08 8.42 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 173.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.7 t -107.56 107.85 18.88 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.187 0.518 . . . . 0.0 111.187 -176.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.418 ' CD1' ' HB2' ' A' ' 33' ' ' ASP . 3.2 mt -104.56 162.27 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.19 -38.57 0.78 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.09 13.68 1.29 Allowed Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.054 175.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.9 148.82 45.01 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 120.961 0.41 . . . . 0.0 110.618 -173.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.617 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -94.55 87.92 5.27 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 167.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.418 ' HB2' ' CD1' ' A' ' 28' ' ' ILE . 32.1 t70 -74.52 96.73 2.98 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 122.019 0.914 . . . . 0.0 109.38 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.481 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 69.7 m -86.45 167.85 14.31 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.12 -1.4 . . . . 0.0 112.968 -171.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 30.4 m -129.23 119.92 19.83 Favored Pre-proline 0 N--CA 1.434 -1.264 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 168.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.433 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 72.0 Cg_endo -84.4 -157.98 0.09 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.303 0 C-N-CA 122.16 1.907 . . . . 0.0 111.609 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.572 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.776 -0.63 . . . . 0.0 110.601 -179.522 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.653 0.263 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.624 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 103.84 104.65 2.92 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.886 -0.674 . . . . 0.0 111.769 -179.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.493 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.7 pt -91.88 178.51 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.698 0.285 . . . . 0.0 110.452 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -104.24 110.79 23.14 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 177.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.562 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -160.82 -178.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -173.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.562 ' H ' HG23 ' A' ' 5' ' ' VAL . 26.3 m-20 -128.6 107.77 9.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.366 0.603 . . . . 0.0 110.069 -178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 p -91.63 135.69 33.69 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.204 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -82.8 -20.72 35.22 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.413 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 22.3 p-80 -177.93 159.06 1.32 Allowed 'General case' 0 CA--C 1.522 -0.114 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.272 175.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 p -52.72 -44.88 66.65 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.428 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -54.49 -34.32 54.89 Favored Glycine 0 C--O 1.228 -0.273 0 CA-C-N 115.908 -0.587 . . . . 0.0 114.002 -177.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -91.48 3.12 55.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 117.744 0.772 . . . . 0.0 111.99 -177.432 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -84.09 -2.51 56.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.62 0.724 . . . . 0.0 109.543 -177.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 72.3 mt -61.09 -55.93 26.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.829 -1.078 . . . . 0.0 111.404 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -52.03 -54.86 36.24 Favored Pre-proline 0 CA--C 1.542 0.664 0 N-CA-C 113.341 0.867 . . . . 0.0 113.341 -172.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.18 -31.58 22.81 Favored 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 121.276 1.318 . . . . 0.0 112.406 -176.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 7.8 t -81.59 -22.09 37.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.21 0.528 . . . . 0.0 110.198 -178.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -65.41 -38.79 90.99 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 174.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -62.3 -43.94 97.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.98 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.35 -40.45 90.75 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.759 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 129.22 17.51 1.78 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.969 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.54 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -109.8 -178.02 3.42 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.748 179.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.3 mtm180 -103.8 -63.58 1.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.891 0.377 . . . . 0.0 111.589 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.61 157.43 25.36 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 -177.411 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.9 144.47 16.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.988 -174.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttp -110.12 167.55 10.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 110.229 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 36.3 t -108.54 110.72 22.27 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.437 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.463 HG23 ' N ' ' A' ' 29' ' ' ASN . 10.1 mt -117.15 176.03 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 28' ' ' ILE . 9.6 p30 -38.4 -43.97 0.87 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -169.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -155.83 17.07 0.47 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.784 173.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -124.54 148.85 47.52 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.665 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.624 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -92.83 89.17 6.49 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 173.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -77.12 107.69 9.67 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.615 0.721 . . . . 0.0 109.388 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.449 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.9 m -111.06 171.49 7.44 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.841 -171.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.427 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 75.4 m -122.18 122.9 27.39 Favored Pre-proline 0 N--CA 1.436 -1.13 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 168.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.498 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 95.8 Cg_endo -84.55 -162.95 0.17 Allowed 'Trans proline' 0 N--CA 1.445 -1.332 0 C-N-CA 122.197 1.931 . . . . 0.0 112.474 -177.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.624 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.03 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 120.624 0.249 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.486 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.87 127.24 5.85 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -174.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.4 pt -100.74 172.71 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.419 0.628 . . . . 0.0 111.732 -169.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -102.64 95.29 6.12 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.815 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.452 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -155.67 -177.39 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.948 -0.569 . . . . 0.0 109.734 -172.799 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.452 ' H ' HG23 ' A' ' 5' ' ' VAL . 16.4 m-20 -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.817 0.341 . . . . 0.0 110.42 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.531 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 2.4 p -92.83 128.97 38.88 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 62.5 tttm -81.73 -19.53 41.24 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 167.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.449 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 6.5 p-80 -166.28 151.19 8.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.804 -177.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 t -74.3 73.8 1.83 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.68 177.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.14 -28.84 0.03 OUTLIER Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.105 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 9.8 pt20 -87.98 3.39 48.91 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 121.142 -0.223 . . . . 0.0 111.146 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.568 ' O ' ' HB2' ' A' ' 17' ' ' CYS . 73.5 m -77.17 -11.52 59.83 Favored 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.355 -175.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.4 mt -62.19 -54.52 39.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.844 -0.617 . . . . 0.0 111.846 -174.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -53.51 -54.92 40.35 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.403 -178.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.95 -23.62 25.16 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 121.786 1.657 . . . . 0.0 112.538 178.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 19.4 t -69.72 -35.53 75.12 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.447 0.641 . . . . 0.0 109.629 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -70.47 -30.66 67.54 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.924 177.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 52.9 tttm -68.56 -41.43 79.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.705 173.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.42 -40.38 93.29 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.741 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 119.76 17.6 4.62 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.479 177.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.534 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 61.3 mtt -116.12 177.68 4.59 Favored 'General case' 0 C--N 1.32 -0.699 0 O-C-N 122.6 -0.353 . . . . 0.0 110.432 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 -91.76 -74.09 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 120.458 -0.497 . . . . 0.0 111.983 -169.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.493 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -110.23 158.95 17.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.886 -174.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.7 161.41 22.88 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.46 -175.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 0.4 OUTLIER -145.83 144.84 30.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -177.21 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 39.2 t -89.05 121.45 31.4 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.413 -178.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.421 HG23 ' N ' ' A' ' 29' ' ' ASN . 6.5 mt -114.96 167.69 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.421 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -67.2 53.1 0.05 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -175.015 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 155.1 -36.77 0.65 Allowed Glycine 0 N--CA 1.438 -1.176 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.309 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.561 ' HZ3' ' HB3' ' A' ' 31' ' ' LYS . 0.4 OUTLIER -124.45 174.1 8.0 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 117.505 0.652 . . . . 0.0 111.663 -172.623 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.531 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -108.08 98.16 7.76 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 166.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.486 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.7 t70 -76.19 117.85 18.31 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.592 0.711 . . . . 0.0 110.367 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.403 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 48.3 m -106.83 160.68 15.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.443 -175.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.493 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 48.2 m -112.24 125.75 29.6 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 169.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -79.9 -159.83 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.673 2.249 . . . . 0.0 111.688 -176.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.3 mptt . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.705 -0.664 . . . . 0.0 109.794 178.977 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 121.015 0.436 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.469 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 107.77 114.66 3.84 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.862 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.447 HG12 ' CB ' ' A' ' 32' ' ' CYS . 10.3 pt -100.51 -179.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.126 0.489 . . . . 0.0 111.155 -173.261 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -108.16 118.51 36.94 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.373 -0.83 . . . . 0.0 108.993 175.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.569 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.4 p -167.32 -174.97 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -172.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.569 ' H ' HG23 ' A' ' 5' ' ' VAL . 7.3 p-10 -126.94 110.88 13.48 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.673 0.749 . . . . 0.0 110.395 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -92.84 127.45 38.36 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.476 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -73.97 -25.88 60.17 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 165.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -174.75 163.76 3.47 Favored 'General case' 0 C--O 1.226 -0.165 0 CA-C-N 114.511 -1.222 . . . . 0.0 109.459 -179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 p -59.21 -37.07 76.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.692 0.282 . . . . 0.0 111.72 -177.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.56 -33.45 66.85 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 116.269 -0.423 . . . . 0.0 114.065 -176.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 6.34 44.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.413 0.607 . . . . 0.0 111.185 -178.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.537 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 46.0 t -84.47 -15.25 46.71 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.253 0.549 . . . . 0.0 109.744 179.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.8 mt -58.18 -50.76 72.39 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.816 -175.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.57 ' HZ3' ' HB2' ' A' ' 15' ' ' LYS . 3.5 ttmp? -59.96 -56.25 37.46 Favored Pre-proline 0 N--CA 1.445 -0.709 0 CA-C-N 115.453 -0.794 . . . . 0.0 113.063 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.8 -26.17 32.66 Favored 'Trans proline' 0 C--N 1.356 0.934 0 C-N-CA 121.024 1.149 . . . . 0.0 111.45 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.541 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 42.0 t -68.07 -37.02 80.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.783 175.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.407 ' HB2' ' NZ ' ' A' ' 18' ' ' LYS . 2.7 ttmp? -68.64 -39.94 80.51 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.733 176.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -59.16 -33.14 70.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.231 175.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.08 -36.85 55.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.739 177.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.06 2.18 5.18 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.354 -0.926 . . . . 0.0 114.29 172.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.541 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.0 mpp? -96.03 -169.01 1.85 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 117.705 0.753 . . . . 0.0 111.051 -177.081 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 -99.87 -59.61 1.68 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.02 0.438 . . . . 0.0 111.45 -175.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.442 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -128.99 158.98 37.33 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.345 -175.973 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.537 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -135.27 155.02 21.89 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.813 -177.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -117.86 166.73 12.12 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 48.7 t -103.81 106.29 16.75 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.913 -178.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 30' ' ' GLY . 12.8 mt -116.03 171.71 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.467 ' C ' HD21 ' A' ' 29' ' ' ASN . 0.3 OUTLIER -58.48 65.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.493 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 95.94 6.41 59.22 Favored Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 31.1 ttmt -123.73 133.57 53.84 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -176.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.469 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.3 OUTLIER -97.07 87.78 4.31 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 172.434 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.86 113.08 15.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.49 0.662 . . . . 0.0 109.566 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.456 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 99.0 m -101.66 173.42 6.43 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.17 -172.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.442 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 87.9 m -126.09 124.97 24.7 Favored Pre-proline 0 N--CA 1.44 -0.958 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 168.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.92 -156.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 122.744 2.296 . . . . 0.0 111.868 -176.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 5.5 mptp? . . . . . 0 C--O 1.247 0.954 0 CA-C-O 118.603 -0.713 . . . . 0.0 110.672 178.265 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.447 HG11 ' O ' ' A' ' 34' ' ' CYS . 76.3 t . . . . . 0 N--CA 1.479 1.016 0 CA-C-O 120.813 0.34 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.569 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 102.53 97.97 2.4 Favored Glycine 0 N--CA 1.443 -0.893 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.183 179.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' A' ' 32' ' ' CYS . 2.1 pt -94.77 -179.55 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -106.49 106.45 16.97 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.555 HG23 ' H ' ' A' ' 6' ' ' ASP . 3.6 p -154.0 -177.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -172.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.555 ' H ' HG23 ' A' ' 5' ' ' VAL . 12.0 m-20 -128.92 102.97 6.76 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 120.96 0.41 . . . . 0.0 110.787 -178.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.1 p -94.33 131.36 40.04 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.345 176.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -85.26 -18.0 35.29 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 165.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.419 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 8.6 p-80 -167.68 162.63 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.775 -176.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.3 p -66.88 -37.73 84.97 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -174.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.71 -26.28 59.92 Favored Glycine 0 CA--C 1.519 0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 113.897 -174.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.419 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 17.5 pt20 -88.39 -4.67 58.61 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 117.384 0.592 . . . . 0.0 110.908 -177.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -88.42 -2.36 58.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.534 0.683 . . . . 0.0 109.85 -175.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.3 mt -62.58 -57.16 12.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.169 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.435 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.2 tmmm? -50.76 -57.86 12.06 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 114.695 -1.138 . . . . 0.0 112.811 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.445 ' HB2' HD13 ' A' ' 3' ' ' ILE . 37.1 Cg_endo -64.94 -33.55 51.43 Favored 'Trans proline' 0 C--N 1.352 0.724 0 C-N-CA 121.628 1.552 . . . . 0.0 113.356 -173.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -83.5 -21.72 32.72 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.084 0.468 . . . . 0.0 110.463 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -72.78 -36.26 67.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -68.15 -36.32 79.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.783 173.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.69 -45.94 84.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.442 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.89 21.23 0.56 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.842 176.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.462 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 2.1 mpt? -109.7 -175.42 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 O-C-N 122.669 -0.312 . . . . 0.0 110.493 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.0 mtm180 -96.37 -61.44 1.43 Allowed 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.183 -0.607 . . . . 0.0 111.958 -176.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.456 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -108.06 -158.11 0.64 Allowed 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.074 -173.42 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.21 141.63 6.93 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.328 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -130.36 166.9 19.45 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 177.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.4 t -107.15 110.68 22.82 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.959 -175.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.478 HG23 ' N ' ' A' ' 29' ' ' ASN . 8.3 mt -113.37 171.46 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 174.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.478 ' N ' HG23 ' A' ' 28' ' ' ILE . 12.6 m-80 -38.6 -53.71 1.59 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.908 0.483 . . . . 0.0 111.869 -171.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.71 21.82 2.17 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 173.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.41 ' O ' ' HB ' ' A' ' 28' ' ' ILE . 30.1 ttmt -122.67 132.79 54.43 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 110.305 -0.258 . . . . 0.0 110.305 -171.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.569 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.4 t -87.84 90.52 8.41 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -77.13 104.81 7.84 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.465 0.65 . . . . 0.0 109.753 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.447 ' O ' HG11 ' A' ' 1' ' ' VAL . 4.3 p -128.47 141.11 51.49 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.253 -173.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.456 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 38.4 m -92.91 127.87 45.86 Favored Pre-proline 0 N--CA 1.441 -0.915 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.462 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 46.4 Cg_endo -84.03 -154.09 0.05 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 122.521 2.147 . . . . 0.0 111.714 -176.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 37' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.567 178.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 34' ' ' CYS . 27.2 m . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.847 0.356 . . . . 0.0 110.306 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.517 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 100.65 118.11 4.23 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -176.157 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.8 pt -102.55 170.61 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.43 0.634 . . . . 0.0 111.082 -174.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -104.79 92.09 4.11 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.255 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.462 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.7 OUTLIER -147.69 -179.2 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.498 -173.385 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.462 ' H ' HG23 ' A' ' 5' ' ' VAL . 10.9 m-20 -128.4 102.69 6.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.163 0.506 . . . . 0.0 110.298 -178.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.578 ' HA ' ' NE2' ' A' ' 12' ' ' GLN . 1.9 p -92.91 133.57 35.97 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.337 -176.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -84.68 -21.84 30.03 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 164.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.456 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 14.1 p-80 -168.63 163.99 12.23 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.759 -176.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.6 p -65.09 -41.4 95.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.724 0.297 . . . . 0.0 111.577 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.85 -18.27 46.03 Favored Glycine 0 C--O 1.228 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 114.61 -172.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.578 ' NE2' ' HA ' ' A' ' 7' ' ' CYS . 9.7 pt20 -89.12 -17.48 29.14 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 117.73 0.765 . . . . 0.0 110.634 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.4 m -90.83 24.39 2.75 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-O 121.009 0.433 . . . . 0.0 111.432 -175.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.65 -41.58 19.24 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 169.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.5 ttpt -62.31 -58.25 18.44 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.599 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.87 -27.05 21.65 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.318 1.345 . . . . 0.0 112.17 -177.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 40.7 t -74.12 -30.94 62.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.374 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 11.3 tppt? -67.86 -36.92 81.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 177.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.4 tttp -73.56 -28.86 62.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.903 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.49 -36.82 85.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.34 176.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.63 10.79 5.26 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.95 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.533 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.2 mpt? -107.88 -175.4 2.77 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.576 -0.367 . . . . 0.0 110.344 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 -93.61 -62.48 1.35 Allowed 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.473 -0.491 . . . . 0.0 111.268 -177.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.49 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.8 160.27 22.94 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.978 -175.961 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.87 146.22 17.61 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.402 -176.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 61.6 mtpt -134.97 167.15 21.45 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.1 t -104.81 121.55 43.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.867 -174.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 29' ' ' ASN . 8.9 mt -117.41 178.5 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.816 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.477 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -64.67 56.23 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -174.722 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 134.65 -23.03 3.62 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 121.354 -0.451 . . . . 0.0 112.661 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -123.06 169.16 11.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.832 0.316 . . . . 0.0 110.236 -173.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.545 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 5.2 m -114.39 100.79 8.59 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.538 0.685 . . . . 0.0 109.289 167.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.517 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.6 t70 -77.96 149.14 34.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.033 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.451 ' O ' HG22 ' A' ' 1' ' ' VAL . 98.4 m -137.43 160.16 39.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -170.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.49 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 89.0 m -116.28 123.12 31.15 Favored Pre-proline 0 N--CA 1.437 -1.076 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 167.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -79.72 -163.24 0.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.555 2.17 . . . . 0.0 112.215 -174.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.425 -0.798 . . . . 0.0 110.234 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.48 1.067 0 CA-C-O 120.55 0.214 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 104.8 130.52 6.83 Favored Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 5' ' ' VAL . 15.5 pt -108.48 178.72 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.187 0.518 . . . . 0.0 111.486 -171.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -105.04 37.8 2.09 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.001 -175.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.64 HG11 ' SG ' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -98.43 158.33 3.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.21 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -102.84 112.52 25.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.922 0.391 . . . . 0.0 110.407 -174.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.623 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 6.0 p -91.5 131.94 36.61 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.9 mmtp -82.03 -19.58 40.09 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 164.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 -170.2 164.7 9.11 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.093 177.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.0 p -57.99 -38.94 77.05 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.887 0.375 . . . . 0.0 111.568 -176.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.58 -36.56 54.43 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.771 -176.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -91.71 14.6 14.8 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.265 0.533 . . . . 0.0 112.415 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.623 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 58.6 m -90.13 -21.89 22.03 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 171.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.6 -46.8 83.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.223 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.4 ttpp -62.24 -58.61 16.49 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -176.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' CG ' HG12 ' A' ' 5' ' ' VAL . 32.8 Cg_endo -69.92 -29.1 23.64 Favored 'Trans proline' 0 C--N 1.354 0.844 0 C-N-CA 121.237 1.291 . . . . 0.0 112.695 -177.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 13.9 m -74.06 -27.15 60.77 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 120.748 0.309 . . . . 0.0 110.801 176.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -70.69 -37.66 73.61 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.8 ttpp -67.93 -32.75 73.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.577 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.66 -46.79 71.38 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.019 176.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.85 14.15 1.9 Allowed Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.69 -0.687 . . . . 0.0 112.914 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -99.89 173.89 6.46 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.108 0.454 . . . . 0.0 111.002 -178.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -94.78 -53.56 3.81 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.961 0.41 . . . . 0.0 111.859 -170.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.483 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.6 OUTLIER -110.19 -157.29 0.61 Allowed 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.044 -175.447 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.671 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.0 132.04 2.26 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.575 -0.822 . . . . 0.0 112.921 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -131.89 152.43 51.06 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 35.7 t -95.52 119.16 33.54 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.118 0.485 . . . . 0.0 110.806 -174.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mt -109.49 164.0 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.171 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.95 -38.69 1.01 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -145.53 11.25 1.73 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.067 175.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.2 mttm -123.9 146.63 48.3 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 -174.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.64 ' SG ' HG11 ' A' ' 5' ' ' VAL . 5.7 m -96.8 89.66 4.98 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 163.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -77.99 115.19 17.54 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.747 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.671 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 35.1 m -132.86 141.27 48.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.868 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.467 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 34.9 m -91.84 132.4 33.02 Favored Pre-proline 0 N--CA 1.447 -0.588 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -176.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -81.21 -159.7 0.11 Allowed 'Trans proline' 0 N--CA 1.46 -0.444 0 C-N-CA 123.13 2.553 . . . . 0.0 112.166 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 mptt . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.352 178.502 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.479 1.004 0 CA-C-O 120.638 0.256 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 98.35 126.24 5.48 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.182 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.7 pt -106.42 177.81 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.049 0.452 . . . . 0.0 111.35 -172.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -101.17 94.91 6.21 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.284 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.454 HG12 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -156.97 -179.1 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -175.773 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.454 ' N ' HG12 ' A' ' 5' ' ' VAL . 5.6 m-20 -137.15 110.99 8.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.448 0.642 . . . . 0.0 110.479 177.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.523 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 7.3 p -93.01 140.36 29.56 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.186 -178.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -85.32 -21.75 28.8 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 164.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.558 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 10.0 p-80 -164.45 162.67 22.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.893 -176.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 12.7 p -68.51 -32.17 71.95 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -175.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.05 -28.75 64.27 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.506 -176.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.558 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 21.1 pt20 -84.94 -11.08 56.32 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.894 0.347 . . . . 0.0 111.04 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -72.3 -23.99 61.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.816 0.341 . . . . 0.0 110.212 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 -44.99 80.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.099 -174.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.482 ' HA ' ' HE3' ' A' ' 15' ' ' LYS . 1.1 tpmt? -65.32 -59.04 10.5 Favored Pre-proline 0 N--CA 1.444 -0.736 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -176.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.86 -24.46 46.45 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.629 1.552 . . . . 0.0 112.505 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.67 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 45.6 t -74.81 -33.14 62.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.27 0.557 . . . . 0.0 110.219 176.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.8 tttp -71.51 -35.75 70.85 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.671 0.748 . . . . 0.0 109.403 177.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -70.43 -27.0 63.92 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.838 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.685 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 133.62 11.16 1.73 Allowed Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.716 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.67 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -108.96 -171.14 1.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 117.399 0.6 . . . . 0.0 110.784 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -97.75 -66.34 0.91 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.884 0.373 . . . . 0.0 111.537 -174.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.457 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.19 160.33 22.36 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.902 -176.567 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.0 141.25 12.38 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.353 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -117.14 156.58 27.39 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.2 t -97.24 115.78 28.24 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.06 0.457 . . . . 0.0 110.714 -175.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.7 mt -114.92 163.61 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -39.61 -42.39 1.17 Allowed 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 -172.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -141.46 12.21 2.73 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.025 175.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.4 mttm -124.94 140.47 52.89 Favored 'General case' 0 N--CA 1.445 -0.72 0 O-C-N 122.901 -0.176 . . . . 0.0 110.836 -175.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.523 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.2 m -92.11 82.31 5.05 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 160.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.499 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -76.84 128.81 35.28 Favored 'General case' 0 CA--C 1.514 -0.412 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.895 -176.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 77.7 m -109.31 171.99 7.12 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.115 -169.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.457 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.2 m -120.54 124.48 27.6 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 166.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -81.32 -161.07 0.14 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.446 2.097 . . . . 0.0 111.786 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 119.026 -0.512 . . . . 0.0 110.809 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.8 m . . . . . 0 N--CA 1.479 0.993 0 CA-C-O 121.066 0.46 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.595 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 117.37 113.11 2.65 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.365 -176.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.505 HG12 ' CB ' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -97.03 175.85 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.163 0.506 . . . . 0.0 111.076 -172.723 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -99.34 113.65 26.08 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.11 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.564 HG23 ' H ' ' A' ' 6' ' ' ASP . 3.0 p -162.34 -177.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.564 ' H ' HG23 ' A' ' 5' ' ' VAL . 9.6 m-20 -132.92 100.2 4.83 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.535 0.683 . . . . 0.0 110.795 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.5 p -93.91 141.78 28.12 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 114.777 -1.101 . . . . 0.0 111.477 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -90.13 -17.93 26.76 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 164.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.534 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 11.0 p-80 -172.7 155.07 3.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.935 -175.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.3 p -68.51 -21.7 64.57 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -174.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.0 -34.72 88.97 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.113 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.534 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -85.7 -4.5 59.18 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.897 0.379 . . . . 0.0 110.232 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.47 -10.94 58.82 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.258 0.551 . . . . 0.0 109.734 -172.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -62.31 -53.53 53.73 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.903 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.482 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 23.5 ttpp -50.52 -55.04 29.06 Favored Pre-proline 0 CA--C 1.541 0.625 0 CA-C-N 115.139 -0.937 . . . . 0.0 113.03 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.482 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.9 Cg_endo -72.63 -26.44 16.38 Favored 'Trans proline' 0 C--N 1.357 0.999 0 C-N-CA 121.397 1.398 . . . . 0.0 112.367 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 38.8 t -70.14 -34.2 72.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.229 0.538 . . . . 0.0 110.288 178.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.56 ' HZ1' ' HB3' ' A' ' 18' ' ' LYS . 3.8 mmmp? -72.6 -31.93 65.56 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.333 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.5 tptt -67.63 -30.74 70.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.808 174.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.28 -43.41 28.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.162 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.46 8.06 2.06 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.181 -1.009 . . . . 0.0 114.057 174.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 3.9 mpp? -106.02 -178.42 3.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 117.765 0.782 . . . . 0.0 110.914 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.445 ' NE ' ' HA ' ' A' ' 37' ' ' LYS . 70.6 mtm180 -91.67 -63.59 1.23 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.885 0.374 . . . . 0.0 111.686 -176.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.441 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -118.04 157.87 26.02 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.361 -175.287 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.12 157.68 21.27 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.112 -177.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -128.91 153.69 47.26 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 21.0 t -92.54 109.62 21.03 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.011 0.434 . . . . 0.0 110.893 -173.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mt -112.24 164.23 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 174.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -43.44 -37.64 2.46 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -173.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.23 17.91 1.04 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.002 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -123.48 147.07 47.56 Favored 'General case' 0 CA--C 1.513 -0.444 0 O-C-N 122.527 -0.396 . . . . 0.0 110.827 -176.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.595 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 6.4 t -96.77 87.45 4.32 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 166.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -75.62 95.42 3.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 122.062 0.934 . . . . 0.0 109.653 -176.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 68.7 m -92.5 175.71 6.73 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.522 -1.217 . . . . 0.0 113.129 -169.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.441 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 33.3 m -136.61 126.72 16.08 Favored Pre-proline 0 N--CA 1.439 -1.008 0 CA-C-N 114.541 -1.209 . . . . 0.0 107.89 168.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.418 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 83.0 Cg_endo -80.0 -158.44 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.301 2.001 . . . . 0.0 112.049 -179.244 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.483 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.101 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.443 177.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.479 1.012 0 CA-C-O 120.67 0.271 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.559 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 109.43 118.56 4.08 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.491 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.6 OUTLIER -104.9 175.03 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 117.001 0.401 . . . . 0.0 110.369 -176.418 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -106.62 107.38 18.37 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.575 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.2 p -155.64 -176.86 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.408 -170.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.575 ' H ' HG23 ' A' ' 5' ' ' VAL . 9.9 m-20 -122.6 105.77 10.39 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -91.93 150.06 21.22 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-O 121.39 0.614 . . . . 0.0 111.174 178.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.9 mtpt -91.29 -33.9 15.15 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 115.003 -0.999 . . . . 0.0 108.843 170.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -149.11 166.24 29.36 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.304 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 t -82.34 64.31 6.93 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.831 175.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.668 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -177.38 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.065 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.98 9.59 5.24 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.956 0.408 . . . . 0.0 111.933 -178.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.1 t -85.45 13.65 6.49 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.9 0.857 . . . . 0.0 109.075 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.668 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 80.9 mt -60.47 -48.87 79.86 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.02 -178.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -54.55 -55.68 35.07 Favored Pre-proline 0 CA--C 1.541 0.596 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -175.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -71.64 -27.61 18.28 Favored 'Trans proline' 0 C--N 1.354 0.835 0 C-N-CA 121.177 1.252 . . . . 0.0 111.767 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.571 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 44.0 t -69.6 -34.28 73.9 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.018 178.109 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -72.17 -36.07 69.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.883 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -65.3 -32.44 74.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.714 176.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.13 -42.12 47.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.056 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 124.2 25.21 1.69 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.726 172.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.571 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -114.67 178.47 4.27 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.35 0.575 . . . . 0.0 111.072 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 73.8 mtm180 -83.61 -71.73 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 111.729 -173.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.501 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -115.29 159.11 21.43 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -175.45 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.62 124.79 3.76 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.577 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -100.57 168.33 9.78 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.928 0.394 . . . . 0.0 110.219 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 22.4 t -108.34 116.84 32.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.161 0.505 . . . . 0.0 110.895 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.484 ' O ' ' N ' ' A' ' 30' ' ' GLY . 9.0 mt -124.14 172.75 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 176.128 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.512 ' N ' HD21 ' A' ' 29' ' ' ASN . 0.0 OUTLIER -59.52 63.85 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -172.266 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 100.55 5.87 53.55 Favored Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 ttmm -122.68 129.66 52.07 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -173.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.559 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 7.1 t -89.85 89.97 7.98 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 172.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -77.35 105.0 8.19 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.665 0.745 . . . . 0.0 109.283 178.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 93.2 m -101.51 169.22 8.99 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.822 -1.081 . . . . 0.0 111.79 -175.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.501 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 59.6 m -115.52 125.2 29.03 Favored Pre-proline 0 N--CA 1.441 -0.906 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 167.445 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.55 -160.66 0.13 Allowed 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.555 2.17 . . . . 0.0 111.813 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.297 -0.859 . . . . 0.0 110.166 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.645 0.259 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.572 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 113.66 110.89 2.96 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.45 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.6 pt -87.22 178.05 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.082 0.468 . . . . 0.0 110.896 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -103.27 92.75 4.64 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.031 -177.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.56 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.1 p -145.4 -178.17 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.56 ' H ' HG23 ' A' ' 5' ' ' VAL . 7.0 m-20 -131.48 101.52 5.55 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.339 0.59 . . . . 0.0 110.541 -176.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.2 p -93.07 132.49 37.13 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.641 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -90.13 -18.37 25.95 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 166.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 m80 -151.05 167.72 26.81 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.8 179.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.408 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 22.2 p -80.93 -21.6 40.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.876 0.369 . . . . 0.0 110.764 177.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.18 -39.55 72.17 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 121.203 -0.523 . . . . 0.0 112.746 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -79.62 2.9 20.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.995 0.426 . . . . 0.0 110.54 178.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.408 ' HB3' ' O ' ' A' ' 10' ' ' SER . 42.6 t -85.04 -16.33 41.07 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.583 0.706 . . . . 0.0 109.566 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.7 mt -65.04 -57.78 7.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.209 -178.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.7 tppp? -49.42 -53.97 34.99 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.129 -0.941 . . . . 0.0 113.493 -174.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.96 -27.87 20.21 Favored 'Trans proline' 0 C--N 1.355 0.911 0 C-N-CA 121.374 1.383 . . . . 0.0 112.873 -177.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.527 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 3.3 m -78.45 -25.78 46.0 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 120.819 0.343 . . . . 0.0 110.903 178.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.03 -23.65 55.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 173.27 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -72.83 -36.81 67.57 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.245 -0.888 . . . . 0.0 109.14 172.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.61 -49.96 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.789 178.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.36 20.22 0.57 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.1 177.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.509 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 1.8 mpt? -103.18 178.23 4.61 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 122.737 -0.272 . . . . 0.0 111.367 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.5 mtm180 -97.39 -57.87 2.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.206 0.526 . . . . 0.0 111.805 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.516 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.5 OUTLIER -105.88 -161.44 0.8 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.819 -174.195 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.727 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -160.41 138.21 5.41 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.481 178.113 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -132.23 143.97 50.3 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 t -95.78 112.59 24.28 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-O 120.929 0.395 . . . . 0.0 110.672 -174.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.9 mt -110.01 163.22 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 176.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -44.73 -36.99 3.44 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -172.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -142.73 12.25 2.42 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.855 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -123.84 158.21 32.38 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 117.231 0.516 . . . . 0.0 111.55 -175.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.572 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -105.6 88.47 2.84 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 162.786 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -77.64 90.28 3.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.739 0.781 . . . . 0.0 110.032 -178.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.727 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 34.9 m -111.28 142.54 43.37 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.75 -174.253 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.5 m -96.34 128.67 35.81 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.509 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 88.1 Cg_endo -83.81 -162.06 0.16 Allowed 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.55 2.167 . . . . 0.0 112.581 -177.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.411 -0.805 . . . . 0.0 110.367 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.629 0.252 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.449 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.78 124.87 5.41 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -178.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.2 pt -103.5 -174.37 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -177.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.481 ' O ' HG13 ' A' ' 5' ' ' VAL . 24.2 t-20 -87.68 -87.2 0.15 Allowed 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.506 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER 50.78 -172.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 124.05 0.844 . . . . 0.0 112.078 175.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.506 ' H ' HG23 ' A' ' 5' ' ' VAL . 3.6 p30 -141.07 115.55 9.48 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 174.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.1 p -93.53 130.54 39.36 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.373 0.606 . . . . 0.0 112.036 177.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.563 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 64.5 tttm -84.66 -21.43 30.22 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 163.286 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.435 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.7 p-80 -175.96 159.34 2.17 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.135 -177.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.9 p -67.5 -26.81 66.54 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -174.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.02 -34.49 79.31 Favored Glycine 0 CA--C 1.517 0.184 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.812 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.563 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 10.3 pt20 -90.66 5.56 47.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.029 0.443 . . . . 0.0 110.393 -178.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.577 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 42.2 t -88.11 -14.45 38.76 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.193 0.521 . . . . 0.0 110.316 -175.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -64.79 -51.72 60.68 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.033 -177.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.46 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 59.7 tttp -50.88 -56.89 15.9 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -177.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.46 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 58.7 Cg_endo -71.27 -26.79 20.48 Favored 'Trans proline' 0 C--N 1.355 0.913 0 C-N-CA 121.335 1.357 . . . . 0.0 111.702 -177.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.1 t -74.15 -30.49 62.3 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.053 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 tppt? -74.16 -30.83 62.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.83 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.485 ' HZ2' ' HB2' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -70.95 -28.32 64.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.454 174.82 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.5 -36.0 65.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.845 174.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.05 19.95 5.78 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.294 173.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.602 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -103.88 -174.61 2.58 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 122.714 -0.286 . . . . 0.0 111.0 -178.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -90.87 -57.95 2.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.885 0.374 . . . . 0.0 110.719 -175.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.484 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -136.11 161.09 36.69 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.186 -176.893 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.577 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -122.56 163.86 15.79 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.386 178.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 35.4 tptt -138.01 145.41 41.85 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.5 t -91.27 106.16 18.31 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.14 0.495 . . . . 0.0 110.057 -177.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.604 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 9.1 mt -96.3 -161.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.604 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 0.1 OUTLIER -65.19 44.87 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 120.294 1.407 . . . . 0.0 113.267 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 118.59 -2.4 15.6 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.111 -0.566 . . . . 0.0 113.39 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -120.89 159.72 24.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 117.555 0.678 . . . . 0.0 111.121 -175.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.2 m -100.51 87.87 3.49 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.042 174.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.449 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.2 t70 -78.98 124.43 28.24 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 171.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.0 m -107.58 168.12 9.47 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.112 -0.495 . . . . 0.0 112.183 -171.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.484 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 92.9 m -119.9 122.53 28.99 Favored Pre-proline 0 N--CA 1.441 -0.905 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 168.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -85.64 -159.27 0.1 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.704 2.269 . . . . 0.0 111.431 -177.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.812 -0.613 . . . . 0.0 110.194 178.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.781 0.324 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.59 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 108.77 125.9 5.26 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.482 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.4 pt -110.21 176.32 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.0 0.428 . . . . 0.0 110.827 -175.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -107.72 97.24 6.99 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -178.162 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.573 HG23 ' H ' ' A' ' 6' ' ' ASP . 3.7 p -141.87 -177.73 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.927 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.573 ' H ' HG23 ' A' ' 5' ' ' VAL . 11.8 m-20 -126.35 92.57 3.59 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-O 121.609 0.718 . . . . 0.0 110.964 -177.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.9 p -94.55 135.16 36.32 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.473 -1.24 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.0 tptp -85.42 -17.57 36.23 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 166.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.473 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 7.9 p-80 -169.17 155.1 6.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.801 -176.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.69 ' OG ' ' HA ' ' A' ' 26' ' ' LYS . 39.2 t -60.91 -30.23 70.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.852 -175.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.08 -33.23 68.78 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.187 -0.53 . . . . 0.0 113.447 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.473 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 19.1 pt20 -90.78 1.8 56.6 Favored 'General case' 0 C--N 1.326 -0.425 0 O-C-N 122.488 -0.419 . . . . 0.0 110.959 -177.106 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.28 -11.03 57.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.193 0.52 . . . . 0.0 110.011 -175.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 64.0 mt -63.88 -53.39 51.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.454 -176.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.441 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 8.6 tmtt? -51.61 -57.12 15.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.368 -177.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 54.7 Cg_endo -68.86 -26.02 32.41 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 121.477 1.451 . . . . 0.0 111.948 -178.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.689 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.7 t -70.27 -35.76 73.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.928 177.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.8 mmmt -72.71 -32.01 65.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.183 177.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -70.98 -31.74 68.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.701 176.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.56 -52.3 16.13 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.483 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 143.77 12.43 0.33 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.536 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.689 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -106.26 -174.72 2.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 117.316 0.558 . . . . 0.0 110.511 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 76.6 mtm180 -98.98 -58.5 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 111.004 -176.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.454 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -123.45 156.41 35.6 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.022 -176.801 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.7 150.82 20.2 Favored Glycine 0 N--CA 1.448 -0.562 0 O-C-N 123.615 0.572 . . . . 0.0 111.969 -176.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.69 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 59.1 tttm -130.24 149.74 51.8 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -94.21 116.82 29.27 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.687 -178.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.626 HG23 ' N ' ' A' ' 29' ' ' ASN . 6.8 mt -120.07 -122.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.061 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.626 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -91.37 49.55 1.62 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 118.862 0.755 . . . . 0.0 111.243 -175.962 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 89.44 10.81 65.16 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.893 -0.67 . . . . 0.0 111.515 -177.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 22.8 ptmt -120.14 150.02 41.28 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.59 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.3 t -93.53 83.93 4.6 Favored 'General case' 0 C--N 1.315 -0.919 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 172.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.407 ' CB ' HD11 ' A' ' 28' ' ' ILE . 16.0 t70 -76.39 107.38 8.61 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 63.6 m -105.99 173.44 6.31 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.999 -1.001 . . . . 0.0 112.351 -170.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.454 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 90.0 m -122.29 124.6 26.81 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 167.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -82.07 -157.9 0.09 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.978 2.452 . . . . 0.0 112.122 -175.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.6 mppt? . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.491 -0.766 . . . . 0.0 109.747 178.195 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.481 1.095 0 CA-C-O 120.986 0.422 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.74 113.89 3.87 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.1 pt -87.98 175.66 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.166 0.508 . . . . 0.0 111.693 -166.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -106.68 89.68 3.09 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.024 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.484 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -146.81 -175.48 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.492 -171.288 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.484 ' H ' HG23 ' A' ' 5' ' ' VAL . 10.2 p-10 -129.9 107.6 9.5 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.749 0.785 . . . . 0.0 110.408 176.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 4.2 p -92.45 135.18 34.26 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.805 -177.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -83.52 -23.99 31.87 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 164.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -173.17 167.42 4.87 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 115.045 -0.98 . . . . 0.0 109.624 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' CYS . 25.6 p -65.7 -30.07 70.7 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.67 0.272 . . . . 0.0 111.682 -175.756 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.58 -39.52 66.74 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 121.175 -0.536 . . . . 0.0 112.495 178.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.67 14.82 14.07 Favored 'General case' 0 C--N 1.33 -0.277 0 O-C-N 122.577 -0.367 . . . . 0.0 111.905 178.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 10' ' ' SER . 35.0 m -90.26 -21.46 22.09 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.876 0.369 . . . . 0.0 110.156 173.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.5 mt -61.12 -56.29 22.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.831 -173.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.522 ' HZ2' ' HB2' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -57.08 -56.6 31.9 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.491 -177.113 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -66.63 -23.77 48.95 Favored 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 121.328 1.352 . . . . 0.0 112.31 -178.597 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.5 t -72.13 -37.25 69.5 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.234 0.54 . . . . 0.0 110.109 176.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -78.41 -26.81 46.5 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.857 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -71.0 -29.48 65.45 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.32 172.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.92 -51.76 17.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.433 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.53 9.93 0.62 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.113 177.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.65 -174.4 2.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.975 0.388 . . . . 0.0 110.242 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -99.93 -75.5 0.57 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.999 0.428 . . . . 0.0 111.504 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.432 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -101.68 157.95 16.45 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.92 -175.144 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 141.73 11.54 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.391 -175.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 87.6 tttt -126.85 152.94 46.33 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.6 t -97.84 118.49 34.51 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.636 HG23 ' N ' ' A' ' 29' ' ' ASN . 8.8 mt -118.36 -119.24 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.55 -172.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.636 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.77 45.77 1.28 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.313 0.578 . . . . 0.0 110.824 -175.693 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.96 1.95 58.37 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.519 -177.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -117.32 143.76 45.6 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 23.1 m -86.68 86.43 7.33 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 167.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.489 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.7 t70 -77.24 135.7 38.48 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.16 -178.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 85.7 m -126.49 168.11 14.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.33 -168.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.432 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 97.7 m -119.75 127.58 26.33 Favored Pre-proline 0 N--CA 1.444 -0.734 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 165.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.51 -159.88 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.601 2.201 . . . . 0.0 112.22 -175.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.546 -0.74 . . . . 0.0 110.195 -178.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.768 0.318 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 113.9 127.46 4.53 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -175.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.514 HD11 ' SG ' ' A' ' 17' ' ' CYS . 19.1 pt -103.77 -178.53 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.006 0.431 . . . . 0.0 111.249 -172.215 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -99.51 2.55 44.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.565 0.697 . . . . 0.0 110.292 -173.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.555 HG11 ' SG ' ' A' ' 32' ' ' CYS . 1.2 t -69.36 152.51 9.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.418 176.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.411 ' N ' HG13 ' A' ' 5' ' ' VAL . 5.8 p-10 -106.52 128.41 54.08 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.386 -176.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.713 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 2.7 p -91.43 139.64 30.52 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -177.07 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 35.1 ttpt -88.16 -22.68 23.93 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 163.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.553 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 16.1 p-80 -172.47 164.1 5.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.35 179.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 p -61.39 -42.89 99.44 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -174.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.63 -30.6 59.46 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 116.079 -0.51 . . . . 0.0 113.805 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.553 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.73 6.0 45.88 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 117.099 0.449 . . . . 0.0 111.554 -177.306 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.713 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 54.7 m -84.79 -21.52 29.91 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.077 0.465 . . . . 0.0 109.882 175.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.424 HD11 ' N ' ' A' ' 14' ' ' LEU . 10.0 mp -57.49 -49.26 76.88 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.492 178.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.574 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.3 tmtp? -53.48 -59.47 9.33 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.316 -175.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.574 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 47.5 Cg_endo -73.13 -29.16 11.99 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 121.25 1.3 . . . . 0.0 113.309 -178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.514 ' SG ' HD11 ' A' ' 3' ' ' ILE . 11.9 m -71.7 -29.73 64.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 120.635 0.255 . . . . 0.0 111.129 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.33 -27.99 62.77 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.242 0.544 . . . . 0.0 109.955 175.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -73.51 -37.87 65.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.567 172.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.77 -44.15 86.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.883 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.05 18.5 0.84 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.766 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.54 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -107.61 -173.16 2.22 Favored 'General case' 0 C--N 1.322 -0.622 0 O-C-N 122.588 -0.36 . . . . 0.0 110.85 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.9 mtm180 -108.29 -58.29 2.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.067 0.46 . . . . 0.0 111.745 -175.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.452 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -105.02 -153.83 0.5 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.77 -174.655 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.73 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.02 136.28 3.65 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.703 179.462 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -134.81 150.6 50.53 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 43.9 t -102.55 111.32 23.57 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -177.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.639 HG23 ' N ' ' A' ' 29' ' ' ASN . 9.4 mt -105.41 -115.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.22 -174.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.639 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.99 43.23 1.14 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 118.709 0.686 . . . . 0.0 110.588 -177.29 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.39 2.39 60.35 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.761 -176.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.526 ' HG2' ' ND2' ' A' ' 29' ' ' ASN . 16.8 ptpt -114.49 150.9 34.12 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.555 ' SG ' HG11 ' A' ' 5' ' ' VAL . 59.0 m -91.16 90.17 7.68 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.334 173.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.5 t70 -79.22 118.98 21.67 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 172.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.73 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 33.9 m -133.85 139.97 46.57 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 -173.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.452 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 88.3 m -86.32 131.93 44.69 Favored Pre-proline 0 N--CA 1.447 -0.595 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 67.5 Cg_endo -82.22 -161.57 0.15 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.657 2.238 . . . . 0.0 112.547 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.297 -0.859 . . . . 0.0 109.875 -179.158 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.482 1.138 0 CA-C-O 120.794 0.331 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 101.81 112.81 3.62 Favored Glycine 0 N--CA 1.443 -0.851 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -175.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.413 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.4 pt -92.12 177.48 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.328 0.585 . . . . 0.0 111.314 -171.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -103.08 86.63 2.73 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.304 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.499 HG23 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -145.0 -179.87 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.674 -173.41 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.499 ' H ' HG23 ' A' ' 5' ' ' VAL . 19.7 m-20 -132.58 106.74 8.0 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.916 0.389 . . . . 0.0 109.955 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -91.78 136.93 32.77 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.398 0.618 . . . . 0.0 111.309 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -83.86 -19.8 34.24 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 168.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.7 p-80 -170.89 167.3 7.49 Favored 'General case' 0 N--CA 1.461 0.083 0 CA-C-N 115.111 -0.95 . . . . 0.0 110.442 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.7 p -65.61 -40.4 92.58 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -176.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.85 -32.96 59.52 Favored Glycine 0 CA--C 1.52 0.376 0 CA-C-N 116.247 -0.433 . . . . 0.0 114.172 -175.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -90.4 -1.39 57.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.251 0.525 . . . . 0.0 111.287 -177.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 48.1 t -74.69 -23.12 58.57 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.656 0.741 . . . . 0.0 110.0 -178.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -60.01 -42.57 94.61 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.211 -179.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 75.9 tttt -56.09 -61.57 6.27 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.806 -176.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -78.51 -33.52 1.77 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 121.527 1.485 . . . . 0.0 113.965 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 6.0 t -74.91 -25.26 58.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.011 0.434 . . . . 0.0 110.734 -173.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -75.07 -35.61 61.82 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.039 0.447 . . . . 0.0 110.046 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -71.74 -25.8 62.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.981 177.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.15 -52.64 53.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.173 175.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.5 3.66 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.334 -0.936 . . . . 0.0 113.532 178.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -103.53 -178.74 3.75 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.346 0.573 . . . . 0.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -100.07 -56.61 2.33 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.353 -174.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.501 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.8 OUTLIER -107.25 -159.26 0.69 Allowed 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.698 -175.895 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.58 136.68 3.44 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.491 179.075 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -127.29 167.0 16.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.744 0.307 . . . . 0.0 110.352 177.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.8 t -110.1 100.13 9.1 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.511 HG23 ' N ' ' A' ' 29' ' ' ASN . 2.4 mp -95.78 -92.83 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.646 -172.427 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.511 ' N ' HG23 ' A' ' 28' ' ' ILE . 1.4 m120 -93.36 45.06 1.15 Allowed 'General case' 0 CA--C 1.505 -0.755 0 CA-C-O 121.88 0.848 . . . . 0.0 109.899 174.657 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.9 6.37 72.77 Favored Glycine 0 C--N 1.314 -0.654 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.282 -171.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.402 ' HD3' ' C ' ' A' ' 31' ' ' LYS . 0.0 OUTLIER -112.84 159.1 19.36 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.714 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.466 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 1.4 m -93.82 92.59 7.51 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.328 -176.244 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.505 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 19.3 t70 -86.92 124.24 32.91 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 167.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.438 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 7.5 m -135.11 158.47 44.27 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 121.056 -0.258 . . . . 0.0 110.846 -171.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.501 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 33.0 m -96.22 128.74 35.77 Favored Pre-proline 0 N--CA 1.446 -0.632 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 175.702 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -82.23 -160.03 0.12 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.572 2.181 . . . . 0.0 112.308 -178.016 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.206 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.863 0.363 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 121.14 126.35 3.29 Favored Glycine 0 N--CA 1.443 -0.891 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.226 -174.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -104.04 -178.01 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.329 0.585 . . . . 0.0 111.533 -173.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -105.3 109.07 20.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.893 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.5 HG23 ' H ' ' A' ' 6' ' ' ASP . 1.4 p -163.03 -178.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -173.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.5 ' H ' HG23 ' A' ' 5' ' ' VAL . 10.5 m-20 -127.74 110.47 12.66 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.535 ' HA ' ' OE1' ' A' ' 12' ' ' GLN . 2.0 p -91.04 123.91 34.86 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.415 0.626 . . . . 0.0 111.702 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -74.98 -25.48 58.87 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 167.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 28.4 p-80 -177.38 163.26 1.99 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.734 177.303 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.4 p -63.48 -36.35 83.47 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -175.561 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.49 -39.32 65.48 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.176 -0.535 . . . . 0.0 113.067 -178.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.535 ' OE1' ' HA ' ' A' ' 7' ' ' CYS . 0.0 OUTLIER -90.55 -0.12 57.56 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 122.66 -0.317 . . . . 0.0 110.959 -177.718 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.625 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 32.6 t -76.02 -22.07 56.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.587 0.708 . . . . 0.0 109.625 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.413 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 10.9 mp -57.43 -43.01 83.5 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.792 -1.095 . . . . 0.0 111.065 177.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -59.51 -61.05 8.63 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 115.597 -0.728 . . . . 0.0 112.843 -174.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.68 -31.34 13.37 Favored 'Trans proline' 0 C--N 1.354 0.823 0 C-N-CA 121.453 1.435 . . . . 0.0 112.622 -175.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 8.8 t -77.63 -23.46 49.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.173 -176.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 22' ' ' MET . 27.2 ttpp -68.35 -38.46 81.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 175.143 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -68.71 -28.25 66.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.504 176.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.0 -10.94 59.84 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.866 177.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.0 -26.12 6.56 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.501 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.585 ' O ' ' HA ' ' A' ' 18' ' ' LYS . 1.9 mpt? -83.47 175.98 9.4 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 117.261 0.531 . . . . 0.0 111.391 -174.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.7 mtm180 -94.29 -61.43 1.52 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.566 -175.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.56 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -121.81 158.57 28.58 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.044 -176.4 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.625 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -133.86 157.55 22.87 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.524 -177.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 52.8 tptt -127.18 157.57 39.41 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 176.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.4 t -104.61 97.87 7.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.602 . . . . 0.0 109.875 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.648 HG23 ' N ' ' A' ' 29' ' ' ASN . 3.5 mp -90.06 -110.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.738 -175.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.648 ' N ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.53 47.11 1.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 121.628 -0.67 . . . . 0.0 110.391 179.367 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 79.42 19.83 70.65 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -172.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.426 ' HE2' ' HA3' ' A' ' 2' ' ' GLY . 32.1 tttt -120.1 138.53 53.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.929 -0.635 . . . . 0.0 109.536 -179.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.452 ' SG ' HG11 ' A' ' 5' ' ' VAL . 1.3 m -87.56 83.02 7.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.718 173.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.553 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 16.3 t70 -79.13 124.43 28.31 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 168.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.56 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.7 m -124.11 178.17 5.45 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.105 0.479 . . . . 0.0 112.069 -167.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.434 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 95.2 m -125.12 125.53 25.28 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 170.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.401 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 86.1 Cg_endo -82.51 -159.64 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.745 2.297 . . . . 0.0 112.199 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 11.3 mptt . . . . . 0 C--O 1.247 0.949 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.322 177.713 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.435 0.16 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.564 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 97.38 138.9 10.37 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -174.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 10.1 pt -109.51 176.76 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-O 121.362 0.601 . . . . 0.0 111.872 -170.096 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -100.74 100.23 10.88 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.858 178.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.44 HG12 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -162.92 179.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -174.281 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.44 ' N ' HG12 ' A' ' 5' ' ' VAL . 6.4 m-20 -128.02 112.82 15.05 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.032 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.655 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.2 p -88.8 129.76 35.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.608 0.718 . . . . 0.0 111.663 -177.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -87.15 -15.08 39.45 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 167.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.469 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 26.7 p-80 178.41 158.15 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.493 178.071 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.5 p -58.32 -35.45 71.9 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 111.648 -175.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.78 -32.64 70.31 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 115.99 -0.55 . . . . 0.0 113.641 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.83 7.78 38.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.576 0.688 . . . . 0.0 111.446 -177.486 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 74.8 m -82.05 -15.6 53.02 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.143 176.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.85 -56.59 19.34 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.186 -171.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -57.12 -54.15 57.69 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.55 -27.58 39.04 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 121.265 1.31 . . . . 0.0 112.557 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.417 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.6 t -73.01 -33.95 66.09 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.26 0.552 . . . . 0.0 110.209 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -73.13 -39.16 65.97 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.914 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.2 ttmm -69.17 -28.85 66.78 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.916 176.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.06 -43.54 78.4 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.891 175.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 125.72 15.04 3.0 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.849 176.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.518 ' SD ' ' HB2' ' A' ' 34' ' ' CYS . 60.9 mtt -116.13 -179.17 3.59 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 122.649 -0.324 . . . . 0.0 110.611 -178.164 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtm180 -92.77 -79.1 0.4 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.046 -170.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.504 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -107.17 158.9 16.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -175.584 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.98 137.15 9.21 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.328 -176.015 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -117.73 154.16 32.17 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.1 t -96.77 107.74 20.27 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.251 0.548 . . . . 0.0 110.354 -176.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.608 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 1.9 mp -94.49 -169.97 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 179.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.608 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 9.8 p30 -39.67 -43.17 1.32 Allowed 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 118.889 0.768 . . . . 0.0 112.244 -174.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 6' ' ' ASP . . . -152.41 2.63 0.33 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.201 -1.0 . . . . 0.0 112.305 172.68 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.25 152.01 40.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.997 0.427 . . . . 0.0 111.807 -169.548 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.655 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 65.2 m -91.59 92.91 8.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.509 176.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.564 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 22.3 t70 -80.82 135.94 36.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.605 175.228 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.518 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 81.1 m -123.84 157.51 33.99 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.268 -0.424 . . . . 0.0 112.121 -169.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.3 m -103.27 128.57 27.27 Favored Pre-proline 0 N--CA 1.442 -0.857 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 169.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -83.51 -163.63 0.22 Allowed 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.339 2.026 . . . . 0.0 112.167 -175.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm . . . . . 0 C--O 1.246 0.87 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.14 179.805 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.477 0.913 0 CA-C-O 120.928 0.394 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 111.93 106.13 2.84 Favored Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -176.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.1 pt -89.87 178.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.413 0.625 . . . . 0.0 111.639 -170.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -103.86 105.84 16.17 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.652 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.54 HG23 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -157.98 -175.91 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.364 -172.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.54 ' H ' HG23 ' A' ' 5' ' ' VAL . 4.9 m-20 -132.92 106.1 7.49 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.253 0.549 . . . . 0.0 110.236 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -92.94 125.6 37.62 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.187 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.428 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 56.7 tptt -74.88 -22.14 58.82 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 167.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 13.5 p-80 -171.74 163.7 6.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 114.636 -1.165 . . . . 0.0 109.794 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 p -66.35 -33.4 75.65 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.787 0.291 . . . . 0.0 111.787 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.14 -34.38 62.39 Favored Glycine 0 CA--C 1.519 0.308 0 C-N-CA 121.273 -0.489 . . . . 0.0 113.353 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.428 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 6.5 pt20 -90.7 -1.73 57.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.836 0.351 . . . . 0.0 110.63 -177.389 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.1 t -79.86 -16.72 54.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.412 0.625 . . . . 0.0 110.258 -173.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.417 HD11 ' N ' ' A' ' 14' ' ' LEU . 9.6 mp -64.96 -48.74 72.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.864 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.448 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 73.2 tttt -53.81 -57.52 17.26 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -174.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.448 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.7 Cg_endo -67.97 -29.57 34.03 Favored 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 121.81 1.674 . . . . 0.0 112.397 -175.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 2.2 m -78.32 -29.07 47.49 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.46 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 13.7 tmtt? -67.59 -38.4 83.96 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.9 ttmm -68.01 -35.28 78.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.747 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.24 -12.99 60.72 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.28 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 108.23 14.21 17.23 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.783 -0.723 . . . . 0.0 113.358 175.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' MET . . . . . 0.504 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -104.32 179.67 4.2 Favored 'General case' 0 C--N 1.319 -0.738 0 O-C-N 122.333 -0.51 . . . . 0.0 110.758 178.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.45 -57.11 2.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.03 0.443 . . . . 0.0 111.658 -175.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.514 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.7 OUTLIER -105.5 -159.21 0.7 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.79 -174.681 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.638 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -170.6 133.14 2.69 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.271 -0.966 . . . . 0.0 112.9 178.371 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.49 147.09 50.31 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.9 t -96.7 112.02 23.94 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.837 0.351 . . . . 0.0 110.508 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.454 HG23 ' N ' ' A' ' 29' ' ' ASN . 7.0 mt -104.85 170.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.454 ' N ' HG23 ' A' ' 28' ' ' ILE . 9.2 p30 -45.09 -34.88 2.79 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -171.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.35 -1.76 1.03 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 119.365 -1.397 . . . . 0.0 113.931 174.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -124.02 153.7 40.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 118.184 0.992 . . . . 0.0 111.53 -172.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.5 OUTLIER -92.79 92.5 7.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 169.772 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -78.87 103.4 8.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.478 175.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.638 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 20.0 m -125.03 142.53 51.43 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.293 -174.422 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 41.2 m -88.42 129.83 47.87 Favored Pre-proline 0 N--CA 1.448 -0.574 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 90.2 Cg_endo -81.36 -158.73 0.1 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.798 2.332 . . . . 0.0 112.261 -177.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.498 -0.763 . . . . 0.0 110.771 -177.784 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.75 0.309 . . . . 0.0 110.769 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 114.46 130.8 5.04 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.4 pt -103.21 177.11 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-O 121.177 0.513 . . . . 0.0 111.658 -170.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -101.32 70.48 1.32 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.255 -175.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -131.44 179.53 4.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.324 -176.5 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.454 ' N ' HG13 ' A' ' 5' ' ' VAL . 7.2 p-10 -128.33 111.28 13.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.56 0.695 . . . . 0.0 109.966 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.454 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.8 p -92.9 132.07 37.36 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.969 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 mtmt -87.6 -18.45 29.64 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 163.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.463 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.2 p-80 -167.49 167.39 13.72 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.616 -1.175 . . . . 0.0 110.329 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.459 ' HB3' ' H ' ' A' ' 27' ' ' CYS . 4.9 p -72.27 -31.26 65.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -176.048 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.27 -27.87 66.04 Favored Glycine 0 CA--C 1.517 0.212 0 C-N-CA 121.11 -0.567 . . . . 0.0 113.408 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -89.0 3.65 50.94 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 122.597 -0.355 . . . . 0.0 110.721 -178.193 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 88.9 m -86.86 -16.12 37.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.829 0.347 . . . . 0.0 110.483 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.9 mt -62.67 -62.78 1.5 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.913 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.485 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 54.5 tttm -55.23 -58.44 15.04 Favored Pre-proline 0 N--CA 1.446 -0.633 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 37.2 Cg_endo -66.5 -28.1 45.94 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 121.403 1.402 . . . . 0.0 112.922 -173.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 4.2 t -82.76 -26.65 31.69 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.19 0.519 . . . . 0.0 109.897 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -72.33 -36.31 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.8 tptm -72.14 -32.7 67.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.825 173.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.8 -48.1 80.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.586 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 144.95 8.78 0.35 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.887 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.433 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.78 178.36 4.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.71 0.255 . . . . 0.0 110.326 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.6 mtm180 -96.84 -54.18 3.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.864 0.364 . . . . 0.0 111.241 -173.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.456 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -112.48 -153.15 0.52 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.886 -176.633 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.35 139.06 3.18 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.725 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -133.03 151.47 52.05 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 177.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.459 ' H ' ' HB3' ' A' ' 10' ' ' SER . 42.6 t -88.01 131.87 34.48 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.632 HG22 ' N ' ' A' ' 29' ' ' ASN . 6.4 mt -122.89 -112.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.207 -177.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.632 ' N ' HG22 ' A' ' 28' ' ' ILE . 15.6 p30 -92.22 46.73 1.27 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.417 0.627 . . . . 0.0 110.586 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.28 -5.71 65.54 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.662 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -109.1 154.57 22.09 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 120.729 0.299 . . . . 0.0 110.262 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.454 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 35.9 m -96.73 90.55 5.32 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.807 172.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -86.0 135.13 33.77 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.857 175.276 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 3.2 m -135.39 178.62 6.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.893 0.378 . . . . 0.0 111.063 -170.374 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.456 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 57.9 m -113.64 127.42 26.84 Favored Pre-proline 0 N--CA 1.443 -0.787 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 171.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -84.87 -161.37 0.13 Allowed 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.894 2.396 . . . . 0.0 112.102 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.585 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.947 0 CA-C-O 118.595 -0.716 . . . . 0.0 110.035 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.9 m . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.655 0.264 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.624 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 110.96 109.51 3.14 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.903 178.055 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.526 HG12 ' CB ' ' A' ' 32' ' ' CYS . 1.1 pt -98.24 175.66 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.666 0.27 . . . . 0.0 110.314 -177.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -103.76 109.63 21.42 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.614 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.7 p -156.53 -175.95 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -172.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.614 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.1 m-20 -127.77 97.28 4.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.449 0.642 . . . . 0.0 111.041 -176.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 5.8 p -94.36 134.18 37.14 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.223 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -88.93 -14.64 36.24 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 166.007 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -171.34 161.66 6.54 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 114.643 -1.162 . . . . 0.0 110.445 174.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.5 p -58.61 -40.44 83.3 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -176.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.61 -41.69 50.24 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 114.112 0.405 . . . . 0.0 114.112 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -83.52 -2.72 56.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.031 0.415 . . . . 0.0 111.467 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.29 -11.95 57.19 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.233 0.54 . . . . 0.0 110.159 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.8 mp -63.44 -42.88 98.67 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.55 -178.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -56.8 -58.33 18.17 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.339 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.69 -24.04 22.16 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 121.47 1.447 . . . . 0.0 112.062 -178.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 46.3 t -69.33 -38.96 78.42 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 178.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -71.47 -35.18 70.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.42 178.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.3 tmtm? -61.6 -38.12 86.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.289 -0.868 . . . . 0.0 109.539 175.24 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.15 -44.1 76.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.54 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.25 8.14 0.75 Allowed Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.912 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.46 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 4.2 mpp? -108.1 -173.83 2.38 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 117.594 0.697 . . . . 0.0 111.208 -179.054 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 64.1 mtm180 -93.21 -60.69 1.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.451 -174.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.497 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -130.75 161.14 32.37 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.567 -176.279 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.501 ' HA2' ' HA ' ' A' ' 34' ' ' CYS . . . -131.22 140.02 11.43 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.858 -175.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -101.55 170.08 8.42 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 173.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.7 t -107.56 107.85 18.88 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.187 0.518 . . . . 0.0 111.187 -176.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.571 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.2 mt -104.56 162.27 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.405 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.19 -38.57 0.78 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.09 13.68 1.29 Allowed Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.054 175.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.9 148.82 45.01 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 120.961 0.41 . . . . 0.0 110.618 -173.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.624 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -94.55 87.92 5.27 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 167.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.571 ' HB2' HD12 ' A' ' 28' ' ' ILE . 32.1 t70 -74.52 96.73 2.98 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 122.019 0.914 . . . . 0.0 109.38 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.501 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 69.7 m -86.45 167.85 14.31 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.12 -1.4 . . . . 0.0 112.968 -171.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.497 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 30.4 m -129.23 119.92 19.83 Favored Pre-proline 0 N--CA 1.434 -1.264 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 168.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.46 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 72.0 Cg_endo -84.4 -157.98 0.09 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.303 0 C-N-CA 122.16 1.907 . . . . 0.0 111.609 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.679 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.776 -0.63 . . . . 0.0 110.601 -179.522 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.653 0.263 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 103.84 104.65 2.92 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.886 -0.674 . . . . 0.0 111.769 -179.078 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.7 pt -91.88 178.51 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.698 0.285 . . . . 0.0 110.452 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -104.24 110.79 23.14 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 177.121 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.6 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -160.82 -178.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -173.449 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.6 ' H ' HG22 ' A' ' 5' ' ' VAL . 26.3 m-20 -128.6 107.77 9.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.366 0.603 . . . . 0.0 110.069 -178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 p -91.63 135.69 33.69 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.204 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -82.8 -20.72 35.22 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.413 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 22.3 p-80 -177.93 159.06 1.32 Allowed 'General case' 0 CA--C 1.522 -0.114 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.272 175.267 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 p -52.72 -44.88 66.65 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -54.49 -34.32 54.89 Favored Glycine 0 C--O 1.228 -0.273 0 CA-C-N 115.908 -0.587 . . . . 0.0 114.002 -177.254 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -91.48 3.12 55.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 117.744 0.772 . . . . 0.0 111.99 -177.432 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -84.09 -2.51 56.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.62 0.724 . . . . 0.0 109.543 -177.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 72.3 mt -61.09 -55.93 26.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.829 -1.078 . . . . 0.0 111.404 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -52.03 -54.86 36.24 Favored Pre-proline 0 CA--C 1.542 0.664 0 N-CA-C 113.341 0.867 . . . . 0.0 113.341 -172.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.18 -31.58 22.81 Favored 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 121.276 1.318 . . . . 0.0 112.406 -176.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.546 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 7.8 t -81.59 -22.09 37.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.21 0.528 . . . . 0.0 110.198 -178.279 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -65.41 -38.79 90.99 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 174.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -62.3 -43.94 97.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.98 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.35 -40.45 90.75 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.759 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 129.22 17.51 1.78 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.969 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.546 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -109.8 -178.02 3.42 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.748 179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.3 mtm180 -103.8 -63.58 1.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.891 0.377 . . . . 0.0 111.589 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.442 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.61 157.43 25.36 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 -177.411 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.9 144.47 16.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.988 -174.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttp -110.12 167.55 10.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 110.229 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 36.3 t -108.54 110.72 22.27 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.437 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.469 HG22 ' N ' ' A' ' 29' ' ' ASN . 10.1 mt -117.15 176.03 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.469 ' N ' HG22 ' A' ' 28' ' ' ILE . 9.6 p30 -38.4 -43.97 0.87 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -169.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -155.83 17.07 0.47 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.784 173.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.403 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -124.54 148.85 47.52 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.665 -175.528 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.63 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -92.83 89.17 6.49 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 173.041 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -77.12 107.69 9.67 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.615 0.721 . . . . 0.0 109.388 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.9 m -111.06 171.49 7.44 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.841 -171.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.44 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 75.4 m -122.18 122.9 27.39 Favored Pre-proline 0 N--CA 1.436 -1.13 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 168.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.516 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 95.8 Cg_endo -84.55 -162.95 0.17 Allowed 'Trans proline' 0 N--CA 1.445 -1.332 0 C-N-CA 122.197 1.931 . . . . 0.0 112.474 -177.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.723 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.03 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 120.624 0.249 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.87 127.24 5.85 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -174.51 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.4 pt -100.74 172.71 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.419 0.628 . . . . 0.0 111.732 -169.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -102.64 95.29 6.12 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.815 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -155.67 -177.39 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.948 -0.569 . . . . 0.0 109.734 -172.799 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.484 ' N ' HG13 ' A' ' 5' ' ' VAL . 16.4 m-20 -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.817 0.341 . . . . 0.0 110.42 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 2.4 p -92.83 128.97 38.88 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LYS . . . . . 0.454 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 62.5 tttm -81.73 -19.53 41.24 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 167.747 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.456 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 6.5 p-80 -166.28 151.19 8.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.804 -177.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 t -74.3 73.8 1.83 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.68 177.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.14 -28.84 0.03 OUTLIER Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.105 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.456 ' HB3' ' NE2' ' A' ' 9' ' ' HIS . 9.8 pt20 -87.98 3.39 48.91 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 121.142 -0.223 . . . . 0.0 111.146 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.591 ' O ' ' HB2' ' A' ' 17' ' ' CYS . 73.5 m -77.17 -11.52 59.83 Favored 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.355 -175.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.4 mt -62.19 -54.52 39.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.844 -0.617 . . . . 0.0 111.846 -174.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -53.51 -54.92 40.35 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.403 -178.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.95 -23.62 25.16 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 121.786 1.657 . . . . 0.0 112.538 178.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.591 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 19.4 t -69.72 -35.53 75.12 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.447 0.641 . . . . 0.0 109.629 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -70.47 -30.66 67.54 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.924 177.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 52.9 tttm -68.56 -41.43 79.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.705 173.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.42 -40.38 93.29 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.741 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 119.76 17.6 4.62 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.479 177.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.551 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 61.3 mtt -116.12 177.68 4.59 Favored 'General case' 0 C--N 1.32 -0.699 0 O-C-N 122.6 -0.353 . . . . 0.0 110.432 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 -91.76 -74.09 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 120.458 -0.497 . . . . 0.0 111.983 -169.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.507 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -110.23 158.95 17.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.886 -174.988 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.7 161.41 22.88 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.46 -175.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 0.4 OUTLIER -145.83 144.84 30.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -177.21 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 39.2 t -89.05 121.45 31.4 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.413 -178.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 6.5 mt -114.96 167.69 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -67.2 53.1 0.05 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -175.015 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 155.1 -36.77 0.65 Allowed Glycine 0 N--CA 1.438 -1.176 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.309 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -124.45 174.1 8.0 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 117.505 0.652 . . . . 0.0 111.663 -172.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -108.08 98.16 7.76 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 166.259 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.522 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.7 t70 -76.19 117.85 18.31 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.592 0.711 . . . . 0.0 110.367 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.421 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 48.3 m -106.83 160.68 15.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.443 -175.318 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.507 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 48.2 m -112.24 125.75 29.6 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 169.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -79.9 -159.83 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.673 2.249 . . . . 0.0 111.688 -176.07 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.3 mptt . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.705 -0.664 . . . . 0.0 109.794 178.977 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 121.015 0.436 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 107.77 114.66 3.84 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.862 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.476 HG12 ' HB2' ' A' ' 32' ' ' CYS . 10.3 pt -100.51 -179.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.126 0.489 . . . . 0.0 111.155 -173.261 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -108.16 118.51 36.94 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.373 -0.83 . . . . 0.0 108.993 175.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.4 p -167.32 -174.97 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -172.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.567 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.3 p-10 -126.94 110.88 13.48 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.673 0.749 . . . . 0.0 110.395 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -92.84 127.45 38.36 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.476 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -73.97 -25.88 60.17 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 165.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -174.75 163.76 3.47 Favored 'General case' 0 C--O 1.226 -0.165 0 CA-C-N 114.511 -1.222 . . . . 0.0 109.459 -179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 p -59.21 -37.07 76.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.692 0.282 . . . . 0.0 111.72 -177.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.56 -33.45 66.85 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 116.269 -0.423 . . . . 0.0 114.065 -176.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 6.34 44.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.413 0.607 . . . . 0.0 111.185 -178.08 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.542 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 46.0 t -84.47 -15.25 46.71 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.253 0.549 . . . . 0.0 109.744 179.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.8 mt -58.18 -50.76 72.39 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.816 -175.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.456 ' NZ ' ' HB2' ' A' ' 15' ' ' LYS . 3.5 ttmp? -59.96 -56.25 37.46 Favored Pre-proline 0 N--CA 1.445 -0.709 0 CA-C-N 115.453 -0.794 . . . . 0.0 113.063 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.8 -26.17 32.66 Favored 'Trans proline' 0 C--N 1.356 0.934 0 C-N-CA 121.024 1.149 . . . . 0.0 111.45 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 42.0 t -68.07 -37.02 80.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.783 175.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.407 ' HB2' ' NZ ' ' A' ' 18' ' ' LYS . 2.7 ttmp? -68.64 -39.94 80.51 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.733 176.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -59.16 -33.14 70.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.231 175.295 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.08 -36.85 55.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.739 177.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.06 2.18 5.18 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.354 -0.926 . . . . 0.0 114.29 172.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.558 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.0 mpp? -96.03 -169.01 1.85 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 117.705 0.753 . . . . 0.0 111.051 -177.081 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 -99.87 -59.61 1.68 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.02 0.438 . . . . 0.0 111.45 -175.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.455 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -128.99 158.98 37.33 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.345 -175.973 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.542 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -135.27 155.02 21.89 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.813 -177.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -117.86 166.73 12.12 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 48.7 t -103.81 106.29 16.75 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.913 -178.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 29' ' ' ASN . 12.8 mt -116.03 171.71 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.463 ' N ' HG22 ' A' ' 28' ' ' ILE . 17.4 p30 -58.48 65.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.493 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 95.94 6.41 59.22 Favored Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 31.1 ttmt -123.73 133.57 53.84 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -176.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.3 OUTLIER -97.07 87.78 4.31 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 172.434 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.86 113.08 15.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.49 0.662 . . . . 0.0 109.566 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.471 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 99.0 m -101.66 173.42 6.43 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.17 -172.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.455 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 87.9 m -126.09 124.97 24.7 Favored Pre-proline 0 N--CA 1.44 -0.958 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 168.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.92 -156.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 122.744 2.296 . . . . 0.0 111.868 -176.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 5.5 mptp? . . . . . 0 C--O 1.247 0.954 0 CA-C-O 118.603 -0.713 . . . . 0.0 110.672 178.265 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 34' ' ' CYS . 76.3 t . . . . . 0 N--CA 1.479 1.016 0 CA-C-O 120.813 0.34 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.564 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 102.53 97.97 2.4 Favored Glycine 0 N--CA 1.443 -0.893 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.183 179.05 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.559 HG12 ' CB ' ' A' ' 32' ' ' CYS . 2.1 pt -94.77 -179.55 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -106.49 106.45 16.97 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.628 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.6 p -154.0 -177.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -172.25 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 5' ' ' VAL . 12.0 m-20 -128.92 102.97 6.76 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 120.96 0.41 . . . . 0.0 110.787 -178.256 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.1 p -94.33 131.36 40.04 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.345 176.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -85.26 -18.0 35.29 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 165.231 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.436 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 8.6 p-80 -167.68 162.63 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.775 -176.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.3 p -66.88 -37.73 84.97 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -174.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.71 -26.28 59.92 Favored Glycine 0 CA--C 1.519 0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 113.897 -174.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.436 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 17.5 pt20 -88.39 -4.67 58.61 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 117.384 0.592 . . . . 0.0 110.908 -177.435 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -88.42 -2.36 58.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.534 0.683 . . . . 0.0 109.85 -175.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.3 mt -62.58 -57.16 12.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.169 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.459 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.2 tmmm? -50.76 -57.86 12.06 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 114.695 -1.138 . . . . 0.0 112.811 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.541 ' HB2' HD11 ' A' ' 3' ' ' ILE . 37.1 Cg_endo -64.94 -33.55 51.43 Favored 'Trans proline' 0 C--N 1.352 0.724 0 C-N-CA 121.628 1.552 . . . . 0.0 113.356 -173.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -83.5 -21.72 32.72 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.084 0.468 . . . . 0.0 110.463 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -72.78 -36.26 67.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -68.15 -36.32 79.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.783 173.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.69 -45.94 84.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.442 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.89 21.23 0.56 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.842 176.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.468 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 2.1 mpt? -109.7 -175.42 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 O-C-N 122.669 -0.312 . . . . 0.0 110.493 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.0 mtm180 -96.37 -61.44 1.43 Allowed 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.183 -0.607 . . . . 0.0 111.958 -176.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -108.06 -158.11 0.64 Allowed 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.074 -173.42 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.21 141.63 6.93 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.328 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -130.36 166.9 19.45 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 177.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.4 t -107.15 110.68 22.82 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.959 -175.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.432 HD12 ' HB2' ' A' ' 33' ' ' ASP . 8.3 mt -113.37 171.46 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 174.559 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.409 ' N ' HG22 ' A' ' 28' ' ' ILE . 12.6 m-80 -38.6 -53.71 1.59 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.908 0.483 . . . . 0.0 111.869 -171.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.71 21.82 2.17 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 173.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.413 ' O ' ' HB ' ' A' ' 28' ' ' ILE . 30.1 ttmt -122.67 132.79 54.43 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 110.305 -0.258 . . . . 0.0 110.305 -171.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.564 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.4 t -87.84 90.52 8.41 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.432 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.3 t70 -77.13 104.81 7.84 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.465 0.65 . . . . 0.0 109.753 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.44 ' O ' HG13 ' A' ' 1' ' ' VAL . 4.3 p -128.47 141.11 51.49 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.253 -173.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 38.4 m -92.91 127.87 45.86 Favored Pre-proline 0 N--CA 1.441 -0.915 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 46.4 Cg_endo -84.03 -154.09 0.05 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 122.521 2.147 . . . . 0.0 111.714 -176.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.457 ' HD2' ' N ' ' A' ' 37' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.567 178.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.612 HG21 ' O ' ' A' ' 34' ' ' CYS . 27.2 m . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.847 0.356 . . . . 0.0 110.306 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 100.65 118.11 4.23 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -176.157 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.8 pt -102.55 170.61 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.43 0.634 . . . . 0.0 111.082 -174.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -104.79 92.09 4.11 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.255 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.439 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.7 OUTLIER -147.69 -179.2 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.498 -173.385 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.9 m-20 -128.4 102.69 6.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.163 0.506 . . . . 0.0 110.298 -178.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.589 ' HA ' ' NE2' ' A' ' 12' ' ' GLN . 1.9 p -92.91 133.57 35.97 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.337 -176.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -84.68 -21.84 30.03 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 164.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.464 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 14.1 p-80 -168.63 163.99 12.23 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.759 -176.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.6 p -65.09 -41.4 95.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.724 0.297 . . . . 0.0 111.577 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.416 ' O ' HD23 ' A' ' 14' ' ' LEU . . . -59.85 -18.27 46.03 Favored Glycine 0 C--O 1.228 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 114.61 -172.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.589 ' NE2' ' HA ' ' A' ' 7' ' ' CYS . 9.7 pt20 -89.12 -17.48 29.14 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 117.73 0.765 . . . . 0.0 110.634 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.4 m -90.83 24.39 2.75 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-O 121.009 0.433 . . . . 0.0 111.432 -175.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 11' ' ' GLY . 4.1 mm? -82.65 -41.58 19.24 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 169.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.5 ttpt -62.31 -58.25 18.44 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.599 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.87 -27.05 21.65 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.318 1.345 . . . . 0.0 112.17 -177.501 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 40.7 t -74.12 -30.94 62.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.374 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 11.3 tppt? -67.86 -36.92 81.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 177.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.4 tttp -73.56 -28.86 62.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.903 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.49 -36.82 85.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.34 176.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.63 10.79 5.26 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.95 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.547 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.2 mpt? -107.88 -175.4 2.77 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.576 -0.367 . . . . 0.0 110.344 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 -93.61 -62.48 1.35 Allowed 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.473 -0.491 . . . . 0.0 111.268 -177.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.504 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.8 160.27 22.94 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.978 -175.961 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.87 146.22 17.61 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.402 -176.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 61.6 mtpt -134.97 167.15 21.45 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.1 t -104.81 121.55 43.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.867 -174.493 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.486 HG22 ' N ' ' A' ' 29' ' ' ASN . 8.9 mt -117.41 178.5 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.816 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.486 ' N ' HG22 ' A' ' 28' ' ' ILE . 18.4 p30 -64.67 56.23 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -174.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 134.65 -23.03 3.62 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 121.354 -0.451 . . . . 0.0 112.661 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -123.06 169.16 11.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.832 0.316 . . . . 0.0 110.236 -173.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 5.2 m -114.39 100.79 8.59 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.538 0.685 . . . . 0.0 109.289 167.01 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.537 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.6 t70 -77.96 149.14 34.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.033 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.612 ' O ' HG21 ' A' ' 1' ' ' VAL . 98.4 m -137.43 160.16 39.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -170.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 89.0 m -116.28 123.12 31.15 Favored Pre-proline 0 N--CA 1.437 -1.076 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 167.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -79.72 -163.24 0.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.555 2.17 . . . . 0.0 112.215 -174.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.425 -0.798 . . . . 0.0 110.234 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.48 1.067 0 CA-C-O 120.55 0.214 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 104.8 130.52 6.83 Favored Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.514 HG13 ' H ' ' A' ' 5' ' ' VAL . 15.5 pt -108.48 178.72 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.187 0.518 . . . . 0.0 111.486 -171.555 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -105.04 37.8 2.09 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.001 -175.001 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.64 HG12 ' SG ' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -98.43 158.33 3.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.21 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -102.84 112.52 25.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.922 0.391 . . . . 0.0 110.407 -174.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.633 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 6.0 p -91.5 131.94 36.61 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.9 mmtp -82.03 -19.58 40.09 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 164.806 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 -170.2 164.7 9.11 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.093 177.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.0 p -57.99 -38.94 77.05 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.887 0.375 . . . . 0.0 111.568 -176.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.58 -36.56 54.43 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.771 -176.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -91.71 14.6 14.8 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.265 0.533 . . . . 0.0 112.415 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.633 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 58.6 m -90.13 -21.89 22.03 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 171.303 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.6 -46.8 83.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.223 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.4 ttpp -62.24 -58.61 16.49 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -176.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' CG ' HG11 ' A' ' 5' ' ' VAL . 32.8 Cg_endo -69.92 -29.1 23.64 Favored 'Trans proline' 0 C--N 1.354 0.844 0 C-N-CA 121.237 1.291 . . . . 0.0 112.695 -177.459 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 13.9 m -74.06 -27.15 60.77 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 120.748 0.309 . . . . 0.0 110.801 176.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -70.69 -37.66 73.61 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.8 ttpp -67.93 -32.75 73.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.577 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.66 -46.79 71.38 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.019 176.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.85 14.15 1.9 Allowed Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.69 -0.687 . . . . 0.0 112.914 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -99.89 173.89 6.46 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.108 0.454 . . . . 0.0 111.002 -178.062 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -94.78 -53.56 3.81 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.961 0.41 . . . . 0.0 111.859 -170.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.48 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -110.19 -157.29 0.61 Allowed 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.044 -175.447 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.689 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.0 132.04 2.26 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.575 -0.822 . . . . 0.0 112.921 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -131.89 152.43 51.06 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 35.7 t -95.52 119.16 33.54 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.118 0.485 . . . . 0.0 110.806 -174.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.465 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.6 mt -109.49 164.0 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.171 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.466 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.95 -38.69 1.01 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -145.53 11.25 1.73 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.067 175.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.415 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 61.2 mttm -123.9 146.63 48.3 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 -174.208 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.64 ' SG ' HG12 ' A' ' 5' ' ' VAL . 5.7 m -96.8 89.66 4.98 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 163.065 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.465 ' HB2' HD12 ' A' ' 28' ' ' ILE . 18.5 t70 -77.99 115.19 17.54 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.747 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.689 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 35.1 m -132.86 141.27 48.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.868 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.48 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 34.9 m -91.84 132.4 33.02 Favored Pre-proline 0 N--CA 1.447 -0.588 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -176.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -81.21 -159.7 0.11 Allowed 'Trans proline' 0 N--CA 1.46 -0.444 0 C-N-CA 123.13 2.553 . . . . 0.0 112.166 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 mptt . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.352 178.502 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.479 1.004 0 CA-C-O 120.638 0.256 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.533 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 98.35 126.24 5.48 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.182 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.7 pt -106.42 177.81 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.049 0.452 . . . . 0.0 111.35 -172.254 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -101.17 94.91 6.21 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.284 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.482 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -156.97 -179.1 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -175.773 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.482 ' N ' HG13 ' A' ' 5' ' ' VAL . 5.6 m-20 -137.15 110.99 8.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.448 0.642 . . . . 0.0 110.479 177.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 7.3 p -93.01 140.36 29.56 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.186 -178.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -85.32 -21.75 28.8 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 164.093 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.579 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 10.0 p-80 -164.45 162.67 22.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.893 -176.339 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 12.7 p -68.51 -32.17 71.95 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -175.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.05 -28.75 64.27 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.506 -176.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.579 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 21.1 pt20 -84.94 -11.08 56.32 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.894 0.347 . . . . 0.0 111.04 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -72.3 -23.99 61.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.816 0.341 . . . . 0.0 110.212 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 -44.99 80.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.099 -174.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.522 ' HA ' ' HE3' ' A' ' 15' ' ' LYS . 1.1 tpmt? -65.32 -59.04 10.5 Favored Pre-proline 0 N--CA 1.444 -0.736 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -176.319 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.86 -24.46 46.45 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.629 1.552 . . . . 0.0 112.505 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.688 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 45.6 t -74.81 -33.14 62.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.27 0.557 . . . . 0.0 110.219 176.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.8 tttp -71.51 -35.75 70.85 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.671 0.748 . . . . 0.0 109.403 177.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -70.43 -27.0 63.92 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.838 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.685 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 133.62 11.16 1.73 Allowed Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.716 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.688 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -108.96 -171.14 1.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 117.399 0.6 . . . . 0.0 110.784 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -97.75 -66.34 0.91 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.884 0.373 . . . . 0.0 111.537 -174.071 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.471 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.19 160.33 22.36 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.902 -176.567 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.0 141.25 12.38 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.353 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -117.14 156.58 27.39 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.2 t -97.24 115.78 28.24 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.06 0.457 . . . . 0.0 110.714 -175.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.414 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.7 mt -114.92 163.61 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -39.61 -42.39 1.17 Allowed 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 -172.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -141.46 12.21 2.73 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.025 175.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 21.4 mttm -124.94 140.47 52.89 Favored 'General case' 0 N--CA 1.445 -0.72 0 O-C-N 122.901 -0.176 . . . . 0.0 110.836 -175.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.2 m -92.11 82.31 5.05 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 160.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.533 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -76.84 128.81 35.28 Favored 'General case' 0 CA--C 1.514 -0.412 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.895 -176.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 77.7 m -109.31 171.99 7.12 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.115 -169.257 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.471 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.2 m -120.54 124.48 27.6 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 166.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -81.32 -161.07 0.14 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.446 2.097 . . . . 0.0 111.786 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.477 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 119.026 -0.512 . . . . 0.0 110.809 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.8 m . . . . . 0 N--CA 1.479 0.993 0 CA-C-O 121.066 0.46 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.604 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 117.37 113.11 2.65 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.365 -176.587 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.54 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -97.03 175.85 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.163 0.506 . . . . 0.0 111.076 -172.723 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -99.34 113.65 26.08 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.11 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.641 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.0 p -162.34 -177.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.641 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.6 m-20 -132.92 100.2 4.83 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.535 0.683 . . . . 0.0 110.795 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.5 p -93.91 141.78 28.12 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 114.777 -1.101 . . . . 0.0 111.477 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -90.13 -17.93 26.76 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 164.441 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.55 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 11.0 p-80 -172.7 155.07 3.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.935 -175.846 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.3 p -68.51 -21.7 64.57 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -174.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.0 -34.72 88.97 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.113 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.55 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -85.7 -4.5 59.18 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.897 0.379 . . . . 0.0 110.232 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.47 -10.94 58.82 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.258 0.551 . . . . 0.0 109.734 -172.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -62.31 -53.53 53.73 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.903 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.512 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 23.5 ttpp -50.52 -55.04 29.06 Favored Pre-proline 0 CA--C 1.541 0.625 0 CA-C-N 115.139 -0.937 . . . . 0.0 113.03 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.512 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.9 Cg_endo -72.63 -26.44 16.38 Favored 'Trans proline' 0 C--N 1.357 0.999 0 C-N-CA 121.397 1.398 . . . . 0.0 112.367 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 38.8 t -70.14 -34.2 72.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.229 0.538 . . . . 0.0 110.288 178.157 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -72.6 -31.93 65.56 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.333 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.5 tptt -67.63 -30.74 70.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.808 174.247 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.28 -43.41 28.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.162 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.46 8.06 2.06 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.181 -1.009 . . . . 0.0 114.057 174.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.609 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 3.9 mpp? -106.02 -178.42 3.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 117.765 0.782 . . . . 0.0 110.914 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.453 ' NE ' ' HA ' ' A' ' 37' ' ' LYS . 70.6 mtm180 -91.67 -63.59 1.23 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.885 0.374 . . . . 0.0 111.686 -176.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.452 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -118.04 157.87 26.02 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.361 -175.287 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.12 157.68 21.27 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.112 -177.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -128.91 153.69 47.26 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 21.0 t -92.54 109.62 21.03 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.011 0.434 . . . . 0.0 110.893 -173.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.543 HD12 ' HB2' ' A' ' 33' ' ' ASP . 5.1 mt -112.24 164.23 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 174.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -43.44 -37.64 2.46 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -173.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.23 17.91 1.04 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.002 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -123.48 147.07 47.56 Favored 'General case' 0 CA--C 1.513 -0.444 0 O-C-N 122.527 -0.396 . . . . 0.0 110.827 -176.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.604 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 6.4 t -96.77 87.45 4.32 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 166.298 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.543 ' HB2' HD12 ' A' ' 28' ' ' ILE . 20.5 t70 -75.62 95.42 3.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 122.062 0.934 . . . . 0.0 109.653 -176.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 68.7 m -92.5 175.71 6.73 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.522 -1.217 . . . . 0.0 113.129 -169.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.452 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 33.3 m -136.61 126.72 16.08 Favored Pre-proline 0 N--CA 1.439 -1.008 0 CA-C-N 114.541 -1.209 . . . . 0.0 107.89 168.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.421 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 83.0 Cg_endo -80.0 -158.44 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.301 2.001 . . . . 0.0 112.049 -179.244 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.589 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.101 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.443 177.343 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.479 1.012 0 CA-C-O 120.67 0.271 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 109.43 118.56 4.08 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.6 OUTLIER -104.9 175.03 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 117.001 0.401 . . . . 0.0 110.369 -176.418 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -106.62 107.38 18.37 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.2 p -155.64 -176.86 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.408 -170.744 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.9 m-20 -122.6 105.77 10.39 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -91.93 150.06 21.22 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-O 121.39 0.614 . . . . 0.0 111.174 178.339 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.9 mtpt -91.29 -33.9 15.15 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 115.003 -0.999 . . . . 0.0 108.843 170.484 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -149.11 166.24 29.36 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.304 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 t -82.34 64.31 6.93 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.831 175.64 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.676 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -177.38 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.065 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.98 9.59 5.24 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.956 0.408 . . . . 0.0 111.933 -178.433 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.1 t -85.45 13.65 6.49 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.9 0.857 . . . . 0.0 109.075 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.676 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 80.9 mt -60.47 -48.87 79.86 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.02 -178.825 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -54.55 -55.68 35.07 Favored Pre-proline 0 CA--C 1.541 0.596 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -175.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -71.64 -27.61 18.28 Favored 'Trans proline' 0 C--N 1.354 0.835 0 C-N-CA 121.177 1.252 . . . . 0.0 111.767 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 44.0 t -69.6 -34.28 73.9 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.018 178.109 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -72.17 -36.07 69.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.883 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -65.3 -32.44 74.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.714 176.21 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.13 -42.12 47.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.056 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 124.2 25.21 1.69 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.726 172.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -114.67 178.47 4.27 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.35 0.575 . . . . 0.0 111.072 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 73.8 mtm180 -83.61 -71.73 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 111.729 -173.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -115.29 159.11 21.43 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -175.45 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.62 124.79 3.76 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.577 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -100.57 168.33 9.78 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.928 0.394 . . . . 0.0 110.219 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 22.4 t -108.34 116.84 32.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.161 0.505 . . . . 0.0 110.895 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.512 HD12 ' HB2' ' A' ' 33' ' ' ASP . 9.0 mt -124.14 172.75 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 176.128 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.432 ' N ' HG22 ' A' ' 28' ' ' ILE . 48.1 p-10 -59.52 63.85 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -172.266 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 100.55 5.87 53.55 Favored Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 18.1 ttmm -122.68 129.66 52.07 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -173.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.567 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 7.1 t -89.85 89.97 7.98 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 172.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' HB2' HD12 ' A' ' 28' ' ' ILE . 7.1 t70 -77.35 105.0 8.19 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.665 0.745 . . . . 0.0 109.283 178.43 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 93.2 m -101.51 169.22 8.99 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.822 -1.081 . . . . 0.0 111.79 -175.089 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.512 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 59.6 m -115.52 125.2 29.03 Favored Pre-proline 0 N--CA 1.441 -0.906 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 167.445 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.55 -160.66 0.13 Allowed 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.555 2.17 . . . . 0.0 111.813 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.297 -0.859 . . . . 0.0 110.166 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.645 0.259 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.581 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 113.66 110.89 2.96 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.489 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.6 pt -87.22 178.05 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.082 0.468 . . . . 0.0 110.896 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -103.27 92.75 4.64 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.031 -177.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.555 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.1 p -145.4 -178.17 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.555 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.0 m-20 -131.48 101.52 5.55 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.339 0.59 . . . . 0.0 110.541 -176.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.427 ' HB2' ' O ' ' A' ' 9' ' ' HIS . 2.2 p -93.07 132.49 37.13 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.641 -178.358 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -90.13 -18.37 25.95 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 166.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 7.2 m80 -151.05 167.72 26.81 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.8 179.449 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 22.2 p -80.93 -21.6 40.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.876 0.369 . . . . 0.0 110.764 177.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.18 -39.55 72.17 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 121.203 -0.523 . . . . 0.0 112.746 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -79.62 2.9 20.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.995 0.426 . . . . 0.0 110.54 178.788 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 10' ' ' SER . 42.6 t -85.04 -16.33 41.07 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.583 0.706 . . . . 0.0 109.566 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.7 mt -65.04 -57.78 7.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.209 -178.117 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.7 tppp? -49.42 -53.97 34.99 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.129 -0.941 . . . . 0.0 113.493 -174.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.96 -27.87 20.21 Favored 'Trans proline' 0 C--N 1.355 0.911 0 C-N-CA 121.374 1.383 . . . . 0.0 112.873 -177.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 3.3 m -78.45 -25.78 46.0 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 120.819 0.343 . . . . 0.0 110.903 178.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.03 -23.65 55.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 173.27 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -72.83 -36.81 67.57 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.245 -0.888 . . . . 0.0 109.14 172.4 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.61 -49.96 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.789 178.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.36 20.22 0.57 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.1 177.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.498 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 1.8 mpt? -103.18 178.23 4.61 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 122.737 -0.272 . . . . 0.0 111.367 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.5 mtm180 -97.39 -57.87 2.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.206 0.526 . . . . 0.0 111.805 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.5 OUTLIER -105.88 -161.44 0.8 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.819 -174.195 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.746 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -160.41 138.21 5.41 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.481 178.113 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -132.23 143.97 50.3 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 t -95.78 112.59 24.28 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-O 120.929 0.395 . . . . 0.0 110.672 -174.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.478 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.9 mt -110.01 163.22 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 176.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -44.73 -36.99 3.44 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -172.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -142.73 12.25 2.42 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.855 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.429 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 97.9 mttt -123.84 158.21 32.38 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 117.231 0.516 . . . . 0.0 111.55 -175.327 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.581 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -105.6 88.47 2.84 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 162.786 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.478 ' HB2' HD12 ' A' ' 28' ' ' ILE . 21.2 t70 -77.64 90.28 3.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.739 0.781 . . . . 0.0 110.032 -178.41 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.746 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 34.9 m -111.28 142.54 43.37 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.75 -174.253 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 87.5 m -96.34 128.67 35.81 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.498 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 88.1 Cg_endo -83.81 -162.06 0.16 Allowed 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.55 2.167 . . . . 0.0 112.581 -177.433 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.411 -0.805 . . . . 0.0 110.367 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.629 0.252 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.78 124.87 5.41 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -178.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.2 pt -103.5 -174.37 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -177.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.438 ' O ' HG12 ' A' ' 5' ' ' VAL . 24.2 t-20 -87.68 -87.2 0.15 Allowed 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.256 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.508 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER 50.78 -172.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 124.05 0.844 . . . . 0.0 112.078 175.911 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.508 ' H ' HG22 ' A' ' 5' ' ' VAL . 3.6 p30 -141.07 115.55 9.48 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 174.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.1 p -93.53 130.54 39.36 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.373 0.606 . . . . 0.0 112.036 177.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -84.66 -21.43 30.22 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 163.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.451 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.7 p-80 -175.96 159.34 2.17 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.135 -177.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.9 p -67.5 -26.81 66.54 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -174.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.02 -34.49 79.31 Favored Glycine 0 CA--C 1.517 0.184 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.812 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.451 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 2.6 pt20 -90.66 5.56 47.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.029 0.443 . . . . 0.0 110.393 -178.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.582 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 42.2 t -88.11 -14.45 38.76 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.193 0.521 . . . . 0.0 110.316 -175.459 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -64.79 -51.72 60.68 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.033 -177.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.486 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 59.7 tttp -50.88 -56.89 15.9 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -177.717 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.486 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 58.7 Cg_endo -71.27 -26.79 20.48 Favored 'Trans proline' 0 C--N 1.355 0.913 0 C-N-CA 121.335 1.357 . . . . 0.0 111.702 -177.672 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.1 t -74.15 -30.49 62.3 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.053 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 tppt? -74.16 -30.83 62.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.83 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.95 -28.32 64.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.454 174.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.5 -36.0 65.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.845 174.26 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.05 19.95 5.78 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.294 173.179 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.619 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -103.88 -174.61 2.58 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 122.714 -0.286 . . . . 0.0 111.0 -178.751 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -90.87 -57.95 2.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.885 0.374 . . . . 0.0 110.719 -175.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.495 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -136.11 161.09 36.69 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.186 -176.893 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.582 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -122.56 163.86 15.79 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.386 178.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 35.4 tptt -138.01 145.41 41.85 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.5 t -91.27 106.16 18.31 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.14 0.495 . . . . 0.0 110.057 -177.373 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.802 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.1 mt -96.3 -161.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.802 ' H ' HG22 ' A' ' 28' ' ' ILE . 32.8 p-10 -65.19 44.87 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 120.294 1.407 . . . . 0.0 113.267 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 118.59 -2.4 15.6 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.111 -0.566 . . . . 0.0 113.39 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -120.89 159.72 24.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 117.555 0.678 . . . . 0.0 111.121 -175.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.2 m -100.51 87.87 3.49 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.042 174.209 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.467 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.2 t70 -78.98 124.43 28.24 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 171.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.0 m -107.58 168.12 9.47 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.112 -0.495 . . . . 0.0 112.183 -171.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.495 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 92.9 m -119.9 122.53 28.99 Favored Pre-proline 0 N--CA 1.441 -0.905 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 168.207 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -85.64 -159.27 0.1 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.704 2.269 . . . . 0.0 111.431 -177.186 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.812 -0.613 . . . . 0.0 110.194 178.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.781 0.324 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.599 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 108.77 125.9 5.26 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.523 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.4 pt -110.21 176.32 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.0 0.428 . . . . 0.0 110.827 -175.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -107.72 97.24 6.99 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -178.162 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.681 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.7 p -141.87 -177.73 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.927 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.681 ' H ' HG22 ' A' ' 5' ' ' VAL . 11.8 m-20 -126.35 92.57 3.59 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-O 121.609 0.718 . . . . 0.0 110.964 -177.079 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.9 p -94.55 135.16 36.32 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.473 -1.24 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.0 tptp -85.42 -17.57 36.23 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 166.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.49 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 7.9 p-80 -169.17 155.1 6.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.801 -176.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.704 ' OG ' ' HA ' ' A' ' 26' ' ' LYS . 39.2 t -60.91 -30.23 70.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.852 -175.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.08 -33.23 68.78 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.187 -0.53 . . . . 0.0 113.447 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.49 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 19.1 pt20 -90.78 1.8 56.6 Favored 'General case' 0 C--N 1.326 -0.425 0 O-C-N 122.488 -0.419 . . . . 0.0 110.959 -177.106 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.28 -11.03 57.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.193 0.52 . . . . 0.0 110.011 -175.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 64.0 mt -63.88 -53.39 51.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.454 -176.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.464 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 8.6 tmtt? -51.61 -57.12 15.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.368 -177.163 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.464 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 54.7 Cg_endo -68.86 -26.02 32.41 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 121.477 1.451 . . . . 0.0 111.948 -178.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.707 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.7 t -70.27 -35.76 73.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.928 177.293 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.8 mmmt -72.71 -32.01 65.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.183 177.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -70.98 -31.74 68.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.701 176.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.56 -52.3 16.13 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.483 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 143.77 12.43 0.33 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.536 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.707 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -106.26 -174.72 2.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 117.316 0.558 . . . . 0.0 110.511 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 76.6 mtm180 -98.98 -58.5 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 111.004 -176.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -123.45 156.41 35.6 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.022 -176.801 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.7 150.82 20.2 Favored Glycine 0 N--CA 1.448 -0.562 0 O-C-N 123.615 0.572 . . . . 0.0 111.969 -176.179 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.704 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 59.1 tttm -130.24 149.74 51.8 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -94.21 116.82 29.27 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.687 -178.616 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.697 HG22 ' H ' ' A' ' 29' ' ' ASN . 6.8 mt -120.07 -122.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.061 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.697 ' H ' HG22 ' A' ' 28' ' ' ILE . 16.4 p30 -91.37 49.55 1.62 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 118.862 0.755 . . . . 0.0 111.243 -175.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 89.44 10.81 65.16 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.893 -0.67 . . . . 0.0 111.515 -177.655 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 22.8 ptmt -120.14 150.02 41.28 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.599 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.3 t -93.53 83.93 4.6 Favored 'General case' 0 C--N 1.315 -0.919 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 172.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.424 ' CB ' HD12 ' A' ' 28' ' ' ILE . 16.0 t70 -76.39 107.38 8.61 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 63.6 m -105.99 173.44 6.31 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.999 -1.001 . . . . 0.0 112.351 -170.699 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 90.0 m -122.29 124.6 26.81 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 167.557 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -82.07 -157.9 0.09 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.978 2.452 . . . . 0.0 112.122 -175.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.6 mppt? . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.491 -0.766 . . . . 0.0 109.747 178.195 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.481 1.095 0 CA-C-O 120.986 0.422 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.74 113.89 3.87 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.1 pt -87.98 175.66 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.166 0.508 . . . . 0.0 111.693 -166.279 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -106.68 89.68 3.09 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.024 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.482 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -146.81 -175.48 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.492 -171.288 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.482 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.2 p-10 -129.9 107.6 9.5 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.749 0.785 . . . . 0.0 110.408 176.582 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 4.2 p -92.45 135.18 34.26 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.805 -177.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -83.52 -23.99 31.87 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 164.258 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.412 ' CD2' ' HG2' ' A' ' 12' ' ' GLN . 10.6 p-80 -173.17 167.42 4.87 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 115.045 -0.98 . . . . 0.0 109.624 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' CYS . 25.6 p -65.7 -30.07 70.7 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.67 0.272 . . . . 0.0 111.682 -175.756 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.58 -39.52 66.74 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 121.175 -0.536 . . . . 0.0 112.495 178.585 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.412 ' HG2' ' CD2' ' A' ' 9' ' ' HIS . 3.9 pt20 -91.67 14.82 14.07 Favored 'General case' 0 C--N 1.33 -0.277 0 O-C-N 122.577 -0.367 . . . . 0.0 111.905 178.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 10' ' ' SER . 35.0 m -90.26 -21.46 22.09 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.876 0.369 . . . . 0.0 110.156 173.137 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.5 mt -61.12 -56.29 22.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.831 -173.045 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -56.6 31.9 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.491 -177.113 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -66.63 -23.77 48.95 Favored 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 121.328 1.352 . . . . 0.0 112.31 -178.597 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.5 t -72.13 -37.25 69.5 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.234 0.54 . . . . 0.0 110.109 176.726 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -78.41 -26.81 46.5 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.857 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -71.0 -29.48 65.45 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.32 172.446 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.92 -51.76 17.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.433 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.53 9.93 0.62 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.113 177.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.607 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.65 -174.4 2.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.975 0.388 . . . . 0.0 110.242 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -99.93 -75.5 0.57 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.999 0.428 . . . . 0.0 111.504 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.444 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -101.68 157.95 16.45 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.92 -175.144 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 141.73 11.54 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.391 -175.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 87.6 tttt -126.85 152.94 46.33 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.6 t -97.84 118.49 34.51 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.675 HG22 ' H ' ' A' ' 29' ' ' ASN . 8.8 mt -118.36 -119.24 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.55 -172.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.675 ' H ' HG22 ' A' ' 28' ' ' ILE . 16.0 p30 -90.77 45.77 1.28 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.313 0.578 . . . . 0.0 110.824 -175.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.96 1.95 58.37 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.519 -177.106 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -117.32 143.76 45.6 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 23.1 m -86.68 86.43 7.33 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 167.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.528 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.7 t70 -77.24 135.7 38.48 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.16 -178.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 85.7 m -126.49 168.11 14.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.33 -168.368 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.444 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 97.7 m -119.75 127.58 26.33 Favored Pre-proline 0 N--CA 1.444 -0.734 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 165.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.51 -159.88 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.601 2.201 . . . . 0.0 112.22 -175.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.546 -0.74 . . . . 0.0 110.195 -178.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.768 0.318 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 113.9 127.46 4.53 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -175.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.513 ' CD1' ' HB ' ' A' ' 5' ' ' VAL . 19.1 pt -103.77 -178.53 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.006 0.431 . . . . 0.0 111.249 -172.215 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -99.51 2.55 44.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.565 0.697 . . . . 0.0 110.292 -173.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.527 HG12 ' SG ' ' A' ' 32' ' ' CYS . 1.2 t -69.36 152.51 9.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.418 176.504 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -106.52 128.41 54.08 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.386 -176.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.727 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 2.7 p -91.43 139.64 30.52 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -177.07 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LYS . . . . . 0.408 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 35.1 ttpt -88.16 -22.68 23.93 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 163.394 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.562 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 16.1 p-80 -172.47 164.1 5.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.35 179.337 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 p -61.39 -42.89 99.44 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -174.542 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.63 -30.6 59.46 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 116.079 -0.51 . . . . 0.0 113.805 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.562 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.73 6.0 45.88 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 117.099 0.449 . . . . 0.0 111.554 -177.306 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.727 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 54.7 m -84.79 -21.52 29.91 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.077 0.465 . . . . 0.0 109.882 175.404 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.49 -49.26 76.88 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.492 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.609 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.3 tmtp? -53.48 -59.47 9.33 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.316 -175.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.609 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 47.5 Cg_endo -73.13 -29.16 11.99 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 121.25 1.3 . . . . 0.0 113.309 -178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 11.9 m -71.7 -29.73 64.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 120.635 0.255 . . . . 0.0 111.129 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.33 -27.99 62.77 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.242 0.544 . . . . 0.0 109.955 175.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -73.51 -37.87 65.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.567 172.693 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.77 -44.15 86.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.883 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.05 18.5 0.84 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.766 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.546 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -107.61 -173.16 2.22 Favored 'General case' 0 C--N 1.322 -0.622 0 O-C-N 122.588 -0.36 . . . . 0.0 110.85 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.9 mtm180 -108.29 -58.29 2.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.067 0.46 . . . . 0.0 111.745 -175.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.466 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -105.02 -153.83 0.5 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.77 -174.655 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.75 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.02 136.28 3.65 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.703 179.462 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -134.81 150.6 50.53 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.369 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 43.9 t -102.55 111.32 23.57 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -177.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.678 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.4 mt -105.41 -115.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.22 -174.338 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.678 ' H ' HG22 ' A' ' 28' ' ' ILE . 17.3 p30 -90.99 43.23 1.14 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 118.709 0.686 . . . . 0.0 110.588 -177.29 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.39 2.39 60.35 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.761 -176.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 16.8 ptpt -114.49 150.9 34.12 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.527 ' SG ' HG12 ' A' ' 5' ' ' VAL . 59.0 m -91.16 90.17 7.68 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.334 173.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.511 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.5 t70 -79.22 118.98 21.67 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 172.055 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.75 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 33.9 m -133.85 139.97 46.57 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 -173.799 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.466 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 88.3 m -86.32 131.93 44.69 Favored Pre-proline 0 N--CA 1.447 -0.595 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.509 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 67.5 Cg_endo -82.22 -161.57 0.15 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.657 2.238 . . . . 0.0 112.547 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.297 -0.859 . . . . 0.0 109.875 -179.158 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.482 1.138 0 CA-C-O 120.794 0.331 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 101.81 112.81 3.62 Favored Glycine 0 N--CA 1.443 -0.851 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -175.371 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.452 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.4 pt -92.12 177.48 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.328 0.585 . . . . 0.0 111.314 -171.353 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -103.08 86.63 2.73 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.304 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.494 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -145.0 -179.87 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.674 -173.41 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.494 ' H ' HG22 ' A' ' 5' ' ' VAL . 19.7 m-20 -132.58 106.74 8.0 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.916 0.389 . . . . 0.0 109.955 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -91.78 136.93 32.77 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.398 0.618 . . . . 0.0 111.309 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -83.86 -19.8 34.24 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 168.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.7 p-80 -170.89 167.3 7.49 Favored 'General case' 0 N--CA 1.461 0.083 0 CA-C-N 115.111 -0.95 . . . . 0.0 110.442 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.7 p -65.61 -40.4 92.58 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -176.306 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.85 -32.96 59.52 Favored Glycine 0 CA--C 1.52 0.376 0 CA-C-N 116.247 -0.433 . . . . 0.0 114.172 -175.089 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -90.4 -1.39 57.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.251 0.525 . . . . 0.0 111.287 -177.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 48.1 t -74.69 -23.12 58.57 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.656 0.741 . . . . 0.0 110.0 -178.182 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -60.01 -42.57 94.61 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.211 -179.389 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 75.9 tttt -56.09 -61.57 6.27 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.806 -176.318 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -78.51 -33.52 1.77 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 121.527 1.485 . . . . 0.0 113.965 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 6.0 t -74.91 -25.26 58.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.011 0.434 . . . . 0.0 110.734 -173.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -75.07 -35.61 61.82 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.039 0.447 . . . . 0.0 110.046 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -71.74 -25.8 62.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.981 177.037 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.15 -52.64 53.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.173 175.705 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.5 3.66 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.334 -0.936 . . . . 0.0 113.532 178.078 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -103.53 -178.74 3.75 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.346 0.573 . . . . 0.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -100.07 -56.61 2.33 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.353 -174.15 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.515 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.8 OUTLIER -107.25 -159.26 0.69 Allowed 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.698 -175.895 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.401 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -175.58 136.68 3.44 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.491 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -127.29 167.0 16.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.744 0.307 . . . . 0.0 110.352 177.253 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.8 t -110.1 100.13 9.1 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.527 ' CD1' ' HB3' ' A' ' 33' ' ' ASP . 2.4 mp -95.78 -92.83 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.646 -172.427 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.516 ' N ' HG22 ' A' ' 28' ' ' ILE . 22.0 m-20 -93.36 45.06 1.15 Allowed 'General case' 0 CA--C 1.505 -0.755 0 CA-C-O 121.88 0.848 . . . . 0.0 109.899 174.657 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.9 6.37 72.77 Favored Glycine 0 C--N 1.314 -0.654 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.282 -171.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 159.1 19.36 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.714 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 1.4 m -93.82 92.59 7.51 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.328 -176.244 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.527 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 19.3 t70 -86.92 124.24 32.91 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 167.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 7.5 m -135.11 158.47 44.27 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 121.056 -0.258 . . . . 0.0 110.846 -171.828 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 33.0 m -96.22 128.74 35.77 Favored Pre-proline 0 N--CA 1.446 -0.632 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 175.702 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -82.23 -160.03 0.12 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.572 2.181 . . . . 0.0 112.308 -178.016 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.206 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.863 0.363 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.482 ' HA3' ' HE2' ' A' ' 31' ' ' LYS . . . 121.14 126.35 3.29 Favored Glycine 0 N--CA 1.443 -0.891 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.226 -174.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -104.04 -178.01 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.329 0.585 . . . . 0.0 111.533 -173.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -105.3 109.07 20.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.893 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.528 HG22 ' H ' ' A' ' 6' ' ' ASP . 1.4 p -163.03 -178.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -173.009 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.528 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.5 m-20 -127.74 110.47 12.66 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.838 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.524 ' HA ' ' OE1' ' A' ' 12' ' ' GLN . 2.0 p -91.04 123.91 34.86 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.415 0.626 . . . . 0.0 111.702 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -74.98 -25.48 58.87 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 167.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 28.4 p-80 -177.38 163.26 1.99 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.734 177.303 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 6.4 p -63.48 -36.35 83.47 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -175.561 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.49 -39.32 65.48 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.176 -0.535 . . . . 0.0 113.067 -178.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.524 ' OE1' ' HA ' ' A' ' 7' ' ' CYS . 0.0 OUTLIER -90.55 -0.12 57.56 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 122.66 -0.317 . . . . 0.0 110.959 -177.718 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.626 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 32.6 t -76.02 -22.07 56.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.587 0.708 . . . . 0.0 109.625 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 10.9 mp -57.43 -43.01 83.5 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.792 -1.095 . . . . 0.0 111.065 177.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -59.51 -61.05 8.63 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 115.597 -0.728 . . . . 0.0 112.843 -174.292 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.68 -31.34 13.37 Favored 'Trans proline' 0 C--N 1.354 0.823 0 C-N-CA 121.453 1.435 . . . . 0.0 112.622 -175.012 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 8.8 t -77.63 -23.46 49.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.173 -176.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HA ' ' O ' ' A' ' 22' ' ' MET . 27.2 ttpp -68.35 -38.46 81.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 175.143 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -68.71 -28.25 66.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.504 176.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.0 -10.94 59.84 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.866 177.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.0 -26.12 6.56 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.501 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.593 ' O ' ' HA ' ' A' ' 18' ' ' LYS . 1.9 mpt? -83.47 175.98 9.4 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 117.261 0.531 . . . . 0.0 111.391 -174.24 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.7 mtm180 -94.29 -61.43 1.52 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.566 -175.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.558 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -121.81 158.57 28.58 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.044 -176.4 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.626 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -133.86 157.55 22.87 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.524 -177.493 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.401 ' HB3' HD11 ' A' ' 28' ' ' ILE . 52.8 tptt -127.18 157.57 39.41 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 176.146 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.4 t -104.61 97.87 7.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.602 . . . . 0.0 109.875 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.654 HG22 ' N ' ' A' ' 29' ' ' ASN . 3.5 mp -90.06 -110.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.738 -175.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.654 ' N ' HG22 ' A' ' 28' ' ' ILE . 13.2 p30 -92.53 47.11 1.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 121.628 -0.67 . . . . 0.0 110.391 179.367 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 79.42 19.83 70.65 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -172.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.482 ' HE2' ' HA3' ' A' ' 2' ' ' GLY . 32.1 tttt -120.1 138.53 53.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.929 -0.635 . . . . 0.0 109.536 -179.16 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.469 ' SG ' HG11 ' A' ' 5' ' ' VAL . 1.3 m -87.56 83.02 7.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.718 173.243 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.57 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 16.3 t70 -79.13 124.43 28.31 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 168.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.558 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.7 m -124.11 178.17 5.45 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.105 0.479 . . . . 0.0 112.069 -167.292 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.446 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 95.2 m -125.12 125.53 25.28 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 170.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -82.51 -159.64 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.745 2.297 . . . . 0.0 112.199 -177.156 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 11.3 mptt . . . . . 0 C--O 1.247 0.949 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.322 177.713 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.435 0.16 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.598 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 97.38 138.9 10.37 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -174.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.408 HG12 ' O ' ' A' ' 32' ' ' CYS . 10.1 pt -109.51 176.76 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-O 121.362 0.601 . . . . 0.0 111.872 -170.096 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -100.74 100.23 10.88 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.858 178.493 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -162.92 179.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -174.281 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.443 ' N ' HG13 ' A' ' 5' ' ' VAL . 6.4 m-20 -128.02 112.82 15.05 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.032 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.676 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.2 p -88.8 129.76 35.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.608 0.718 . . . . 0.0 111.663 -177.597 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -87.15 -15.08 39.45 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 167.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' HIS . . . . . 0.472 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 26.7 p-80 178.41 158.15 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.493 178.071 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.5 p -58.32 -35.45 71.9 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 111.648 -175.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.78 -32.64 70.31 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 115.99 -0.55 . . . . 0.0 113.641 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.83 7.78 38.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.576 0.688 . . . . 0.0 111.446 -177.486 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 74.8 m -82.05 -15.6 53.02 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.143 176.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.85 -56.59 19.34 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.186 -171.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -57.12 -54.15 57.69 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.661 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.55 -27.58 39.04 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 121.265 1.31 . . . . 0.0 112.557 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.6 t -73.01 -33.95 66.09 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.26 0.552 . . . . 0.0 110.209 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -73.13 -39.16 65.97 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.914 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.2 ttmm -69.17 -28.85 66.78 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.916 176.106 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.06 -43.54 78.4 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.891 175.347 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 125.72 15.04 3.0 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.849 176.488 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.537 ' SD ' ' HB2' ' A' ' 34' ' ' CYS . 60.9 mtt -116.13 -179.17 3.59 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 122.649 -0.324 . . . . 0.0 110.611 -178.164 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtm180 -92.77 -79.1 0.4 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.046 -170.501 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -107.17 158.9 16.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -175.584 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.98 137.15 9.21 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.328 -176.015 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 26.7 ttpp -117.73 154.16 32.17 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.1 t -96.77 107.74 20.27 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.251 0.548 . . . . 0.0 110.354 -176.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.574 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 1.9 mp -94.49 -169.97 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 179.746 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.574 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 9.8 p30 -39.67 -43.17 1.32 Allowed 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 118.889 0.768 . . . . 0.0 112.244 -174.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 6' ' ' ASP . . . -152.41 2.63 0.33 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.201 -1.0 . . . . 0.0 112.305 172.68 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.25 152.01 40.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.997 0.427 . . . . 0.0 111.807 -169.548 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.676 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 65.2 m -91.59 92.91 8.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.509 176.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.598 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 22.3 t70 -80.82 135.94 36.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.605 175.228 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.537 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 81.1 m -123.84 157.51 33.99 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.268 -0.424 . . . . 0.0 112.121 -169.39 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.516 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.3 m -103.27 128.57 27.27 Favored Pre-proline 0 N--CA 1.442 -0.857 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 169.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -83.51 -163.63 0.22 Allowed 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.339 2.026 . . . . 0.0 112.167 -175.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm . . . . . 0 C--O 1.246 0.87 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.14 179.805 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.477 0.913 0 CA-C-O 120.928 0.394 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 111.93 106.13 2.84 Favored Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -176.569 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.409 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.1 pt -89.87 178.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.413 0.625 . . . . 0.0 111.639 -170.539 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -103.86 105.84 16.17 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.652 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -157.98 -175.91 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.364 -172.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 4.9 m-20 -132.92 106.1 7.49 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.253 0.549 . . . . 0.0 110.236 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -92.94 125.6 37.62 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.187 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 56.7 tptt -74.88 -22.14 58.82 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 167.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 13.5 p-80 -171.74 163.7 6.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 114.636 -1.165 . . . . 0.0 109.794 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 p -66.35 -33.4 75.65 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.787 0.291 . . . . 0.0 111.787 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.14 -34.38 62.39 Favored Glycine 0 CA--C 1.519 0.308 0 C-N-CA 121.273 -0.489 . . . . 0.0 113.353 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 6.5 pt20 -90.7 -1.73 57.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.836 0.351 . . . . 0.0 110.63 -177.389 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.1 t -79.86 -16.72 54.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.412 0.625 . . . . 0.0 110.258 -173.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.6 mp -64.96 -48.74 72.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.864 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 73.2 tttt -53.81 -57.52 17.26 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -174.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.478 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.7 Cg_endo -67.97 -29.57 34.03 Favored 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 121.81 1.674 . . . . 0.0 112.397 -175.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 2.2 m -78.32 -29.07 47.49 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.46 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 13.7 tmtt? -67.59 -38.4 83.96 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.9 ttmm -68.01 -35.28 78.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.747 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.24 -12.99 60.72 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.28 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 108.23 14.21 17.23 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.783 -0.723 . . . . 0.0 113.358 175.014 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' MET . . . . . 0.526 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -104.32 179.67 4.2 Favored 'General case' 0 C--N 1.319 -0.738 0 O-C-N 122.333 -0.51 . . . . 0.0 110.758 178.691 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.45 -57.11 2.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.03 0.443 . . . . 0.0 111.658 -175.188 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.7 OUTLIER -105.5 -159.21 0.7 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.79 -174.681 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.659 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -170.6 133.14 2.69 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.271 -0.966 . . . . 0.0 112.9 178.371 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.49 147.09 50.31 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.7 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.9 t -96.7 112.02 23.94 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.837 0.351 . . . . 0.0 110.508 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.43 ' HB ' ' HG2' ' A' ' 31' ' ' LYS . 7.0 mt -104.85 170.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.644 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -45.09 -34.88 2.79 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -171.47 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.35 -1.76 1.03 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 119.365 -1.397 . . . . 0.0 113.931 174.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.43 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 21.2 ptmt -124.02 153.7 40.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 118.184 0.992 . . . . 0.0 111.53 -172.034 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.558 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.5 OUTLIER -92.79 92.5 7.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 169.772 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -78.87 103.4 8.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.478 175.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.659 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 20.0 m -125.03 142.53 51.43 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.293 -174.422 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.519 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 41.2 m -88.42 129.83 47.87 Favored Pre-proline 0 N--CA 1.448 -0.574 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 90.2 Cg_endo -81.36 -158.73 0.1 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.798 2.332 . . . . 0.0 112.261 -177.282 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.498 -0.763 . . . . 0.0 110.771 -177.784 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.75 0.309 . . . . 0.0 110.769 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 114.46 130.8 5.04 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.4 pt -103.21 177.11 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-O 121.177 0.513 . . . . 0.0 111.658 -170.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -101.32 70.48 1.32 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.255 -175.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -131.44 179.53 4.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.324 -176.5 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.454 ' N ' HG13 ' A' ' 5' ' ' VAL . 7.2 p-10 -128.33 111.28 13.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.56 0.695 . . . . 0.0 109.966 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.454 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.8 p -92.9 132.07 37.36 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.969 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 mtmt -87.6 -18.45 29.64 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 163.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.463 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.2 p-80 -167.49 167.39 13.72 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.616 -1.175 . . . . 0.0 110.329 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.459 ' HB3' ' H ' ' A' ' 27' ' ' CYS . 4.9 p -72.27 -31.26 65.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -176.048 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.27 -27.87 66.04 Favored Glycine 0 CA--C 1.517 0.212 0 C-N-CA 121.11 -0.567 . . . . 0.0 113.408 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -89.0 3.65 50.94 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 122.597 -0.355 . . . . 0.0 110.721 -178.193 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 88.9 m -86.86 -16.12 37.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.829 0.347 . . . . 0.0 110.483 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.9 mt -62.67 -62.78 1.5 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.913 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.485 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 54.5 tttm -55.23 -58.44 15.04 Favored Pre-proline 0 N--CA 1.446 -0.633 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 37.2 Cg_endo -66.5 -28.1 45.94 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 121.403 1.402 . . . . 0.0 112.922 -173.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 4.2 t -82.76 -26.65 31.69 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.19 0.519 . . . . 0.0 109.897 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -72.33 -36.31 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.8 tptm -72.14 -32.7 67.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.825 173.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.8 -48.1 80.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.586 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 144.95 8.78 0.35 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.887 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.433 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.78 178.36 4.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.71 0.255 . . . . 0.0 110.326 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.6 mtm180 -96.84 -54.18 3.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.864 0.364 . . . . 0.0 111.241 -173.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.456 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -112.48 -153.15 0.52 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.886 -176.633 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.35 139.06 3.18 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.725 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -133.03 151.47 52.05 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 177.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.459 ' H ' ' HB3' ' A' ' 10' ' ' SER . 42.6 t -88.01 131.87 34.48 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.632 HG22 ' N ' ' A' ' 29' ' ' ASN . 6.4 mt -122.89 -112.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.207 -177.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.632 ' N ' HG22 ' A' ' 28' ' ' ILE . 15.6 p30 -92.22 46.73 1.27 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.417 0.627 . . . . 0.0 110.586 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.28 -5.71 65.54 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.662 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -109.1 154.57 22.09 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 120.729 0.299 . . . . 0.0 110.262 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.454 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 35.9 m -96.73 90.55 5.32 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.807 172.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -86.0 135.13 33.77 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.857 175.276 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 3.2 m -135.39 178.62 6.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.893 0.378 . . . . 0.0 111.063 -170.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.456 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 57.9 m -113.64 127.42 26.84 Favored Pre-proline 0 N--CA 1.443 -0.787 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 171.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -84.87 -161.37 0.13 Allowed 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.894 2.396 . . . . 0.0 112.102 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.585 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.947 0 CA-C-O 118.595 -0.716 . . . . 0.0 110.035 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.9 m . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.655 0.264 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.624 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 110.96 109.51 3.14 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.903 178.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.526 HG12 ' CB ' ' A' ' 32' ' ' CYS . 1.1 pt -98.24 175.66 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.666 0.27 . . . . 0.0 110.314 -177.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -103.76 109.63 21.42 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.614 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.7 p -156.53 -175.95 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -172.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.614 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.1 m-20 -127.77 97.28 4.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.449 0.642 . . . . 0.0 111.041 -176.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 5.8 p -94.36 134.18 37.14 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.223 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -88.93 -14.64 36.24 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 166.007 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -171.34 161.66 6.54 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 114.643 -1.162 . . . . 0.0 110.445 174.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.5 p -58.61 -40.44 83.3 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -176.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.61 -41.69 50.24 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 114.112 0.405 . . . . 0.0 114.112 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -83.52 -2.72 56.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.031 0.415 . . . . 0.0 111.467 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.29 -11.95 57.19 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.233 0.54 . . . . 0.0 110.159 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.8 mp -63.44 -42.88 98.67 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.55 -178.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -56.8 -58.33 18.17 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.339 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.69 -24.04 22.16 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 121.47 1.447 . . . . 0.0 112.062 -178.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 46.3 t -69.33 -38.96 78.42 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 178.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -71.47 -35.18 70.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.42 178.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.3 tmtm? -61.6 -38.12 86.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.289 -0.868 . . . . 0.0 109.539 175.24 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.15 -44.1 76.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.54 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.25 8.14 0.75 Allowed Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.912 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.46 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 4.2 mpp? -108.1 -173.83 2.38 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 117.594 0.697 . . . . 0.0 111.208 -179.054 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 64.1 mtm180 -93.21 -60.69 1.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.451 -174.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.497 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -130.75 161.14 32.37 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.567 -176.279 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.501 ' HA2' ' HA ' ' A' ' 34' ' ' CYS . . . -131.22 140.02 11.43 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.858 -175.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -101.55 170.08 8.42 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 173.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.7 t -107.56 107.85 18.88 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.187 0.518 . . . . 0.0 111.187 -176.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.571 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.2 mt -104.56 162.27 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.405 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.19 -38.57 0.78 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.09 13.68 1.29 Allowed Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.054 175.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.9 148.82 45.01 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 120.961 0.41 . . . . 0.0 110.618 -173.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.624 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -94.55 87.92 5.27 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 167.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.571 ' HB2' HD12 ' A' ' 28' ' ' ILE . 32.1 t70 -74.52 96.73 2.98 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 122.019 0.914 . . . . 0.0 109.38 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.501 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 69.7 m -86.45 167.85 14.31 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.12 -1.4 . . . . 0.0 112.968 -171.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.497 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 30.4 m -129.23 119.92 19.83 Favored Pre-proline 0 N--CA 1.434 -1.264 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 168.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.46 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 72.0 Cg_endo -84.4 -157.98 0.09 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.303 0 C-N-CA 122.16 1.907 . . . . 0.0 111.609 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.679 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.776 -0.63 . . . . 0.0 110.601 -179.522 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.653 0.263 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 103.84 104.65 2.92 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.886 -0.674 . . . . 0.0 111.769 -179.078 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.7 pt -91.88 178.51 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.698 0.285 . . . . 0.0 110.452 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -104.24 110.79 23.14 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 177.121 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.6 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -160.82 -178.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -173.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.6 ' H ' HG22 ' A' ' 5' ' ' VAL . 26.3 m-20 -128.6 107.77 9.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.366 0.603 . . . . 0.0 110.069 -178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 p -91.63 135.69 33.69 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.204 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -82.8 -20.72 35.22 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.413 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 22.3 p-80 -177.93 159.06 1.32 Allowed 'General case' 0 CA--C 1.522 -0.114 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.272 175.267 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 p -52.72 -44.88 66.65 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -54.49 -34.32 54.89 Favored Glycine 0 C--O 1.228 -0.273 0 CA-C-N 115.908 -0.587 . . . . 0.0 114.002 -177.254 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -91.48 3.12 55.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 117.744 0.772 . . . . 0.0 111.99 -177.432 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -84.09 -2.51 56.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.62 0.724 . . . . 0.0 109.543 -177.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 72.3 mt -61.09 -55.93 26.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.829 -1.078 . . . . 0.0 111.404 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -52.03 -54.86 36.24 Favored Pre-proline 0 CA--C 1.542 0.664 0 N-CA-C 113.341 0.867 . . . . 0.0 113.341 -172.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.18 -31.58 22.81 Favored 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 121.276 1.318 . . . . 0.0 112.406 -176.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.546 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 7.8 t -81.59 -22.09 37.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.21 0.528 . . . . 0.0 110.198 -178.279 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -65.41 -38.79 90.99 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 174.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -62.3 -43.94 97.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.98 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.35 -40.45 90.75 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.759 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 129.22 17.51 1.78 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.969 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.546 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -109.8 -178.02 3.42 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.748 179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.3 mtm180 -103.8 -63.58 1.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.891 0.377 . . . . 0.0 111.589 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.442 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.61 157.43 25.36 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 -177.411 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.9 144.47 16.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.988 -174.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttp -110.12 167.55 10.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 110.229 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 36.3 t -108.54 110.72 22.27 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.437 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.469 HG22 ' N ' ' A' ' 29' ' ' ASN . 10.1 mt -117.15 176.03 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.469 ' N ' HG22 ' A' ' 28' ' ' ILE . 9.6 p30 -38.4 -43.97 0.87 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -169.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -155.83 17.07 0.47 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.784 173.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.403 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -124.54 148.85 47.52 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.665 -175.528 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.63 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -92.83 89.17 6.49 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 173.041 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -77.12 107.69 9.67 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.615 0.721 . . . . 0.0 109.388 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.9 m -111.06 171.49 7.44 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.841 -171.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.44 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 75.4 m -122.18 122.9 27.39 Favored Pre-proline 0 N--CA 1.436 -1.13 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 168.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.516 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 95.8 Cg_endo -84.55 -162.95 0.17 Allowed 'Trans proline' 0 N--CA 1.445 -1.332 0 C-N-CA 122.197 1.931 . . . . 0.0 112.474 -177.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.723 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.03 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 120.624 0.249 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.87 127.24 5.85 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -174.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.4 pt -100.74 172.71 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.419 0.628 . . . . 0.0 111.732 -169.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -102.64 95.29 6.12 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.815 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -155.67 -177.39 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.948 -0.569 . . . . 0.0 109.734 -172.799 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.484 ' N ' HG13 ' A' ' 5' ' ' VAL . 16.4 m-20 -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.817 0.341 . . . . 0.0 110.42 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 2.4 p -92.83 128.97 38.88 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.454 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 62.5 tttm -81.73 -19.53 41.24 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 167.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.456 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 6.5 p-80 -166.28 151.19 8.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.804 -177.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 t -74.3 73.8 1.83 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.68 177.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.14 -28.84 0.03 OUTLIER Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.105 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.456 ' HB3' ' NE2' ' A' ' 9' ' ' HIS . 9.8 pt20 -87.98 3.39 48.91 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 121.142 -0.223 . . . . 0.0 111.146 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.591 ' O ' ' HB2' ' A' ' 17' ' ' CYS . 73.5 m -77.17 -11.52 59.83 Favored 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.355 -175.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.4 mt -62.19 -54.52 39.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.844 -0.617 . . . . 0.0 111.846 -174.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -53.51 -54.92 40.35 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.403 -178.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.95 -23.62 25.16 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 121.786 1.657 . . . . 0.0 112.538 178.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.591 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 19.4 t -69.72 -35.53 75.12 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.447 0.641 . . . . 0.0 109.629 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -70.47 -30.66 67.54 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.924 177.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 52.9 tttm -68.56 -41.43 79.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.705 173.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.42 -40.38 93.29 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.741 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 119.76 17.6 4.62 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.479 177.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.551 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 61.3 mtt -116.12 177.68 4.59 Favored 'General case' 0 C--N 1.32 -0.699 0 O-C-N 122.6 -0.353 . . . . 0.0 110.432 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 -91.76 -74.09 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 120.458 -0.497 . . . . 0.0 111.983 -169.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.507 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -110.23 158.95 17.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.886 -174.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.7 161.41 22.88 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.46 -175.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 0.4 OUTLIER -145.83 144.84 30.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -177.21 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 39.2 t -89.05 121.45 31.4 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.413 -178.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 6.5 mt -114.96 167.69 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 19.1 p30 -67.2 53.1 0.05 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -175.015 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 155.1 -36.77 0.65 Allowed Glycine 0 N--CA 1.438 -1.176 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.309 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -124.45 174.1 8.0 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 117.505 0.652 . . . . 0.0 111.663 -172.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -108.08 98.16 7.76 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 166.259 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.522 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.7 t70 -76.19 117.85 18.31 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.592 0.711 . . . . 0.0 110.367 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.421 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 48.3 m -106.83 160.68 15.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.443 -175.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.507 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 48.2 m -112.24 125.75 29.6 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 169.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -79.9 -159.83 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.673 2.249 . . . . 0.0 111.688 -176.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.3 mptt . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.705 -0.664 . . . . 0.0 109.794 178.977 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 121.015 0.436 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 107.77 114.66 3.84 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.862 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.476 HG12 ' HB2' ' A' ' 32' ' ' CYS . 10.3 pt -100.51 -179.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.126 0.489 . . . . 0.0 111.155 -173.261 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -108.16 118.51 36.94 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.373 -0.83 . . . . 0.0 108.993 175.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.4 p -167.32 -174.97 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -172.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.567 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.3 p-10 -126.94 110.88 13.48 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.673 0.749 . . . . 0.0 110.395 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -92.84 127.45 38.36 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.476 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -73.97 -25.88 60.17 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 165.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -174.75 163.76 3.47 Favored 'General case' 0 C--O 1.226 -0.165 0 CA-C-N 114.511 -1.222 . . . . 0.0 109.459 -179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 p -59.21 -37.07 76.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.692 0.282 . . . . 0.0 111.72 -177.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.56 -33.45 66.85 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 116.269 -0.423 . . . . 0.0 114.065 -176.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 6.34 44.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.413 0.607 . . . . 0.0 111.185 -178.08 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.542 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 46.0 t -84.47 -15.25 46.71 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.253 0.549 . . . . 0.0 109.744 179.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.8 mt -58.18 -50.76 72.39 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.816 -175.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.456 ' NZ ' ' HB2' ' A' ' 15' ' ' LYS . 3.5 ttmp? -59.96 -56.25 37.46 Favored Pre-proline 0 N--CA 1.445 -0.709 0 CA-C-N 115.453 -0.794 . . . . 0.0 113.063 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.8 -26.17 32.66 Favored 'Trans proline' 0 C--N 1.356 0.934 0 C-N-CA 121.024 1.149 . . . . 0.0 111.45 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 42.0 t -68.07 -37.02 80.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.783 175.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.407 ' HB2' ' NZ ' ' A' ' 18' ' ' LYS . 2.7 ttmp? -68.64 -39.94 80.51 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.733 176.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -59.16 -33.14 70.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.231 175.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.08 -36.85 55.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.739 177.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.06 2.18 5.18 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.354 -0.926 . . . . 0.0 114.29 172.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.558 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.0 mpp? -96.03 -169.01 1.85 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 117.705 0.753 . . . . 0.0 111.051 -177.081 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 -99.87 -59.61 1.68 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.02 0.438 . . . . 0.0 111.45 -175.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.455 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -128.99 158.98 37.33 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.345 -175.973 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -135.27 155.02 21.89 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.813 -177.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -117.86 166.73 12.12 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 48.7 t -103.81 106.29 16.75 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.913 -178.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 29' ' ' ASN . 12.8 mt -116.03 171.71 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.463 ' N ' HG22 ' A' ' 28' ' ' ILE . 17.4 p30 -58.48 65.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 95.94 6.41 59.22 Favored Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 31.1 ttmt -123.73 133.57 53.84 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -176.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.3 OUTLIER -97.07 87.78 4.31 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 172.434 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.86 113.08 15.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.49 0.662 . . . . 0.0 109.566 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.471 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 99.0 m -101.66 173.42 6.43 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.17 -172.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.455 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 87.9 m -126.09 124.97 24.7 Favored Pre-proline 0 N--CA 1.44 -0.958 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 168.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.92 -156.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 122.744 2.296 . . . . 0.0 111.868 -176.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 5.5 mptp? . . . . . 0 C--O 1.247 0.954 0 CA-C-O 118.603 -0.713 . . . . 0.0 110.672 178.265 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 34' ' ' CYS . 76.3 t . . . . . 0 N--CA 1.479 1.016 0 CA-C-O 120.813 0.34 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.564 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 102.53 97.97 2.4 Favored Glycine 0 N--CA 1.443 -0.893 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.183 179.05 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.559 HG12 ' CB ' ' A' ' 32' ' ' CYS . 2.1 pt -94.77 -179.55 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -106.49 106.45 16.97 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.628 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.6 p -154.0 -177.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -172.25 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 5' ' ' VAL . 12.0 m-20 -128.92 102.97 6.76 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 120.96 0.41 . . . . 0.0 110.787 -178.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.1 p -94.33 131.36 40.04 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.345 176.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -85.26 -18.0 35.29 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 165.231 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.436 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 8.6 p-80 -167.68 162.63 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.775 -176.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.3 p -66.88 -37.73 84.97 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -174.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.71 -26.28 59.92 Favored Glycine 0 CA--C 1.519 0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 113.897 -174.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.436 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 17.5 pt20 -88.39 -4.67 58.61 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 117.384 0.592 . . . . 0.0 110.908 -177.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -88.42 -2.36 58.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.534 0.683 . . . . 0.0 109.85 -175.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.3 mt -62.58 -57.16 12.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.169 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.459 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.2 tmmm? -50.76 -57.86 12.06 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 114.695 -1.138 . . . . 0.0 112.811 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.541 ' HB2' HD11 ' A' ' 3' ' ' ILE . 37.1 Cg_endo -64.94 -33.55 51.43 Favored 'Trans proline' 0 C--N 1.352 0.724 0 C-N-CA 121.628 1.552 . . . . 0.0 113.356 -173.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -83.5 -21.72 32.72 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.084 0.468 . . . . 0.0 110.463 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -72.78 -36.26 67.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -68.15 -36.32 79.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.783 173.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.69 -45.94 84.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.442 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.89 21.23 0.56 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.842 176.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.468 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 2.1 mpt? -109.7 -175.42 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 O-C-N 122.669 -0.312 . . . . 0.0 110.493 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.0 mtm180 -96.37 -61.44 1.43 Allowed 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.183 -0.607 . . . . 0.0 111.958 -176.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -108.06 -158.11 0.64 Allowed 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.074 -173.42 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.21 141.63 6.93 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.328 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -130.36 166.9 19.45 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 177.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.4 t -107.15 110.68 22.82 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.959 -175.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.432 HD12 ' HB2' ' A' ' 33' ' ' ASP . 8.3 mt -113.37 171.46 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 174.559 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.409 ' N ' HG22 ' A' ' 28' ' ' ILE . 12.6 m-80 -38.6 -53.71 1.59 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.908 0.483 . . . . 0.0 111.869 -171.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.71 21.82 2.17 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 173.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.413 ' O ' ' HB ' ' A' ' 28' ' ' ILE . 30.1 ttmt -122.67 132.79 54.43 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 110.305 -0.258 . . . . 0.0 110.305 -171.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.564 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.4 t -87.84 90.52 8.41 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.432 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.3 t70 -77.13 104.81 7.84 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.465 0.65 . . . . 0.0 109.753 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.44 ' O ' HG13 ' A' ' 1' ' ' VAL . 4.3 p -128.47 141.11 51.49 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.253 -173.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 38.4 m -92.91 127.87 45.86 Favored Pre-proline 0 N--CA 1.441 -0.915 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 46.4 Cg_endo -84.03 -154.09 0.05 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 122.521 2.147 . . . . 0.0 111.714 -176.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.457 ' HD2' ' N ' ' A' ' 37' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.567 178.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.612 HG21 ' O ' ' A' ' 34' ' ' CYS . 27.2 m . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.847 0.356 . . . . 0.0 110.306 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 100.65 118.11 4.23 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -176.157 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.8 pt -102.55 170.61 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.43 0.634 . . . . 0.0 111.082 -174.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -104.79 92.09 4.11 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.255 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.439 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.7 OUTLIER -147.69 -179.2 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.498 -173.385 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.9 m-20 -128.4 102.69 6.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.163 0.506 . . . . 0.0 110.298 -178.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.589 ' HA ' ' NE2' ' A' ' 12' ' ' GLN . 1.9 p -92.91 133.57 35.97 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.337 -176.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -84.68 -21.84 30.03 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 164.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.464 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 14.1 p-80 -168.63 163.99 12.23 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.759 -176.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.6 p -65.09 -41.4 95.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.724 0.297 . . . . 0.0 111.577 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.416 ' O ' HD23 ' A' ' 14' ' ' LEU . . . -59.85 -18.27 46.03 Favored Glycine 0 C--O 1.228 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 114.61 -172.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.589 ' NE2' ' HA ' ' A' ' 7' ' ' CYS . 9.7 pt20 -89.12 -17.48 29.14 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 117.73 0.765 . . . . 0.0 110.634 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.4 m -90.83 24.39 2.75 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-O 121.009 0.433 . . . . 0.0 111.432 -175.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 11' ' ' GLY . 4.1 mm? -82.65 -41.58 19.24 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 169.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.5 ttpt -62.31 -58.25 18.44 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.599 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.87 -27.05 21.65 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.318 1.345 . . . . 0.0 112.17 -177.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 40.7 t -74.12 -30.94 62.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.374 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 11.3 tppt? -67.86 -36.92 81.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 177.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.4 tttp -73.56 -28.86 62.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.903 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.49 -36.82 85.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.34 176.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.63 10.79 5.26 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.95 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.547 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.2 mpt? -107.88 -175.4 2.77 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.576 -0.367 . . . . 0.0 110.344 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 -93.61 -62.48 1.35 Allowed 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.473 -0.491 . . . . 0.0 111.268 -177.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.504 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.8 160.27 22.94 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.978 -175.961 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.87 146.22 17.61 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.402 -176.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 61.6 mtpt -134.97 167.15 21.45 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.1 t -104.81 121.55 43.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.867 -174.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.486 HG22 ' N ' ' A' ' 29' ' ' ASN . 8.9 mt -117.41 178.5 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.816 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.486 ' N ' HG22 ' A' ' 28' ' ' ILE . 18.4 p30 -64.67 56.23 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -174.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 134.65 -23.03 3.62 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 121.354 -0.451 . . . . 0.0 112.661 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -123.06 169.16 11.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.832 0.316 . . . . 0.0 110.236 -173.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 5.2 m -114.39 100.79 8.59 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.538 0.685 . . . . 0.0 109.289 167.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.537 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.6 t70 -77.96 149.14 34.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.033 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.612 ' O ' HG21 ' A' ' 1' ' ' VAL . 98.4 m -137.43 160.16 39.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -170.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 89.0 m -116.28 123.12 31.15 Favored Pre-proline 0 N--CA 1.437 -1.076 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 167.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -79.72 -163.24 0.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.555 2.17 . . . . 0.0 112.215 -174.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.425 -0.798 . . . . 0.0 110.234 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.48 1.067 0 CA-C-O 120.55 0.214 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 104.8 130.52 6.83 Favored Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.514 HG13 ' H ' ' A' ' 5' ' ' VAL . 15.5 pt -108.48 178.72 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.187 0.518 . . . . 0.0 111.486 -171.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -105.04 37.8 2.09 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.001 -175.001 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.64 HG12 ' SG ' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -98.43 158.33 3.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.21 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -102.84 112.52 25.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.922 0.391 . . . . 0.0 110.407 -174.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.633 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 6.0 p -91.5 131.94 36.61 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.9 mmtp -82.03 -19.58 40.09 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 164.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 -170.2 164.7 9.11 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.093 177.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.0 p -57.99 -38.94 77.05 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.887 0.375 . . . . 0.0 111.568 -176.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.58 -36.56 54.43 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.771 -176.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -91.71 14.6 14.8 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.265 0.533 . . . . 0.0 112.415 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.633 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 58.6 m -90.13 -21.89 22.03 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 171.303 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.6 -46.8 83.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.223 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.4 ttpp -62.24 -58.61 16.49 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -176.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' CG ' HG11 ' A' ' 5' ' ' VAL . 32.8 Cg_endo -69.92 -29.1 23.64 Favored 'Trans proline' 0 C--N 1.354 0.844 0 C-N-CA 121.237 1.291 . . . . 0.0 112.695 -177.459 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 13.9 m -74.06 -27.15 60.77 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 120.748 0.309 . . . . 0.0 110.801 176.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -70.69 -37.66 73.61 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.8 ttpp -67.93 -32.75 73.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.577 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.66 -46.79 71.38 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.019 176.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.85 14.15 1.9 Allowed Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.69 -0.687 . . . . 0.0 112.914 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -99.89 173.89 6.46 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.108 0.454 . . . . 0.0 111.002 -178.062 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -94.78 -53.56 3.81 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.961 0.41 . . . . 0.0 111.859 -170.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.48 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -110.19 -157.29 0.61 Allowed 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.044 -175.447 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.689 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.0 132.04 2.26 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.575 -0.822 . . . . 0.0 112.921 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -131.89 152.43 51.06 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 35.7 t -95.52 119.16 33.54 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.118 0.485 . . . . 0.0 110.806 -174.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.465 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.6 mt -109.49 164.0 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.171 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.466 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.95 -38.69 1.01 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -145.53 11.25 1.73 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.067 175.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.415 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 61.2 mttm -123.9 146.63 48.3 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 -174.208 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.64 ' SG ' HG12 ' A' ' 5' ' ' VAL . 5.7 m -96.8 89.66 4.98 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 163.065 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.465 ' HB2' HD12 ' A' ' 28' ' ' ILE . 18.5 t70 -77.99 115.19 17.54 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.747 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.689 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 35.1 m -132.86 141.27 48.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.868 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.48 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 34.9 m -91.84 132.4 33.02 Favored Pre-proline 0 N--CA 1.447 -0.588 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -176.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -81.21 -159.7 0.11 Allowed 'Trans proline' 0 N--CA 1.46 -0.444 0 C-N-CA 123.13 2.553 . . . . 0.0 112.166 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 mptt . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.352 178.502 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.479 1.004 0 CA-C-O 120.638 0.256 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.533 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 98.35 126.24 5.48 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.182 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.7 pt -106.42 177.81 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.049 0.452 . . . . 0.0 111.35 -172.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -101.17 94.91 6.21 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.284 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.482 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -156.97 -179.1 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -175.773 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.482 ' N ' HG13 ' A' ' 5' ' ' VAL . 5.6 m-20 -137.15 110.99 8.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.448 0.642 . . . . 0.0 110.479 177.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 7.3 p -93.01 140.36 29.56 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.186 -178.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -85.32 -21.75 28.8 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 164.093 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.579 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 10.0 p-80 -164.45 162.67 22.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.893 -176.339 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 12.7 p -68.51 -32.17 71.95 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -175.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.05 -28.75 64.27 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.506 -176.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.579 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 21.1 pt20 -84.94 -11.08 56.32 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.894 0.347 . . . . 0.0 111.04 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -72.3 -23.99 61.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.816 0.341 . . . . 0.0 110.212 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 -44.99 80.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.099 -174.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.522 ' HA ' ' HE3' ' A' ' 15' ' ' LYS . 1.1 tpmt? -65.32 -59.04 10.5 Favored Pre-proline 0 N--CA 1.444 -0.736 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -176.319 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.86 -24.46 46.45 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.629 1.552 . . . . 0.0 112.505 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.688 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 45.6 t -74.81 -33.14 62.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.27 0.557 . . . . 0.0 110.219 176.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.8 tttp -71.51 -35.75 70.85 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.671 0.748 . . . . 0.0 109.403 177.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -70.43 -27.0 63.92 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.838 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.685 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 133.62 11.16 1.73 Allowed Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.716 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.688 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -108.96 -171.14 1.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 117.399 0.6 . . . . 0.0 110.784 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -97.75 -66.34 0.91 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.884 0.373 . . . . 0.0 111.537 -174.071 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.471 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.19 160.33 22.36 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.902 -176.567 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.0 141.25 12.38 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.353 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -117.14 156.58 27.39 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.2 t -97.24 115.78 28.24 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.06 0.457 . . . . 0.0 110.714 -175.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.414 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.7 mt -114.92 163.61 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -39.61 -42.39 1.17 Allowed 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 -172.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -141.46 12.21 2.73 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.025 175.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 21.4 mttm -124.94 140.47 52.89 Favored 'General case' 0 N--CA 1.445 -0.72 0 O-C-N 122.901 -0.176 . . . . 0.0 110.836 -175.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.2 m -92.11 82.31 5.05 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 160.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.533 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -76.84 128.81 35.28 Favored 'General case' 0 CA--C 1.514 -0.412 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.895 -176.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 77.7 m -109.31 171.99 7.12 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.115 -169.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.471 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.2 m -120.54 124.48 27.6 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 166.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -81.32 -161.07 0.14 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.446 2.097 . . . . 0.0 111.786 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.477 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 119.026 -0.512 . . . . 0.0 110.809 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.8 m . . . . . 0 N--CA 1.479 0.993 0 CA-C-O 121.066 0.46 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.604 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 117.37 113.11 2.65 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.365 -176.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.54 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -97.03 175.85 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.163 0.506 . . . . 0.0 111.076 -172.723 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -99.34 113.65 26.08 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.11 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.641 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.0 p -162.34 -177.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.641 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.6 m-20 -132.92 100.2 4.83 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.535 0.683 . . . . 0.0 110.795 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.5 p -93.91 141.78 28.12 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 114.777 -1.101 . . . . 0.0 111.477 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -90.13 -17.93 26.76 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 164.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.55 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 11.0 p-80 -172.7 155.07 3.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.935 -175.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.3 p -68.51 -21.7 64.57 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -174.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.0 -34.72 88.97 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.113 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.55 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -85.7 -4.5 59.18 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.897 0.379 . . . . 0.0 110.232 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.47 -10.94 58.82 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.258 0.551 . . . . 0.0 109.734 -172.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -62.31 -53.53 53.73 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.903 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.512 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 23.5 ttpp -50.52 -55.04 29.06 Favored Pre-proline 0 CA--C 1.541 0.625 0 CA-C-N 115.139 -0.937 . . . . 0.0 113.03 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.512 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.9 Cg_endo -72.63 -26.44 16.38 Favored 'Trans proline' 0 C--N 1.357 0.999 0 C-N-CA 121.397 1.398 . . . . 0.0 112.367 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 38.8 t -70.14 -34.2 72.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.229 0.538 . . . . 0.0 110.288 178.157 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -72.6 -31.93 65.56 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.333 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.5 tptt -67.63 -30.74 70.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.808 174.247 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.28 -43.41 28.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.162 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.46 8.06 2.06 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.181 -1.009 . . . . 0.0 114.057 174.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.609 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 3.9 mpp? -106.02 -178.42 3.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 117.765 0.782 . . . . 0.0 110.914 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.453 ' NE ' ' HA ' ' A' ' 37' ' ' LYS . 70.6 mtm180 -91.67 -63.59 1.23 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.885 0.374 . . . . 0.0 111.686 -176.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.452 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -118.04 157.87 26.02 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.361 -175.287 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.12 157.68 21.27 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.112 -177.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -128.91 153.69 47.26 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 21.0 t -92.54 109.62 21.03 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.011 0.434 . . . . 0.0 110.893 -173.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.543 HD12 ' HB2' ' A' ' 33' ' ' ASP . 5.1 mt -112.24 164.23 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 174.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -43.44 -37.64 2.46 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -173.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.23 17.91 1.04 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.002 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -123.48 147.07 47.56 Favored 'General case' 0 CA--C 1.513 -0.444 0 O-C-N 122.527 -0.396 . . . . 0.0 110.827 -176.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.604 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 6.4 t -96.77 87.45 4.32 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 166.298 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.543 ' HB2' HD12 ' A' ' 28' ' ' ILE . 20.5 t70 -75.62 95.42 3.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 122.062 0.934 . . . . 0.0 109.653 -176.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 68.7 m -92.5 175.71 6.73 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.522 -1.217 . . . . 0.0 113.129 -169.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.452 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 33.3 m -136.61 126.72 16.08 Favored Pre-proline 0 N--CA 1.439 -1.008 0 CA-C-N 114.541 -1.209 . . . . 0.0 107.89 168.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.421 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 83.0 Cg_endo -80.0 -158.44 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.301 2.001 . . . . 0.0 112.049 -179.244 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.589 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.101 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.443 177.343 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.479 1.012 0 CA-C-O 120.67 0.271 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 109.43 118.56 4.08 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.6 OUTLIER -104.9 175.03 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 117.001 0.401 . . . . 0.0 110.369 -176.418 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -106.62 107.38 18.37 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.2 p -155.64 -176.86 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.408 -170.744 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.9 m-20 -122.6 105.77 10.39 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -91.93 150.06 21.22 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-O 121.39 0.614 . . . . 0.0 111.174 178.339 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.9 mtpt -91.29 -33.9 15.15 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 115.003 -0.999 . . . . 0.0 108.843 170.484 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -149.11 166.24 29.36 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.304 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 t -82.34 64.31 6.93 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.831 175.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.676 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -177.38 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.065 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.98 9.59 5.24 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.956 0.408 . . . . 0.0 111.933 -178.433 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.1 t -85.45 13.65 6.49 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.9 0.857 . . . . 0.0 109.075 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.676 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 80.9 mt -60.47 -48.87 79.86 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.02 -178.825 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -54.55 -55.68 35.07 Favored Pre-proline 0 CA--C 1.541 0.596 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -175.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -71.64 -27.61 18.28 Favored 'Trans proline' 0 C--N 1.354 0.835 0 C-N-CA 121.177 1.252 . . . . 0.0 111.767 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 44.0 t -69.6 -34.28 73.9 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.018 178.109 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -72.17 -36.07 69.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.883 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -65.3 -32.44 74.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.714 176.21 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.13 -42.12 47.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.056 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 124.2 25.21 1.69 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.726 172.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -114.67 178.47 4.27 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.35 0.575 . . . . 0.0 111.072 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 73.8 mtm180 -83.61 -71.73 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 111.729 -173.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -115.29 159.11 21.43 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -175.45 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.62 124.79 3.76 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.577 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -100.57 168.33 9.78 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.928 0.394 . . . . 0.0 110.219 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 22.4 t -108.34 116.84 32.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.161 0.505 . . . . 0.0 110.895 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.512 HD12 ' HB2' ' A' ' 33' ' ' ASP . 9.0 mt -124.14 172.75 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 176.128 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.432 ' N ' HG22 ' A' ' 28' ' ' ILE . 48.1 p-10 -59.52 63.85 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -172.266 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 100.55 5.87 53.55 Favored Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 18.1 ttmm -122.68 129.66 52.07 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -173.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.567 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 7.1 t -89.85 89.97 7.98 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 172.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' HB2' HD12 ' A' ' 28' ' ' ILE . 7.1 t70 -77.35 105.0 8.19 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.665 0.745 . . . . 0.0 109.283 178.43 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 93.2 m -101.51 169.22 8.99 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.822 -1.081 . . . . 0.0 111.79 -175.089 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.512 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 59.6 m -115.52 125.2 29.03 Favored Pre-proline 0 N--CA 1.441 -0.906 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 167.445 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.55 -160.66 0.13 Allowed 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.555 2.17 . . . . 0.0 111.813 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.297 -0.859 . . . . 0.0 110.166 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.645 0.259 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.581 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 113.66 110.89 2.96 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.489 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.6 pt -87.22 178.05 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.082 0.468 . . . . 0.0 110.896 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -103.27 92.75 4.64 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.031 -177.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.555 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.1 p -145.4 -178.17 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.555 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.0 m-20 -131.48 101.52 5.55 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.339 0.59 . . . . 0.0 110.541 -176.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.427 ' HB2' ' O ' ' A' ' 9' ' ' HIS . 2.2 p -93.07 132.49 37.13 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.641 -178.358 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -90.13 -18.37 25.95 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 166.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 7.2 m80 -151.05 167.72 26.81 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.8 179.449 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 22.2 p -80.93 -21.6 40.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.876 0.369 . . . . 0.0 110.764 177.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.18 -39.55 72.17 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 121.203 -0.523 . . . . 0.0 112.746 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -79.62 2.9 20.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.995 0.426 . . . . 0.0 110.54 178.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 10' ' ' SER . 42.6 t -85.04 -16.33 41.07 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.583 0.706 . . . . 0.0 109.566 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.7 mt -65.04 -57.78 7.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.209 -178.117 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.7 tppp? -49.42 -53.97 34.99 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.129 -0.941 . . . . 0.0 113.493 -174.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.96 -27.87 20.21 Favored 'Trans proline' 0 C--N 1.355 0.911 0 C-N-CA 121.374 1.383 . . . . 0.0 112.873 -177.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 3.3 m -78.45 -25.78 46.0 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 120.819 0.343 . . . . 0.0 110.903 178.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.03 -23.65 55.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 173.27 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -72.83 -36.81 67.57 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.245 -0.888 . . . . 0.0 109.14 172.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.61 -49.96 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.789 178.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.36 20.22 0.57 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.1 177.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.498 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 1.8 mpt? -103.18 178.23 4.61 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 122.737 -0.272 . . . . 0.0 111.367 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.5 mtm180 -97.39 -57.87 2.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.206 0.526 . . . . 0.0 111.805 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.5 OUTLIER -105.88 -161.44 0.8 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.819 -174.195 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.746 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -160.41 138.21 5.41 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.481 178.113 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -132.23 143.97 50.3 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 t -95.78 112.59 24.28 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-O 120.929 0.395 . . . . 0.0 110.672 -174.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.478 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.9 mt -110.01 163.22 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 176.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -44.73 -36.99 3.44 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -172.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -142.73 12.25 2.42 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.855 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.429 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 97.9 mttt -123.84 158.21 32.38 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 117.231 0.516 . . . . 0.0 111.55 -175.327 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.581 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -105.6 88.47 2.84 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 162.786 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.478 ' HB2' HD12 ' A' ' 28' ' ' ILE . 21.2 t70 -77.64 90.28 3.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.739 0.781 . . . . 0.0 110.032 -178.41 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.746 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 34.9 m -111.28 142.54 43.37 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.75 -174.253 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 87.5 m -96.34 128.67 35.81 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.498 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 88.1 Cg_endo -83.81 -162.06 0.16 Allowed 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.55 2.167 . . . . 0.0 112.581 -177.433 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.411 -0.805 . . . . 0.0 110.367 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.629 0.252 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.78 124.87 5.41 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -178.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.2 pt -103.5 -174.37 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -177.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.438 ' O ' HG12 ' A' ' 5' ' ' VAL . 24.2 t-20 -87.68 -87.2 0.15 Allowed 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.256 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.508 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER 50.78 -172.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 124.05 0.844 . . . . 0.0 112.078 175.911 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.508 ' H ' HG22 ' A' ' 5' ' ' VAL . 3.6 p30 -141.07 115.55 9.48 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 174.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.1 p -93.53 130.54 39.36 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.373 0.606 . . . . 0.0 112.036 177.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -84.66 -21.43 30.22 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 163.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.451 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.7 p-80 -175.96 159.34 2.17 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.135 -177.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.9 p -67.5 -26.81 66.54 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -174.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.02 -34.49 79.31 Favored Glycine 0 CA--C 1.517 0.184 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.812 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.451 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 2.6 pt20 -90.66 5.56 47.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.029 0.443 . . . . 0.0 110.393 -178.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.582 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 42.2 t -88.11 -14.45 38.76 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.193 0.521 . . . . 0.0 110.316 -175.459 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -64.79 -51.72 60.68 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.033 -177.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.486 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 59.7 tttp -50.88 -56.89 15.9 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -177.717 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.486 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 58.7 Cg_endo -71.27 -26.79 20.48 Favored 'Trans proline' 0 C--N 1.355 0.913 0 C-N-CA 121.335 1.357 . . . . 0.0 111.702 -177.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.1 t -74.15 -30.49 62.3 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.053 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 tppt? -74.16 -30.83 62.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.83 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.95 -28.32 64.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.454 174.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.5 -36.0 65.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.845 174.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.05 19.95 5.78 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.294 173.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.619 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -103.88 -174.61 2.58 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 122.714 -0.286 . . . . 0.0 111.0 -178.751 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -90.87 -57.95 2.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.885 0.374 . . . . 0.0 110.719 -175.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.495 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -136.11 161.09 36.69 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.186 -176.893 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.582 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -122.56 163.86 15.79 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.386 178.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 35.4 tptt -138.01 145.41 41.85 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.5 t -91.27 106.16 18.31 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.14 0.495 . . . . 0.0 110.057 -177.373 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.802 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.1 mt -96.3 -161.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.802 ' H ' HG22 ' A' ' 28' ' ' ILE . 32.8 p-10 -65.19 44.87 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 120.294 1.407 . . . . 0.0 113.267 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 118.59 -2.4 15.6 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.111 -0.566 . . . . 0.0 113.39 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -120.89 159.72 24.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 117.555 0.678 . . . . 0.0 111.121 -175.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.2 m -100.51 87.87 3.49 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.042 174.209 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.467 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.2 t70 -78.98 124.43 28.24 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 171.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.0 m -107.58 168.12 9.47 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.112 -0.495 . . . . 0.0 112.183 -171.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.495 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 92.9 m -119.9 122.53 28.99 Favored Pre-proline 0 N--CA 1.441 -0.905 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 168.207 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -85.64 -159.27 0.1 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.704 2.269 . . . . 0.0 111.431 -177.186 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.812 -0.613 . . . . 0.0 110.194 178.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.781 0.324 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.599 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 108.77 125.9 5.26 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.523 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.4 pt -110.21 176.32 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.0 0.428 . . . . 0.0 110.827 -175.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -107.72 97.24 6.99 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -178.162 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.681 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.7 p -141.87 -177.73 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.927 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.681 ' H ' HG22 ' A' ' 5' ' ' VAL . 11.8 m-20 -126.35 92.57 3.59 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-O 121.609 0.718 . . . . 0.0 110.964 -177.079 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.9 p -94.55 135.16 36.32 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.473 -1.24 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.0 tptp -85.42 -17.57 36.23 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 166.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.49 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 7.9 p-80 -169.17 155.1 6.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.801 -176.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.704 ' OG ' ' HA ' ' A' ' 26' ' ' LYS . 39.2 t -60.91 -30.23 70.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.852 -175.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.08 -33.23 68.78 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.187 -0.53 . . . . 0.0 113.447 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.49 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 19.1 pt20 -90.78 1.8 56.6 Favored 'General case' 0 C--N 1.326 -0.425 0 O-C-N 122.488 -0.419 . . . . 0.0 110.959 -177.106 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.28 -11.03 57.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.193 0.52 . . . . 0.0 110.011 -175.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 64.0 mt -63.88 -53.39 51.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.454 -176.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.464 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 8.6 tmtt? -51.61 -57.12 15.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.368 -177.163 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.464 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 54.7 Cg_endo -68.86 -26.02 32.41 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 121.477 1.451 . . . . 0.0 111.948 -178.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.707 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.7 t -70.27 -35.76 73.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.928 177.293 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.8 mmmt -72.71 -32.01 65.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.183 177.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -70.98 -31.74 68.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.701 176.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.56 -52.3 16.13 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.483 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 143.77 12.43 0.33 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.536 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.707 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -106.26 -174.72 2.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 117.316 0.558 . . . . 0.0 110.511 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 76.6 mtm180 -98.98 -58.5 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 111.004 -176.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -123.45 156.41 35.6 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.022 -176.801 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.7 150.82 20.2 Favored Glycine 0 N--CA 1.448 -0.562 0 O-C-N 123.615 0.572 . . . . 0.0 111.969 -176.179 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.704 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 59.1 tttm -130.24 149.74 51.8 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -94.21 116.82 29.27 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.687 -178.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.697 HG22 ' H ' ' A' ' 29' ' ' ASN . 6.8 mt -120.07 -122.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.061 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.697 ' H ' HG22 ' A' ' 28' ' ' ILE . 16.4 p30 -91.37 49.55 1.62 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 118.862 0.755 . . . . 0.0 111.243 -175.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 89.44 10.81 65.16 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.893 -0.67 . . . . 0.0 111.515 -177.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 22.8 ptmt -120.14 150.02 41.28 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.599 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.3 t -93.53 83.93 4.6 Favored 'General case' 0 C--N 1.315 -0.919 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 172.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.424 ' CB ' HD12 ' A' ' 28' ' ' ILE . 16.0 t70 -76.39 107.38 8.61 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 63.6 m -105.99 173.44 6.31 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.999 -1.001 . . . . 0.0 112.351 -170.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 90.0 m -122.29 124.6 26.81 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 167.557 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -82.07 -157.9 0.09 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.978 2.452 . . . . 0.0 112.122 -175.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.6 mppt? . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.491 -0.766 . . . . 0.0 109.747 178.195 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.481 1.095 0 CA-C-O 120.986 0.422 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.74 113.89 3.87 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.1 pt -87.98 175.66 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.166 0.508 . . . . 0.0 111.693 -166.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -106.68 89.68 3.09 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.024 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.482 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -146.81 -175.48 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.492 -171.288 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.482 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.2 p-10 -129.9 107.6 9.5 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.749 0.785 . . . . 0.0 110.408 176.582 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 4.2 p -92.45 135.18 34.26 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.805 -177.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -83.52 -23.99 31.87 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 164.258 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.412 ' CD2' ' HG2' ' A' ' 12' ' ' GLN . 10.6 p-80 -173.17 167.42 4.87 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 115.045 -0.98 . . . . 0.0 109.624 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' CYS . 25.6 p -65.7 -30.07 70.7 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.67 0.272 . . . . 0.0 111.682 -175.756 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.58 -39.52 66.74 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 121.175 -0.536 . . . . 0.0 112.495 178.585 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.412 ' HG2' ' CD2' ' A' ' 9' ' ' HIS . 3.9 pt20 -91.67 14.82 14.07 Favored 'General case' 0 C--N 1.33 -0.277 0 O-C-N 122.577 -0.367 . . . . 0.0 111.905 178.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 10' ' ' SER . 35.0 m -90.26 -21.46 22.09 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.876 0.369 . . . . 0.0 110.156 173.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.5 mt -61.12 -56.29 22.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.831 -173.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -56.6 31.9 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.491 -177.113 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -66.63 -23.77 48.95 Favored 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 121.328 1.352 . . . . 0.0 112.31 -178.597 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.5 t -72.13 -37.25 69.5 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.234 0.54 . . . . 0.0 110.109 176.726 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -78.41 -26.81 46.5 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.857 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -71.0 -29.48 65.45 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.32 172.446 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.92 -51.76 17.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.433 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.53 9.93 0.62 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.113 177.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.607 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.65 -174.4 2.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.975 0.388 . . . . 0.0 110.242 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -99.93 -75.5 0.57 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.999 0.428 . . . . 0.0 111.504 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.444 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -101.68 157.95 16.45 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.92 -175.144 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 141.73 11.54 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.391 -175.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 87.6 tttt -126.85 152.94 46.33 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.6 t -97.84 118.49 34.51 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.675 HG22 ' H ' ' A' ' 29' ' ' ASN . 8.8 mt -118.36 -119.24 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.55 -172.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.675 ' H ' HG22 ' A' ' 28' ' ' ILE . 16.0 p30 -90.77 45.77 1.28 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.313 0.578 . . . . 0.0 110.824 -175.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.96 1.95 58.37 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.519 -177.106 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -117.32 143.76 45.6 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 23.1 m -86.68 86.43 7.33 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 167.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.528 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.7 t70 -77.24 135.7 38.48 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.16 -178.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 85.7 m -126.49 168.11 14.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.33 -168.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.444 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 97.7 m -119.75 127.58 26.33 Favored Pre-proline 0 N--CA 1.444 -0.734 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 165.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.51 -159.88 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.601 2.201 . . . . 0.0 112.22 -175.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.546 -0.74 . . . . 0.0 110.195 -178.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.768 0.318 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 113.9 127.46 4.53 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -175.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.513 ' CD1' ' HB ' ' A' ' 5' ' ' VAL . 19.1 pt -103.77 -178.53 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.006 0.431 . . . . 0.0 111.249 -172.215 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -99.51 2.55 44.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.565 0.697 . . . . 0.0 110.292 -173.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.527 HG12 ' SG ' ' A' ' 32' ' ' CYS . 1.2 t -69.36 152.51 9.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.418 176.504 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -106.52 128.41 54.08 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.386 -176.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.727 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 2.7 p -91.43 139.64 30.52 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -177.07 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.408 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 35.1 ttpt -88.16 -22.68 23.93 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 163.394 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.562 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 16.1 p-80 -172.47 164.1 5.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.35 179.337 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 p -61.39 -42.89 99.44 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -174.542 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.63 -30.6 59.46 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 116.079 -0.51 . . . . 0.0 113.805 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.562 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.73 6.0 45.88 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 117.099 0.449 . . . . 0.0 111.554 -177.306 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.727 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 54.7 m -84.79 -21.52 29.91 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.077 0.465 . . . . 0.0 109.882 175.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.49 -49.26 76.88 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.492 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.609 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.3 tmtp? -53.48 -59.47 9.33 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.316 -175.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.609 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 47.5 Cg_endo -73.13 -29.16 11.99 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 121.25 1.3 . . . . 0.0 113.309 -178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 11.9 m -71.7 -29.73 64.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 120.635 0.255 . . . . 0.0 111.129 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.33 -27.99 62.77 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.242 0.544 . . . . 0.0 109.955 175.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -73.51 -37.87 65.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.567 172.693 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.77 -44.15 86.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.883 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.05 18.5 0.84 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.766 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.546 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -107.61 -173.16 2.22 Favored 'General case' 0 C--N 1.322 -0.622 0 O-C-N 122.588 -0.36 . . . . 0.0 110.85 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.9 mtm180 -108.29 -58.29 2.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.067 0.46 . . . . 0.0 111.745 -175.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.466 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -105.02 -153.83 0.5 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.77 -174.655 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.75 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.02 136.28 3.65 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.703 179.462 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -134.81 150.6 50.53 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.369 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 43.9 t -102.55 111.32 23.57 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -177.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.678 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.4 mt -105.41 -115.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.22 -174.338 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.678 ' H ' HG22 ' A' ' 28' ' ' ILE . 17.3 p30 -90.99 43.23 1.14 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 118.709 0.686 . . . . 0.0 110.588 -177.29 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.39 2.39 60.35 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.761 -176.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 16.8 ptpt -114.49 150.9 34.12 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.527 ' SG ' HG12 ' A' ' 5' ' ' VAL . 59.0 m -91.16 90.17 7.68 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.334 173.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.511 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.5 t70 -79.22 118.98 21.67 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 172.055 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.75 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 33.9 m -133.85 139.97 46.57 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 -173.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.466 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 88.3 m -86.32 131.93 44.69 Favored Pre-proline 0 N--CA 1.447 -0.595 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.509 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 67.5 Cg_endo -82.22 -161.57 0.15 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.657 2.238 . . . . 0.0 112.547 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.297 -0.859 . . . . 0.0 109.875 -179.158 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.482 1.138 0 CA-C-O 120.794 0.331 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 101.81 112.81 3.62 Favored Glycine 0 N--CA 1.443 -0.851 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -175.371 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.452 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.4 pt -92.12 177.48 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.328 0.585 . . . . 0.0 111.314 -171.353 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -103.08 86.63 2.73 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.304 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.494 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -145.0 -179.87 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.674 -173.41 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.494 ' H ' HG22 ' A' ' 5' ' ' VAL . 19.7 m-20 -132.58 106.74 8.0 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.916 0.389 . . . . 0.0 109.955 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -91.78 136.93 32.77 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.398 0.618 . . . . 0.0 111.309 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -83.86 -19.8 34.24 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 168.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.7 p-80 -170.89 167.3 7.49 Favored 'General case' 0 N--CA 1.461 0.083 0 CA-C-N 115.111 -0.95 . . . . 0.0 110.442 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.7 p -65.61 -40.4 92.58 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -176.306 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.85 -32.96 59.52 Favored Glycine 0 CA--C 1.52 0.376 0 CA-C-N 116.247 -0.433 . . . . 0.0 114.172 -175.089 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -90.4 -1.39 57.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.251 0.525 . . . . 0.0 111.287 -177.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 48.1 t -74.69 -23.12 58.57 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.656 0.741 . . . . 0.0 110.0 -178.182 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -60.01 -42.57 94.61 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.211 -179.389 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 75.9 tttt -56.09 -61.57 6.27 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.806 -176.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -78.51 -33.52 1.77 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 121.527 1.485 . . . . 0.0 113.965 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 6.0 t -74.91 -25.26 58.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.011 0.434 . . . . 0.0 110.734 -173.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -75.07 -35.61 61.82 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.039 0.447 . . . . 0.0 110.046 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -71.74 -25.8 62.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.981 177.037 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.15 -52.64 53.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.173 175.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.5 3.66 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.334 -0.936 . . . . 0.0 113.532 178.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -103.53 -178.74 3.75 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.346 0.573 . . . . 0.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -100.07 -56.61 2.33 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.353 -174.15 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.515 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.8 OUTLIER -107.25 -159.26 0.69 Allowed 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.698 -175.895 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.401 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -175.58 136.68 3.44 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.491 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -127.29 167.0 16.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.744 0.307 . . . . 0.0 110.352 177.253 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.8 t -110.1 100.13 9.1 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.527 ' CD1' ' HB3' ' A' ' 33' ' ' ASP . 2.4 mp -95.78 -92.83 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.646 -172.427 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.516 ' N ' HG22 ' A' ' 28' ' ' ILE . 22.0 m-20 -93.36 45.06 1.15 Allowed 'General case' 0 CA--C 1.505 -0.755 0 CA-C-O 121.88 0.848 . . . . 0.0 109.899 174.657 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.9 6.37 72.77 Favored Glycine 0 C--N 1.314 -0.654 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.282 -171.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 159.1 19.36 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.714 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 1.4 m -93.82 92.59 7.51 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.328 -176.244 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.527 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 19.3 t70 -86.92 124.24 32.91 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 167.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 7.5 m -135.11 158.47 44.27 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 121.056 -0.258 . . . . 0.0 110.846 -171.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 33.0 m -96.22 128.74 35.77 Favored Pre-proline 0 N--CA 1.446 -0.632 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 175.702 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -82.23 -160.03 0.12 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.572 2.181 . . . . 0.0 112.308 -178.016 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.206 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.863 0.363 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.482 ' HA3' ' HE2' ' A' ' 31' ' ' LYS . . . 121.14 126.35 3.29 Favored Glycine 0 N--CA 1.443 -0.891 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.226 -174.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -104.04 -178.01 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.329 0.585 . . . . 0.0 111.533 -173.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -105.3 109.07 20.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.893 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.528 HG22 ' H ' ' A' ' 6' ' ' ASP . 1.4 p -163.03 -178.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -173.009 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.528 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.5 m-20 -127.74 110.47 12.66 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.838 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.524 ' HA ' ' OE1' ' A' ' 12' ' ' GLN . 2.0 p -91.04 123.91 34.86 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.415 0.626 . . . . 0.0 111.702 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -74.98 -25.48 58.87 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 167.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 28.4 p-80 -177.38 163.26 1.99 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.734 177.303 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 6.4 p -63.48 -36.35 83.47 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -175.561 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.49 -39.32 65.48 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.176 -0.535 . . . . 0.0 113.067 -178.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.524 ' OE1' ' HA ' ' A' ' 7' ' ' CYS . 0.0 OUTLIER -90.55 -0.12 57.56 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 122.66 -0.317 . . . . 0.0 110.959 -177.718 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.626 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 32.6 t -76.02 -22.07 56.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.587 0.708 . . . . 0.0 109.625 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 10.9 mp -57.43 -43.01 83.5 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.792 -1.095 . . . . 0.0 111.065 177.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -59.51 -61.05 8.63 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 115.597 -0.728 . . . . 0.0 112.843 -174.292 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.68 -31.34 13.37 Favored 'Trans proline' 0 C--N 1.354 0.823 0 C-N-CA 121.453 1.435 . . . . 0.0 112.622 -175.012 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 8.8 t -77.63 -23.46 49.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.173 -176.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HA ' ' O ' ' A' ' 22' ' ' MET . 27.2 ttpp -68.35 -38.46 81.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 175.143 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -68.71 -28.25 66.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.504 176.076 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.0 -10.94 59.84 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.866 177.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.0 -26.12 6.56 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.501 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.593 ' O ' ' HA ' ' A' ' 18' ' ' LYS . 1.9 mpt? -83.47 175.98 9.4 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 117.261 0.531 . . . . 0.0 111.391 -174.24 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.7 mtm180 -94.29 -61.43 1.52 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.566 -175.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.558 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -121.81 158.57 28.58 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.044 -176.4 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.626 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -133.86 157.55 22.87 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.524 -177.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.401 ' HB3' HD11 ' A' ' 28' ' ' ILE . 52.8 tptt -127.18 157.57 39.41 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 176.146 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.4 t -104.61 97.87 7.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.602 . . . . 0.0 109.875 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.654 HG22 ' N ' ' A' ' 29' ' ' ASN . 3.5 mp -90.06 -110.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.738 -175.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.654 ' N ' HG22 ' A' ' 28' ' ' ILE . 13.2 p30 -92.53 47.11 1.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 121.628 -0.67 . . . . 0.0 110.391 179.367 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 79.42 19.83 70.65 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -172.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.482 ' HE2' ' HA3' ' A' ' 2' ' ' GLY . 32.1 tttt -120.1 138.53 53.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.929 -0.635 . . . . 0.0 109.536 -179.16 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.469 ' SG ' HG11 ' A' ' 5' ' ' VAL . 1.3 m -87.56 83.02 7.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.718 173.243 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.57 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 16.3 t70 -79.13 124.43 28.31 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 168.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.558 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.7 m -124.11 178.17 5.45 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.105 0.479 . . . . 0.0 112.069 -167.292 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.446 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 95.2 m -125.12 125.53 25.28 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 170.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -82.51 -159.64 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.745 2.297 . . . . 0.0 112.199 -177.156 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 11.3 mptt . . . . . 0 C--O 1.247 0.949 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.322 177.713 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.435 0.16 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.598 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 97.38 138.9 10.37 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -174.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.408 HG12 ' O ' ' A' ' 32' ' ' CYS . 10.1 pt -109.51 176.76 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-O 121.362 0.601 . . . . 0.0 111.872 -170.096 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -100.74 100.23 10.88 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.858 178.493 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -162.92 179.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -174.281 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.443 ' N ' HG13 ' A' ' 5' ' ' VAL . 6.4 m-20 -128.02 112.82 15.05 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.032 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.676 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.2 p -88.8 129.76 35.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.608 0.718 . . . . 0.0 111.663 -177.597 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -87.15 -15.08 39.45 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 167.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.472 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 26.7 p-80 178.41 158.15 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.493 178.071 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.5 p -58.32 -35.45 71.9 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 111.648 -175.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.78 -32.64 70.31 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 115.99 -0.55 . . . . 0.0 113.641 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.83 7.78 38.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.576 0.688 . . . . 0.0 111.446 -177.486 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 74.8 m -82.05 -15.6 53.02 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.143 176.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.85 -56.59 19.34 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.186 -171.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -57.12 -54.15 57.69 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.661 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.55 -27.58 39.04 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 121.265 1.31 . . . . 0.0 112.557 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.6 t -73.01 -33.95 66.09 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.26 0.552 . . . . 0.0 110.209 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -73.13 -39.16 65.97 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.914 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.2 ttmm -69.17 -28.85 66.78 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.916 176.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.06 -43.54 78.4 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.891 175.347 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 125.72 15.04 3.0 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.849 176.488 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.537 ' SD ' ' HB2' ' A' ' 34' ' ' CYS . 60.9 mtt -116.13 -179.17 3.59 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 122.649 -0.324 . . . . 0.0 110.611 -178.164 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtm180 -92.77 -79.1 0.4 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.046 -170.501 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -107.17 158.9 16.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -175.584 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.98 137.15 9.21 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.328 -176.015 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 26.7 ttpp -117.73 154.16 32.17 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.1 t -96.77 107.74 20.27 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.251 0.548 . . . . 0.0 110.354 -176.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.574 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 1.9 mp -94.49 -169.97 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 179.746 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.574 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 9.8 p30 -39.67 -43.17 1.32 Allowed 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 118.889 0.768 . . . . 0.0 112.244 -174.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 6' ' ' ASP . . . -152.41 2.63 0.33 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.201 -1.0 . . . . 0.0 112.305 172.68 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.25 152.01 40.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.997 0.427 . . . . 0.0 111.807 -169.548 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.676 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 65.2 m -91.59 92.91 8.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.509 176.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.598 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 22.3 t70 -80.82 135.94 36.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.605 175.228 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.537 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 81.1 m -123.84 157.51 33.99 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.268 -0.424 . . . . 0.0 112.121 -169.39 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.516 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.3 m -103.27 128.57 27.27 Favored Pre-proline 0 N--CA 1.442 -0.857 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 169.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -83.51 -163.63 0.22 Allowed 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.339 2.026 . . . . 0.0 112.167 -175.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm . . . . . 0 C--O 1.246 0.87 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.14 179.805 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.477 0.913 0 CA-C-O 120.928 0.394 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 111.93 106.13 2.84 Favored Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -176.569 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.409 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.1 pt -89.87 178.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.413 0.625 . . . . 0.0 111.639 -170.539 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -103.86 105.84 16.17 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.652 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -157.98 -175.91 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.364 -172.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 4.9 m-20 -132.92 106.1 7.49 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.253 0.549 . . . . 0.0 110.236 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -92.94 125.6 37.62 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.187 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 56.7 tptt -74.88 -22.14 58.82 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 167.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 13.5 p-80 -171.74 163.7 6.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 114.636 -1.165 . . . . 0.0 109.794 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 p -66.35 -33.4 75.65 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.787 0.291 . . . . 0.0 111.787 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.14 -34.38 62.39 Favored Glycine 0 CA--C 1.519 0.308 0 C-N-CA 121.273 -0.489 . . . . 0.0 113.353 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 6.5 pt20 -90.7 -1.73 57.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.836 0.351 . . . . 0.0 110.63 -177.389 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.1 t -79.86 -16.72 54.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.412 0.625 . . . . 0.0 110.258 -173.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.6 mp -64.96 -48.74 72.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.864 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 73.2 tttt -53.81 -57.52 17.26 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -174.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.478 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.7 Cg_endo -67.97 -29.57 34.03 Favored 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 121.81 1.674 . . . . 0.0 112.397 -175.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 2.2 m -78.32 -29.07 47.49 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.46 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 13.7 tmtt? -67.59 -38.4 83.96 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.9 ttmm -68.01 -35.28 78.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.747 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.24 -12.99 60.72 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.28 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 108.23 14.21 17.23 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.783 -0.723 . . . . 0.0 113.358 175.014 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' MET . . . . . 0.526 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -104.32 179.67 4.2 Favored 'General case' 0 C--N 1.319 -0.738 0 O-C-N 122.333 -0.51 . . . . 0.0 110.758 178.691 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.45 -57.11 2.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.03 0.443 . . . . 0.0 111.658 -175.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.7 OUTLIER -105.5 -159.21 0.7 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.79 -174.681 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.659 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -170.6 133.14 2.69 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.271 -0.966 . . . . 0.0 112.9 178.371 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.49 147.09 50.31 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.7 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.9 t -96.7 112.02 23.94 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.837 0.351 . . . . 0.0 110.508 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.43 ' HB ' ' HG2' ' A' ' 31' ' ' LYS . 7.0 mt -104.85 170.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.644 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -45.09 -34.88 2.79 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -171.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.35 -1.76 1.03 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 119.365 -1.397 . . . . 0.0 113.931 174.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.43 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 21.2 ptmt -124.02 153.7 40.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 118.184 0.992 . . . . 0.0 111.53 -172.034 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.558 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.5 OUTLIER -92.79 92.5 7.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 169.772 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -78.87 103.4 8.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.478 175.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.659 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 20.0 m -125.03 142.53 51.43 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.293 -174.422 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.519 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 41.2 m -88.42 129.83 47.87 Favored Pre-proline 0 N--CA 1.448 -0.574 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 90.2 Cg_endo -81.36 -158.73 0.1 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.798 2.332 . . . . 0.0 112.261 -177.282 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.498 -0.763 . . . . 0.0 110.771 -177.784 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.75 0.309 . . . . 0.0 110.769 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 114.46 130.8 5.04 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.4 pt -103.21 177.11 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-O 121.177 0.513 . . . . 0.0 111.658 -170.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -101.32 70.48 1.32 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.255 -175.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -131.44 179.53 4.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.324 -176.5 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.454 ' N ' HG13 ' A' ' 5' ' ' VAL . 7.2 p-10 -128.33 111.28 13.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.56 0.695 . . . . 0.0 109.966 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.454 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.8 p -92.9 132.07 37.36 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.969 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 mtmt -87.6 -18.45 29.64 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 163.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.463 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.2 p-80 -167.49 167.39 13.72 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.616 -1.175 . . . . 0.0 110.329 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.459 ' HB3' ' H ' ' A' ' 27' ' ' CYS . 4.9 p -72.27 -31.26 65.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -176.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.27 -27.87 66.04 Favored Glycine 0 CA--C 1.517 0.212 0 C-N-CA 121.11 -0.567 . . . . 0.0 113.408 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -89.0 3.65 50.94 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 122.597 -0.355 . . . . 0.0 110.721 -178.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 88.9 m -86.86 -16.12 37.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.829 0.347 . . . . 0.0 110.483 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.9 mt -62.67 -62.78 1.5 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.913 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.485 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 54.5 tttm -55.23 -58.44 15.04 Favored Pre-proline 0 N--CA 1.446 -0.633 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 37.2 Cg_endo -66.5 -28.1 45.94 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 121.403 1.402 . . . . 0.0 112.922 -173.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 4.2 t -82.76 -26.65 31.69 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.19 0.519 . . . . 0.0 109.897 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -72.33 -36.31 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.8 tptm -72.14 -32.7 67.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.825 173.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.8 -48.1 80.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.586 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 144.95 8.78 0.35 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.887 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.433 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.78 178.36 4.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.71 0.255 . . . . 0.0 110.326 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.6 mtm180 -96.84 -54.18 3.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.864 0.364 . . . . 0.0 111.241 -173.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.456 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -112.48 -153.15 0.52 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.886 -176.633 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.35 139.06 3.18 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.725 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -133.03 151.47 52.05 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 177.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.459 ' H ' ' HB3' ' A' ' 10' ' ' SER . 42.6 t -88.01 131.87 34.48 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.632 HG22 ' N ' ' A' ' 29' ' ' ASN . 6.4 mt -122.89 -112.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.207 -177.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.632 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.22 46.73 1.27 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.417 0.627 . . . . 0.0 110.586 -179.579 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.28 -5.71 65.54 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.662 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -109.1 154.57 22.09 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 120.729 0.299 . . . . 0.0 110.262 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.454 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 35.9 m -96.73 90.55 5.32 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.807 172.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -86.0 135.13 33.77 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.857 175.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 3.2 m -135.39 178.62 6.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.893 0.378 . . . . 0.0 111.063 -170.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.456 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 57.9 m -113.64 127.42 26.84 Favored Pre-proline 0 N--CA 1.443 -0.787 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 171.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -84.87 -161.37 0.13 Allowed 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.894 2.396 . . . . 0.0 112.102 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.585 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.947 0 CA-C-O 118.595 -0.716 . . . . 0.0 110.035 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.9 m . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.655 0.264 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.624 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 110.96 109.51 3.14 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.903 178.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.526 HG12 ' CB ' ' A' ' 32' ' ' CYS . 1.1 pt -98.24 175.66 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.666 0.27 . . . . 0.0 110.314 -177.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -103.76 109.63 21.42 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.614 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.7 p -156.53 -175.95 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -172.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.614 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.1 m-20 -127.77 97.28 4.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.449 0.642 . . . . 0.0 111.041 -176.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 5.8 p -94.36 134.18 37.14 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.223 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -88.93 -14.64 36.24 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 166.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -171.34 161.66 6.54 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 114.643 -1.162 . . . . 0.0 110.445 174.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.5 p -58.61 -40.44 83.3 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -176.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.61 -41.69 50.24 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 114.112 0.405 . . . . 0.0 114.112 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -83.52 -2.72 56.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.031 0.415 . . . . 0.0 111.467 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.29 -11.95 57.19 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.233 0.54 . . . . 0.0 110.159 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.8 mp -63.44 -42.88 98.67 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.55 -178.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -56.8 -58.33 18.17 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.339 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.69 -24.04 22.16 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 121.47 1.447 . . . . 0.0 112.062 -178.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 46.3 t -69.33 -38.96 78.42 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 178.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -71.47 -35.18 70.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.42 178.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.3 tmtm? -61.6 -38.12 86.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.289 -0.868 . . . . 0.0 109.539 175.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.15 -44.1 76.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.54 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.25 8.14 0.75 Allowed Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.912 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.46 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 4.2 mpp? -108.1 -173.83 2.38 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 117.594 0.697 . . . . 0.0 111.208 -179.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 64.1 mtm180 -93.21 -60.69 1.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.451 -174.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.497 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -130.75 161.14 32.37 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.567 -176.279 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.501 ' HA2' ' HA ' ' A' ' 34' ' ' CYS . . . -131.22 140.02 11.43 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.858 -175.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -101.55 170.08 8.42 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 173.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.7 t -107.56 107.85 18.88 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.187 0.518 . . . . 0.0 111.187 -176.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.571 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.2 mt -104.56 162.27 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.19 -38.57 0.78 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.09 13.68 1.29 Allowed Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.054 175.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.9 148.82 45.01 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 120.961 0.41 . . . . 0.0 110.618 -173.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.624 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -94.55 87.92 5.27 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 167.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.571 ' HB2' HD12 ' A' ' 28' ' ' ILE . 32.1 t70 -74.52 96.73 2.98 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 122.019 0.914 . . . . 0.0 109.38 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.501 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 69.7 m -86.45 167.85 14.31 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.12 -1.4 . . . . 0.0 112.968 -171.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.497 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 30.4 m -129.23 119.92 19.83 Favored Pre-proline 0 N--CA 1.434 -1.264 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 168.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.46 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 72.0 Cg_endo -84.4 -157.98 0.09 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.303 0 C-N-CA 122.16 1.907 . . . . 0.0 111.609 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.679 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.776 -0.63 . . . . 0.0 110.601 -179.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.653 0.263 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 103.84 104.65 2.92 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.886 -0.674 . . . . 0.0 111.769 -179.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.7 pt -91.88 178.51 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.698 0.285 . . . . 0.0 110.452 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -104.24 110.79 23.14 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 177.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.6 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -160.82 -178.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -173.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.6 ' H ' HG22 ' A' ' 5' ' ' VAL . 26.3 m-20 -128.6 107.77 9.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.366 0.603 . . . . 0.0 110.069 -178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 p -91.63 135.69 33.69 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.204 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -82.8 -20.72 35.22 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.413 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 22.3 p-80 -177.93 159.06 1.32 Allowed 'General case' 0 CA--C 1.522 -0.114 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.272 175.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 p -52.72 -44.88 66.65 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -54.49 -34.32 54.89 Favored Glycine 0 C--O 1.228 -0.273 0 CA-C-N 115.908 -0.587 . . . . 0.0 114.002 -177.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -91.48 3.12 55.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 117.744 0.772 . . . . 0.0 111.99 -177.432 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -84.09 -2.51 56.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.62 0.724 . . . . 0.0 109.543 -177.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 72.3 mt -61.09 -55.93 26.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.829 -1.078 . . . . 0.0 111.404 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -52.03 -54.86 36.24 Favored Pre-proline 0 CA--C 1.542 0.664 0 N-CA-C 113.341 0.867 . . . . 0.0 113.341 -172.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.18 -31.58 22.81 Favored 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 121.276 1.318 . . . . 0.0 112.406 -176.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.546 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 7.8 t -81.59 -22.09 37.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.21 0.528 . . . . 0.0 110.198 -178.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -65.41 -38.79 90.99 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 174.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -62.3 -43.94 97.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.98 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.35 -40.45 90.75 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.759 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 129.22 17.51 1.78 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.969 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.546 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -109.8 -178.02 3.42 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.748 179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.3 mtm180 -103.8 -63.58 1.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.891 0.377 . . . . 0.0 111.589 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.442 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.61 157.43 25.36 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 -177.411 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.9 144.47 16.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.988 -174.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttp -110.12 167.55 10.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 110.229 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 36.3 t -108.54 110.72 22.27 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.437 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.469 HG22 ' N ' ' A' ' 29' ' ' ASN . 10.1 mt -117.15 176.03 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.469 ' N ' HG22 ' A' ' 28' ' ' ILE . 9.6 p30 -38.4 -43.97 0.87 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -169.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -155.83 17.07 0.47 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.784 173.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.403 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -124.54 148.85 47.52 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.665 -175.528 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.63 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -92.83 89.17 6.49 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 173.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -77.12 107.69 9.67 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.615 0.721 . . . . 0.0 109.388 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.9 m -111.06 171.49 7.44 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.841 -171.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.44 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 75.4 m -122.18 122.9 27.39 Favored Pre-proline 0 N--CA 1.436 -1.13 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 168.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.516 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 95.8 Cg_endo -84.55 -162.95 0.17 Allowed 'Trans proline' 0 N--CA 1.445 -1.332 0 C-N-CA 122.197 1.931 . . . . 0.0 112.474 -177.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.723 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.03 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 120.624 0.249 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.87 127.24 5.85 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -174.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.4 pt -100.74 172.71 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.419 0.628 . . . . 0.0 111.732 -169.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -102.64 95.29 6.12 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.815 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -155.67 -177.39 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.948 -0.569 . . . . 0.0 109.734 -172.799 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.484 ' N ' HG13 ' A' ' 5' ' ' VAL . 16.4 m-20 -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.817 0.341 . . . . 0.0 110.42 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 2.4 p -92.83 128.97 38.88 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . 0.454 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 62.5 tttm -81.73 -19.53 41.24 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 167.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.456 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 6.5 p-80 -166.28 151.19 8.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.804 -177.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 t -74.3 73.8 1.83 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.68 177.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.14 -28.84 0.03 OUTLIER Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.105 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.456 ' HB3' ' NE2' ' A' ' 9' ' ' HIS . 9.8 pt20 -87.98 3.39 48.91 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 121.142 -0.223 . . . . 0.0 111.146 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.591 ' O ' ' HB2' ' A' ' 17' ' ' CYS . 73.5 m -77.17 -11.52 59.83 Favored 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.355 -175.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.4 mt -62.19 -54.52 39.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.844 -0.617 . . . . 0.0 111.846 -174.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -53.51 -54.92 40.35 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.403 -178.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.95 -23.62 25.16 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 121.786 1.657 . . . . 0.0 112.538 178.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.591 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 19.4 t -69.72 -35.53 75.12 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.447 0.641 . . . . 0.0 109.629 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -70.47 -30.66 67.54 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.924 177.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 52.9 tttm -68.56 -41.43 79.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.705 173.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.42 -40.38 93.29 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.741 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 119.76 17.6 4.62 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.479 177.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.551 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 61.3 mtt -116.12 177.68 4.59 Favored 'General case' 0 C--N 1.32 -0.699 0 O-C-N 122.6 -0.353 . . . . 0.0 110.432 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 -91.76 -74.09 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 120.458 -0.497 . . . . 0.0 111.983 -169.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.507 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -110.23 158.95 17.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.886 -174.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.7 161.41 22.88 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.46 -175.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 0.4 OUTLIER -145.83 144.84 30.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -177.21 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 39.2 t -89.05 121.45 31.4 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.413 -178.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 6.5 mt -114.96 167.69 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.42 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -67.2 53.1 0.05 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -175.015 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 155.1 -36.77 0.65 Allowed Glycine 0 N--CA 1.438 -1.176 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.309 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -124.45 174.1 8.0 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 117.505 0.652 . . . . 0.0 111.663 -172.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -108.08 98.16 7.76 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 166.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.522 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.7 t70 -76.19 117.85 18.31 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.592 0.711 . . . . 0.0 110.367 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.421 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 48.3 m -106.83 160.68 15.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.443 -175.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.507 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 48.2 m -112.24 125.75 29.6 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 169.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -79.9 -159.83 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.673 2.249 . . . . 0.0 111.688 -176.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.3 mptt . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.705 -0.664 . . . . 0.0 109.794 178.977 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 121.015 0.436 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 107.77 114.66 3.84 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.862 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.476 HG12 ' HB2' ' A' ' 32' ' ' CYS . 10.3 pt -100.51 -179.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.126 0.489 . . . . 0.0 111.155 -173.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -108.16 118.51 36.94 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.373 -0.83 . . . . 0.0 108.993 175.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.4 p -167.32 -174.97 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -172.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.567 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.3 p-10 -126.94 110.88 13.48 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.673 0.749 . . . . 0.0 110.395 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -92.84 127.45 38.36 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.476 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -73.97 -25.88 60.17 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 165.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -174.75 163.76 3.47 Favored 'General case' 0 C--O 1.226 -0.165 0 CA-C-N 114.511 -1.222 . . . . 0.0 109.459 -179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 p -59.21 -37.07 76.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.692 0.282 . . . . 0.0 111.72 -177.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.56 -33.45 66.85 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 116.269 -0.423 . . . . 0.0 114.065 -176.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 6.34 44.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.413 0.607 . . . . 0.0 111.185 -178.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.542 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 46.0 t -84.47 -15.25 46.71 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.253 0.549 . . . . 0.0 109.744 179.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.8 mt -58.18 -50.76 72.39 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.816 -175.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.456 ' NZ ' ' HB2' ' A' ' 15' ' ' LYS . 3.5 ttmp? -59.96 -56.25 37.46 Favored Pre-proline 0 N--CA 1.445 -0.709 0 CA-C-N 115.453 -0.794 . . . . 0.0 113.063 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.8 -26.17 32.66 Favored 'Trans proline' 0 C--N 1.356 0.934 0 C-N-CA 121.024 1.149 . . . . 0.0 111.45 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 42.0 t -68.07 -37.02 80.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.783 175.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.407 ' NZ ' ' HB2' ' A' ' 18' ' ' LYS . 2.7 ttmp? -68.64 -39.94 80.51 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.733 176.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -59.16 -33.14 70.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.231 175.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.08 -36.85 55.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.739 177.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.06 2.18 5.18 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.354 -0.926 . . . . 0.0 114.29 172.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.558 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.0 mpp? -96.03 -169.01 1.85 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 117.705 0.753 . . . . 0.0 111.051 -177.081 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 -99.87 -59.61 1.68 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.02 0.438 . . . . 0.0 111.45 -175.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.455 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -128.99 158.98 37.33 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.345 -175.973 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.542 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -135.27 155.02 21.89 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.813 -177.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -117.86 166.73 12.12 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 48.7 t -103.81 106.29 16.75 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.913 -178.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 29' ' ' ASN . 12.8 mt -116.03 171.71 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.463 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -58.48 65.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.493 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 95.94 6.41 59.22 Favored Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 31.1 ttmt -123.73 133.57 53.84 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -176.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.3 OUTLIER -97.07 87.78 4.31 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 172.434 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.86 113.08 15.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.49 0.662 . . . . 0.0 109.566 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.471 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 99.0 m -101.66 173.42 6.43 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.17 -172.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.455 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 87.9 m -126.09 124.97 24.7 Favored Pre-proline 0 N--CA 1.44 -0.958 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 168.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.92 -156.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 122.744 2.296 . . . . 0.0 111.868 -176.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 5.5 mptp? . . . . . 0 C--O 1.247 0.954 0 CA-C-O 118.603 -0.713 . . . . 0.0 110.672 178.265 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 34' ' ' CYS . 76.3 t . . . . . 0 N--CA 1.479 1.016 0 CA-C-O 120.813 0.34 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.564 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 102.53 97.97 2.4 Favored Glycine 0 N--CA 1.443 -0.893 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.183 179.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.559 HG12 ' CB ' ' A' ' 32' ' ' CYS . 2.1 pt -94.77 -179.55 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -106.49 106.45 16.97 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.628 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.6 p -154.0 -177.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -172.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 5' ' ' VAL . 12.0 m-20 -128.92 102.97 6.76 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 120.96 0.41 . . . . 0.0 110.787 -178.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.1 p -94.33 131.36 40.04 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.345 176.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -85.26 -18.0 35.29 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 165.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.436 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 8.6 p-80 -167.68 162.63 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.775 -176.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.3 p -66.88 -37.73 84.97 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -174.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.71 -26.28 59.92 Favored Glycine 0 CA--C 1.519 0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 113.897 -174.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.436 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 17.5 pt20 -88.39 -4.67 58.61 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 117.384 0.592 . . . . 0.0 110.908 -177.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -88.42 -2.36 58.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.534 0.683 . . . . 0.0 109.85 -175.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.3 mt -62.58 -57.16 12.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.169 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.459 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.2 tmmm? -50.76 -57.86 12.06 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 114.695 -1.138 . . . . 0.0 112.811 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.541 ' HB2' HD11 ' A' ' 3' ' ' ILE . 37.1 Cg_endo -64.94 -33.55 51.43 Favored 'Trans proline' 0 C--N 1.352 0.724 0 C-N-CA 121.628 1.552 . . . . 0.0 113.356 -173.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -83.5 -21.72 32.72 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.084 0.468 . . . . 0.0 110.463 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -72.78 -36.26 67.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -68.15 -36.32 79.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.783 173.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.69 -45.94 84.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.442 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.89 21.23 0.56 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.842 176.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.468 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 2.1 mpt? -109.7 -175.42 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 O-C-N 122.669 -0.312 . . . . 0.0 110.493 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.0 mtm180 -96.37 -61.44 1.43 Allowed 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.183 -0.607 . . . . 0.0 111.958 -176.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -108.06 -158.11 0.64 Allowed 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.074 -173.42 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.21 141.63 6.93 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.328 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -130.36 166.9 19.45 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 177.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.4 t -107.15 110.68 22.82 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.959 -175.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.432 HD12 ' HB2' ' A' ' 33' ' ' ASP . 8.3 mt -113.37 171.46 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 174.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.409 ' N ' HG22 ' A' ' 28' ' ' ILE . 12.6 m-80 -38.6 -53.71 1.59 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.908 0.483 . . . . 0.0 111.869 -171.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.71 21.82 2.17 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 173.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.413 ' O ' ' HB ' ' A' ' 28' ' ' ILE . 30.1 ttmt -122.67 132.79 54.43 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 110.305 -0.258 . . . . 0.0 110.305 -171.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.564 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.4 t -87.84 90.52 8.41 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.432 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.3 t70 -77.13 104.81 7.84 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.465 0.65 . . . . 0.0 109.753 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.44 ' O ' HG13 ' A' ' 1' ' ' VAL . 4.3 p -128.47 141.11 51.49 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.253 -173.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 38.4 m -92.91 127.87 45.86 Favored Pre-proline 0 N--CA 1.441 -0.915 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 46.4 Cg_endo -84.03 -154.09 0.05 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 122.521 2.147 . . . . 0.0 111.714 -176.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.457 ' HD2' ' N ' ' A' ' 37' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.567 178.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.612 HG21 ' O ' ' A' ' 34' ' ' CYS . 27.2 m . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.847 0.356 . . . . 0.0 110.306 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 100.65 118.11 4.23 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -176.157 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.8 pt -102.55 170.61 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.43 0.634 . . . . 0.0 111.082 -174.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -104.79 92.09 4.11 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.255 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.439 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.7 OUTLIER -147.69 -179.2 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.498 -173.385 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.9 m-20 -128.4 102.69 6.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.163 0.506 . . . . 0.0 110.298 -178.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.589 ' HA ' ' NE2' ' A' ' 12' ' ' GLN . 1.9 p -92.91 133.57 35.97 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.337 -176.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -84.68 -21.84 30.03 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 164.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.464 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 14.1 p-80 -168.63 163.99 12.23 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.759 -176.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.6 p -65.09 -41.4 95.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.724 0.297 . . . . 0.0 111.577 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.416 ' O ' HD23 ' A' ' 14' ' ' LEU . . . -59.85 -18.27 46.03 Favored Glycine 0 C--O 1.228 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 114.61 -172.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.589 ' NE2' ' HA ' ' A' ' 7' ' ' CYS . 9.7 pt20 -89.12 -17.48 29.14 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 117.73 0.765 . . . . 0.0 110.634 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.4 m -90.83 24.39 2.75 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-O 121.009 0.433 . . . . 0.0 111.432 -175.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 11' ' ' GLY . 4.1 mm? -82.65 -41.58 19.24 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 169.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.5 ttpt -62.31 -58.25 18.44 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.599 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.87 -27.05 21.65 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.318 1.345 . . . . 0.0 112.17 -177.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 40.7 t -74.12 -30.94 62.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.374 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 11.3 tppt? -67.86 -36.92 81.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 177.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.4 tttp -73.56 -28.86 62.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.903 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.49 -36.82 85.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.34 176.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.63 10.79 5.26 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.95 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.547 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.2 mpt? -107.88 -175.4 2.77 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.576 -0.367 . . . . 0.0 110.344 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 -93.61 -62.48 1.35 Allowed 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.473 -0.491 . . . . 0.0 111.268 -177.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.504 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.8 160.27 22.94 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.978 -175.961 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.87 146.22 17.61 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.402 -176.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 61.6 mtpt -134.97 167.15 21.45 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.1 t -104.81 121.55 43.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.867 -174.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.486 HG22 ' N ' ' A' ' 29' ' ' ASN . 8.9 mt -117.41 178.5 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.816 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.486 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -64.67 56.23 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -174.722 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 134.65 -23.03 3.62 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 121.354 -0.451 . . . . 0.0 112.661 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -123.06 169.16 11.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.832 0.316 . . . . 0.0 110.236 -173.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 5.2 m -114.39 100.79 8.59 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.538 0.685 . . . . 0.0 109.289 167.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.537 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.6 t70 -77.96 149.14 34.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.033 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.612 ' O ' HG21 ' A' ' 1' ' ' VAL . 98.4 m -137.43 160.16 39.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -170.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 89.0 m -116.28 123.12 31.15 Favored Pre-proline 0 N--CA 1.437 -1.076 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 167.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -79.72 -163.24 0.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.555 2.17 . . . . 0.0 112.215 -174.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.425 -0.798 . . . . 0.0 110.234 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.48 1.067 0 CA-C-O 120.55 0.214 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 104.8 130.52 6.83 Favored Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.514 HG13 ' H ' ' A' ' 5' ' ' VAL . 15.5 pt -108.48 178.72 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.187 0.518 . . . . 0.0 111.486 -171.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -105.04 37.8 2.09 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.001 -175.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.64 HG12 ' SG ' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -98.43 158.33 3.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.21 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -102.84 112.52 25.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.922 0.391 . . . . 0.0 110.407 -174.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.633 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 6.0 p -91.5 131.94 36.61 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.9 mmtp -82.03 -19.58 40.09 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 164.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 -170.2 164.7 9.11 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.093 177.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.0 p -57.99 -38.94 77.05 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.887 0.375 . . . . 0.0 111.568 -176.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.58 -36.56 54.43 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.771 -176.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -91.71 14.6 14.8 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.265 0.533 . . . . 0.0 112.415 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.633 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 58.6 m -90.13 -21.89 22.03 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 171.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.6 -46.8 83.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.223 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.4 ttpp -62.24 -58.61 16.49 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -176.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' CG ' HG11 ' A' ' 5' ' ' VAL . 32.8 Cg_endo -69.92 -29.1 23.64 Favored 'Trans proline' 0 C--N 1.354 0.844 0 C-N-CA 121.237 1.291 . . . . 0.0 112.695 -177.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 13.9 m -74.06 -27.15 60.77 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 120.748 0.309 . . . . 0.0 110.801 176.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -70.69 -37.66 73.61 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.8 ttpp -67.93 -32.75 73.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.577 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.66 -46.79 71.38 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.019 176.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.85 14.15 1.9 Allowed Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.69 -0.687 . . . . 0.0 112.914 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -99.89 173.89 6.46 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.108 0.454 . . . . 0.0 111.002 -178.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -94.78 -53.56 3.81 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.961 0.41 . . . . 0.0 111.859 -170.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.48 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -110.19 -157.29 0.61 Allowed 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.044 -175.447 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.689 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.0 132.04 2.26 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.575 -0.822 . . . . 0.0 112.921 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -131.89 152.43 51.06 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 35.7 t -95.52 119.16 33.54 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.118 0.485 . . . . 0.0 110.806 -174.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.465 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.6 mt -109.49 164.0 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.171 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.95 -38.69 1.01 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -145.53 11.25 1.73 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.067 175.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.415 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 61.2 mttm -123.9 146.63 48.3 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 -174.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.64 ' SG ' HG12 ' A' ' 5' ' ' VAL . 5.7 m -96.8 89.66 4.98 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 163.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.465 ' HB2' HD12 ' A' ' 28' ' ' ILE . 18.5 t70 -77.99 115.19 17.54 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.747 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.689 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 35.1 m -132.86 141.27 48.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.868 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.48 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 34.9 m -91.84 132.4 33.02 Favored Pre-proline 0 N--CA 1.447 -0.588 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -176.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -81.21 -159.7 0.11 Allowed 'Trans proline' 0 N--CA 1.46 -0.444 0 C-N-CA 123.13 2.553 . . . . 0.0 112.166 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 mptt . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.352 178.502 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.479 1.004 0 CA-C-O 120.638 0.256 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.533 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 98.35 126.24 5.48 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.182 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.7 pt -106.42 177.81 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.049 0.452 . . . . 0.0 111.35 -172.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -101.17 94.91 6.21 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.284 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.482 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -156.97 -179.1 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -175.773 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.482 ' N ' HG13 ' A' ' 5' ' ' VAL . 5.6 m-20 -137.15 110.99 8.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.448 0.642 . . . . 0.0 110.479 177.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 7.3 p -93.01 140.36 29.56 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.186 -178.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -85.32 -21.75 28.8 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 164.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.579 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 10.0 p-80 -164.45 162.67 22.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.893 -176.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 12.7 p -68.51 -32.17 71.95 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -175.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.05 -28.75 64.27 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.506 -176.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.579 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 21.1 pt20 -84.94 -11.08 56.32 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.894 0.347 . . . . 0.0 111.04 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -72.3 -23.99 61.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.816 0.341 . . . . 0.0 110.212 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 -44.99 80.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.099 -174.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.522 ' HE3' ' HA ' ' A' ' 15' ' ' LYS . 1.1 tpmt? -65.32 -59.04 10.5 Favored Pre-proline 0 N--CA 1.444 -0.736 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -176.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.86 -24.46 46.45 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.629 1.552 . . . . 0.0 112.505 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.688 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 45.6 t -74.81 -33.14 62.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.27 0.557 . . . . 0.0 110.219 176.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.8 tttp -71.51 -35.75 70.85 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.671 0.748 . . . . 0.0 109.403 177.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -70.43 -27.0 63.92 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.838 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.685 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 133.62 11.16 1.73 Allowed Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.716 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.688 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -108.96 -171.14 1.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 117.399 0.6 . . . . 0.0 110.784 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -97.75 -66.34 0.91 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.884 0.373 . . . . 0.0 111.537 -174.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.471 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.19 160.33 22.36 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.902 -176.567 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.0 141.25 12.38 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.353 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -117.14 156.58 27.39 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.2 t -97.24 115.78 28.24 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.06 0.457 . . . . 0.0 110.714 -175.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.414 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.7 mt -114.92 163.61 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -39.61 -42.39 1.17 Allowed 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 -172.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -141.46 12.21 2.73 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.025 175.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 21.4 mttm -124.94 140.47 52.89 Favored 'General case' 0 N--CA 1.445 -0.72 0 O-C-N 122.901 -0.176 . . . . 0.0 110.836 -175.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.2 m -92.11 82.31 5.05 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 160.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.533 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -76.84 128.81 35.28 Favored 'General case' 0 CA--C 1.514 -0.412 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.895 -176.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 77.7 m -109.31 171.99 7.12 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.115 -169.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.471 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.2 m -120.54 124.48 27.6 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 166.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -81.32 -161.07 0.14 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.446 2.097 . . . . 0.0 111.786 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.477 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 119.026 -0.512 . . . . 0.0 110.809 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.8 m . . . . . 0 N--CA 1.479 0.993 0 CA-C-O 121.066 0.46 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.604 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 117.37 113.11 2.65 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.365 -176.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.54 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -97.03 175.85 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.163 0.506 . . . . 0.0 111.076 -172.723 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -99.34 113.65 26.08 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.11 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.641 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.0 p -162.34 -177.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.641 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.6 m-20 -132.92 100.2 4.83 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.535 0.683 . . . . 0.0 110.795 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.5 p -93.91 141.78 28.12 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 114.777 -1.101 . . . . 0.0 111.477 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -90.13 -17.93 26.76 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 164.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.55 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 11.0 p-80 -172.7 155.07 3.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.935 -175.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.3 p -68.51 -21.7 64.57 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -174.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.0 -34.72 88.97 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.113 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.55 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -85.7 -4.5 59.18 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.897 0.379 . . . . 0.0 110.232 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.47 -10.94 58.82 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.258 0.551 . . . . 0.0 109.734 -172.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -62.31 -53.53 53.73 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.903 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.512 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 23.5 ttpp -50.52 -55.04 29.06 Favored Pre-proline 0 CA--C 1.541 0.625 0 CA-C-N 115.139 -0.937 . . . . 0.0 113.03 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.512 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.9 Cg_endo -72.63 -26.44 16.38 Favored 'Trans proline' 0 C--N 1.357 0.999 0 C-N-CA 121.397 1.398 . . . . 0.0 112.367 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 38.8 t -70.14 -34.2 72.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.229 0.538 . . . . 0.0 110.288 178.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -72.6 -31.93 65.56 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.333 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.5 tptt -67.63 -30.74 70.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.808 174.247 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.28 -43.41 28.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.162 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.46 8.06 2.06 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.181 -1.009 . . . . 0.0 114.057 174.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.609 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 3.9 mpp? -106.02 -178.42 3.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 117.765 0.782 . . . . 0.0 110.914 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.453 ' NE ' ' HA ' ' A' ' 37' ' ' LYS . 70.6 mtm180 -91.67 -63.59 1.23 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.885 0.374 . . . . 0.0 111.686 -176.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.452 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -118.04 157.87 26.02 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.361 -175.287 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.12 157.68 21.27 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.112 -177.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -128.91 153.69 47.26 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 21.0 t -92.54 109.62 21.03 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.011 0.434 . . . . 0.0 110.893 -173.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.543 HD12 ' HB2' ' A' ' 33' ' ' ASP . 5.1 mt -112.24 164.23 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 174.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -43.44 -37.64 2.46 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -173.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.23 17.91 1.04 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.002 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -123.48 147.07 47.56 Favored 'General case' 0 CA--C 1.513 -0.444 0 O-C-N 122.527 -0.396 . . . . 0.0 110.827 -176.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.604 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 6.4 t -96.77 87.45 4.32 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 166.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.543 ' HB2' HD12 ' A' ' 28' ' ' ILE . 20.5 t70 -75.62 95.42 3.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 122.062 0.934 . . . . 0.0 109.653 -176.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 68.7 m -92.5 175.71 6.73 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.522 -1.217 . . . . 0.0 113.129 -169.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.452 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 33.3 m -136.61 126.72 16.08 Favored Pre-proline 0 N--CA 1.439 -1.008 0 CA-C-N 114.541 -1.209 . . . . 0.0 107.89 168.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.421 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 83.0 Cg_endo -80.0 -158.44 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.301 2.001 . . . . 0.0 112.049 -179.244 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.589 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.101 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.443 177.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.479 1.012 0 CA-C-O 120.67 0.271 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 109.43 118.56 4.08 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.6 OUTLIER -104.9 175.03 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 117.001 0.401 . . . . 0.0 110.369 -176.418 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -106.62 107.38 18.37 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.2 p -155.64 -176.86 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.408 -170.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.9 m-20 -122.6 105.77 10.39 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -91.93 150.06 21.22 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-O 121.39 0.614 . . . . 0.0 111.174 178.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.9 mtpt -91.29 -33.9 15.15 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 115.003 -0.999 . . . . 0.0 108.843 170.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -149.11 166.24 29.36 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.304 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 t -82.34 64.31 6.93 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.831 175.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.676 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -177.38 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.065 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.98 9.59 5.24 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.956 0.408 . . . . 0.0 111.933 -178.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.1 t -85.45 13.65 6.49 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.9 0.857 . . . . 0.0 109.075 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.676 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 80.9 mt -60.47 -48.87 79.86 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.02 -178.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -54.55 -55.68 35.07 Favored Pre-proline 0 CA--C 1.541 0.596 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -175.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -71.64 -27.61 18.28 Favored 'Trans proline' 0 C--N 1.354 0.835 0 C-N-CA 121.177 1.252 . . . . 0.0 111.767 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 44.0 t -69.6 -34.28 73.9 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.018 178.109 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -72.17 -36.07 69.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.883 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -65.3 -32.44 74.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.714 176.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.13 -42.12 47.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.056 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 124.2 25.21 1.69 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.726 172.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -114.67 178.47 4.27 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.35 0.575 . . . . 0.0 111.072 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 73.8 mtm180 -83.61 -71.73 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 111.729 -173.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -115.29 159.11 21.43 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -175.45 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.62 124.79 3.76 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.577 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -100.57 168.33 9.78 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.928 0.394 . . . . 0.0 110.219 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 22.4 t -108.34 116.84 32.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.161 0.505 . . . . 0.0 110.895 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.561 HG22 HD22 ' A' ' 29' ' ' ASN . 9.0 mt -124.14 172.75 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 176.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.561 HD22 HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -59.52 63.85 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -172.266 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 100.55 5.87 53.55 Favored Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 18.1 ttmm -122.68 129.66 52.07 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -173.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.567 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 7.1 t -89.85 89.97 7.98 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 172.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' HB2' HD12 ' A' ' 28' ' ' ILE . 7.1 t70 -77.35 105.0 8.19 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.665 0.745 . . . . 0.0 109.283 178.43 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 93.2 m -101.51 169.22 8.99 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.822 -1.081 . . . . 0.0 111.79 -175.089 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.512 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 59.6 m -115.52 125.2 29.03 Favored Pre-proline 0 N--CA 1.441 -0.906 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 167.445 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.55 -160.66 0.13 Allowed 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.555 2.17 . . . . 0.0 111.813 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.297 -0.859 . . . . 0.0 110.166 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.645 0.259 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.581 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 113.66 110.89 2.96 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.489 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.6 pt -87.22 178.05 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.082 0.468 . . . . 0.0 110.896 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -103.27 92.75 4.64 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.031 -177.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.555 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.1 p -145.4 -178.17 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.555 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.0 m-20 -131.48 101.52 5.55 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.339 0.59 . . . . 0.0 110.541 -176.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.427 ' HB2' ' O ' ' A' ' 9' ' ' HIS . 2.2 p -93.07 132.49 37.13 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.641 -178.358 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -90.13 -18.37 25.95 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 166.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 7.2 m80 -151.05 167.72 26.81 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.8 179.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 22.2 p -80.93 -21.6 40.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.876 0.369 . . . . 0.0 110.764 177.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.18 -39.55 72.17 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 121.203 -0.523 . . . . 0.0 112.746 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -79.62 2.9 20.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.995 0.426 . . . . 0.0 110.54 178.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 10' ' ' SER . 42.6 t -85.04 -16.33 41.07 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.583 0.706 . . . . 0.0 109.566 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.7 mt -65.04 -57.78 7.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.209 -178.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.7 tppp? -49.42 -53.97 34.99 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.129 -0.941 . . . . 0.0 113.493 -174.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.96 -27.87 20.21 Favored 'Trans proline' 0 C--N 1.355 0.911 0 C-N-CA 121.374 1.383 . . . . 0.0 112.873 -177.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 3.3 m -78.45 -25.78 46.0 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 120.819 0.343 . . . . 0.0 110.903 178.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.03 -23.65 55.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 173.27 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -72.83 -36.81 67.57 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.245 -0.888 . . . . 0.0 109.14 172.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.61 -49.96 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.789 178.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.36 20.22 0.57 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.1 177.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.498 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 1.8 mpt? -103.18 178.23 4.61 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 122.737 -0.272 . . . . 0.0 111.367 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.5 mtm180 -97.39 -57.87 2.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.206 0.526 . . . . 0.0 111.805 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.5 OUTLIER -105.88 -161.44 0.8 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.819 -174.195 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.746 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -160.41 138.21 5.41 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.481 178.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -132.23 143.97 50.3 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 t -95.78 112.59 24.28 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-O 120.929 0.395 . . . . 0.0 110.672 -174.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.478 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.9 mt -110.01 163.22 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 176.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -44.73 -36.99 3.44 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -172.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -142.73 12.25 2.42 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.855 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.429 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 97.9 mttt -123.84 158.21 32.38 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 117.231 0.516 . . . . 0.0 111.55 -175.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.581 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -105.6 88.47 2.84 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 162.786 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.478 ' HB2' HD12 ' A' ' 28' ' ' ILE . 21.2 t70 -77.64 90.28 3.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.739 0.781 . . . . 0.0 110.032 -178.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.746 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 34.9 m -111.28 142.54 43.37 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.75 -174.253 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 87.5 m -96.34 128.67 35.81 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.498 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 88.1 Cg_endo -83.81 -162.06 0.16 Allowed 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.55 2.167 . . . . 0.0 112.581 -177.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.411 -0.805 . . . . 0.0 110.367 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.629 0.252 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.78 124.87 5.41 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -178.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.2 pt -103.5 -174.37 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -177.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.438 ' O ' HG12 ' A' ' 5' ' ' VAL . 24.2 t-20 -87.68 -87.2 0.15 Allowed 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.508 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER 50.78 -172.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 124.05 0.844 . . . . 0.0 112.078 175.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.508 ' H ' HG22 ' A' ' 5' ' ' VAL . 3.6 p30 -141.07 115.55 9.48 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 174.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.1 p -93.53 130.54 39.36 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.373 0.606 . . . . 0.0 112.036 177.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . 0.586 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 64.5 tttm -84.66 -21.43 30.22 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 163.286 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.451 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.7 p-80 -175.96 159.34 2.17 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.135 -177.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.9 p -67.5 -26.81 66.54 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -174.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.02 -34.49 79.31 Favored Glycine 0 CA--C 1.517 0.184 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.812 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.586 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 10.3 pt20 -90.66 5.56 47.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.029 0.443 . . . . 0.0 110.393 -178.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.582 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 42.2 t -88.11 -14.45 38.76 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.193 0.521 . . . . 0.0 110.316 -175.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -64.79 -51.72 60.68 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.033 -177.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.486 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 59.7 tttp -50.88 -56.89 15.9 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -177.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.486 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 58.7 Cg_endo -71.27 -26.79 20.48 Favored 'Trans proline' 0 C--N 1.355 0.913 0 C-N-CA 121.335 1.357 . . . . 0.0 111.702 -177.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.1 t -74.15 -30.49 62.3 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.053 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 tppt? -74.16 -30.83 62.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.83 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.95 -28.32 64.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.454 174.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.5 -36.0 65.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.845 174.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.05 19.95 5.78 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.294 173.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.619 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -103.88 -174.61 2.58 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 122.714 -0.286 . . . . 0.0 111.0 -178.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -90.87 -57.95 2.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.885 0.374 . . . . 0.0 110.719 -175.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.495 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -136.11 161.09 36.69 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.186 -176.893 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.582 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -122.56 163.86 15.79 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.386 178.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 35.4 tptt -138.01 145.41 41.85 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.5 t -91.27 106.16 18.31 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.14 0.495 . . . . 0.0 110.057 -177.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.802 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.1 mt -96.3 -161.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.802 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.1 OUTLIER -65.19 44.87 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 120.294 1.407 . . . . 0.0 113.267 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 118.59 -2.4 15.6 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.111 -0.566 . . . . 0.0 113.39 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -120.89 159.72 24.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 117.555 0.678 . . . . 0.0 111.121 -175.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.2 m -100.51 87.87 3.49 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.042 174.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.467 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.2 t70 -78.98 124.43 28.24 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 171.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.0 m -107.58 168.12 9.47 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.112 -0.495 . . . . 0.0 112.183 -171.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.495 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 92.9 m -119.9 122.53 28.99 Favored Pre-proline 0 N--CA 1.441 -0.905 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 168.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -85.64 -159.27 0.1 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.704 2.269 . . . . 0.0 111.431 -177.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.812 -0.613 . . . . 0.0 110.194 178.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.781 0.324 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.599 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 108.77 125.9 5.26 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.523 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.4 pt -110.21 176.32 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.0 0.428 . . . . 0.0 110.827 -175.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -107.72 97.24 6.99 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -178.162 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.681 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.7 p -141.87 -177.73 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.927 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.681 ' H ' HG22 ' A' ' 5' ' ' VAL . 11.8 m-20 -126.35 92.57 3.59 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-O 121.609 0.718 . . . . 0.0 110.964 -177.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.9 p -94.55 135.16 36.32 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.473 -1.24 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.0 tptp -85.42 -17.57 36.23 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 166.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.49 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 7.9 p-80 -169.17 155.1 6.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.801 -176.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.704 ' OG ' ' HA ' ' A' ' 26' ' ' LYS . 39.2 t -60.91 -30.23 70.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.852 -175.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.08 -33.23 68.78 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.187 -0.53 . . . . 0.0 113.447 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.49 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 19.1 pt20 -90.78 1.8 56.6 Favored 'General case' 0 C--N 1.326 -0.425 0 O-C-N 122.488 -0.419 . . . . 0.0 110.959 -177.106 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.28 -11.03 57.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.193 0.52 . . . . 0.0 110.011 -175.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 64.0 mt -63.88 -53.39 51.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.454 -176.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.464 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 8.6 tmtt? -51.61 -57.12 15.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.368 -177.163 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.464 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 54.7 Cg_endo -68.86 -26.02 32.41 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 121.477 1.451 . . . . 0.0 111.948 -178.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.707 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.7 t -70.27 -35.76 73.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.928 177.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.8 mmmt -72.71 -32.01 65.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.183 177.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -70.98 -31.74 68.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.701 176.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.56 -52.3 16.13 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.483 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 143.77 12.43 0.33 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.536 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.707 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -106.26 -174.72 2.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 117.316 0.558 . . . . 0.0 110.511 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 76.6 mtm180 -98.98 -58.5 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 111.004 -176.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -123.45 156.41 35.6 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.022 -176.801 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.7 150.82 20.2 Favored Glycine 0 N--CA 1.448 -0.562 0 O-C-N 123.615 0.572 . . . . 0.0 111.969 -176.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.704 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 59.1 tttm -130.24 149.74 51.8 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -94.21 116.82 29.27 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.687 -178.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.697 HG22 ' H ' ' A' ' 29' ' ' ASN . 6.8 mt -120.07 -122.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.061 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.697 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -91.37 49.55 1.62 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 118.862 0.755 . . . . 0.0 111.243 -175.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 89.44 10.81 65.16 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.893 -0.67 . . . . 0.0 111.515 -177.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 22.8 ptmt -120.14 150.02 41.28 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.599 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.3 t -93.53 83.93 4.6 Favored 'General case' 0 C--N 1.315 -0.919 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 172.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.424 ' CB ' HD12 ' A' ' 28' ' ' ILE . 16.0 t70 -76.39 107.38 8.61 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 63.6 m -105.99 173.44 6.31 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.999 -1.001 . . . . 0.0 112.351 -170.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 90.0 m -122.29 124.6 26.81 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 167.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -82.07 -157.9 0.09 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.978 2.452 . . . . 0.0 112.122 -175.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.6 mppt? . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.491 -0.766 . . . . 0.0 109.747 178.195 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.481 1.095 0 CA-C-O 120.986 0.422 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.74 113.89 3.87 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.1 pt -87.98 175.66 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.166 0.508 . . . . 0.0 111.693 -166.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -106.68 89.68 3.09 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.024 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.482 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -146.81 -175.48 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.492 -171.288 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.482 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.2 p-10 -129.9 107.6 9.5 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.749 0.785 . . . . 0.0 110.408 176.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 4.2 p -92.45 135.18 34.26 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.805 -177.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -83.52 -23.99 31.87 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 164.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.412 ' CD2' ' HG2' ' A' ' 12' ' ' GLN . 10.6 p-80 -173.17 167.42 4.87 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 115.045 -0.98 . . . . 0.0 109.624 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' CYS . 25.6 p -65.7 -30.07 70.7 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.67 0.272 . . . . 0.0 111.682 -175.756 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.58 -39.52 66.74 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 121.175 -0.536 . . . . 0.0 112.495 178.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.412 ' HG2' ' CD2' ' A' ' 9' ' ' HIS . 3.9 pt20 -91.67 14.82 14.07 Favored 'General case' 0 C--N 1.33 -0.277 0 O-C-N 122.577 -0.367 . . . . 0.0 111.905 178.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 10' ' ' SER . 35.0 m -90.26 -21.46 22.09 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.876 0.369 . . . . 0.0 110.156 173.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.5 mt -61.12 -56.29 22.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.831 -173.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -56.6 31.9 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.491 -177.113 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -66.63 -23.77 48.95 Favored 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 121.328 1.352 . . . . 0.0 112.31 -178.597 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.5 t -72.13 -37.25 69.5 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.234 0.54 . . . . 0.0 110.109 176.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -78.41 -26.81 46.5 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.857 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -71.0 -29.48 65.45 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.32 172.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.92 -51.76 17.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.433 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.53 9.93 0.62 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.113 177.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.607 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.65 -174.4 2.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.975 0.388 . . . . 0.0 110.242 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -99.93 -75.5 0.57 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.999 0.428 . . . . 0.0 111.504 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.444 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -101.68 157.95 16.45 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.92 -175.144 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 141.73 11.54 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.391 -175.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 87.6 tttt -126.85 152.94 46.33 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.6 t -97.84 118.49 34.51 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.675 HG22 ' H ' ' A' ' 29' ' ' ASN . 8.8 mt -118.36 -119.24 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.55 -172.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.675 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.77 45.77 1.28 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.313 0.578 . . . . 0.0 110.824 -175.693 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.96 1.95 58.37 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.519 -177.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -117.32 143.76 45.6 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 23.1 m -86.68 86.43 7.33 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 167.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.528 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.7 t70 -77.24 135.7 38.48 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.16 -178.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 85.7 m -126.49 168.11 14.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.33 -168.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.444 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 97.7 m -119.75 127.58 26.33 Favored Pre-proline 0 N--CA 1.444 -0.734 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 165.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.51 -159.88 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.601 2.201 . . . . 0.0 112.22 -175.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.546 -0.74 . . . . 0.0 110.195 -178.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.768 0.318 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 113.9 127.46 4.53 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -175.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.513 ' CD1' ' HB ' ' A' ' 5' ' ' VAL . 19.1 pt -103.77 -178.53 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.006 0.431 . . . . 0.0 111.249 -172.215 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -99.51 2.55 44.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.565 0.697 . . . . 0.0 110.292 -173.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.527 HG12 ' SG ' ' A' ' 32' ' ' CYS . 1.2 t -69.36 152.51 9.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.418 176.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -106.52 128.41 54.08 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.386 -176.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.727 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 2.7 p -91.43 139.64 30.52 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -177.07 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . 0.408 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 35.1 ttpt -88.16 -22.68 23.93 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 163.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.562 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 16.1 p-80 -172.47 164.1 5.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.35 179.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 p -61.39 -42.89 99.44 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -174.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.63 -30.6 59.46 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 116.079 -0.51 . . . . 0.0 113.805 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.562 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.73 6.0 45.88 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 117.099 0.449 . . . . 0.0 111.554 -177.306 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.727 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 54.7 m -84.79 -21.52 29.91 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.077 0.465 . . . . 0.0 109.882 175.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.49 -49.26 76.88 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.492 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.609 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.3 tmtp? -53.48 -59.47 9.33 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.316 -175.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.609 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 47.5 Cg_endo -73.13 -29.16 11.99 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 121.25 1.3 . . . . 0.0 113.309 -178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 11.9 m -71.7 -29.73 64.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 120.635 0.255 . . . . 0.0 111.129 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.33 -27.99 62.77 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.242 0.544 . . . . 0.0 109.955 175.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -73.51 -37.87 65.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.567 172.693 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.77 -44.15 86.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.883 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.05 18.5 0.84 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.766 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.546 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -107.61 -173.16 2.22 Favored 'General case' 0 C--N 1.322 -0.622 0 O-C-N 122.588 -0.36 . . . . 0.0 110.85 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.9 mtm180 -108.29 -58.29 2.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.067 0.46 . . . . 0.0 111.745 -175.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.466 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -105.02 -153.83 0.5 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.77 -174.655 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.75 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.02 136.28 3.65 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.703 179.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -134.81 150.6 50.53 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 43.9 t -102.55 111.32 23.57 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -177.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.678 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.4 mt -105.41 -115.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.22 -174.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.678 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.99 43.23 1.14 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 118.709 0.686 . . . . 0.0 110.588 -177.29 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.39 2.39 60.35 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.761 -176.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.531 ' HG2' ' ND2' ' A' ' 29' ' ' ASN . 16.8 ptpt -114.49 150.9 34.12 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.527 ' SG ' HG12 ' A' ' 5' ' ' VAL . 59.0 m -91.16 90.17 7.68 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.334 173.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.511 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.5 t70 -79.22 118.98 21.67 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 172.055 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.75 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 33.9 m -133.85 139.97 46.57 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 -173.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.466 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 88.3 m -86.32 131.93 44.69 Favored Pre-proline 0 N--CA 1.447 -0.595 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 67.5 Cg_endo -82.22 -161.57 0.15 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.657 2.238 . . . . 0.0 112.547 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.297 -0.859 . . . . 0.0 109.875 -179.158 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.482 1.138 0 CA-C-O 120.794 0.331 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 101.81 112.81 3.62 Favored Glycine 0 N--CA 1.443 -0.851 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -175.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.452 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.4 pt -92.12 177.48 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.328 0.585 . . . . 0.0 111.314 -171.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -103.08 86.63 2.73 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.304 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.494 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -145.0 -179.87 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.674 -173.41 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.494 ' H ' HG22 ' A' ' 5' ' ' VAL . 19.7 m-20 -132.58 106.74 8.0 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.916 0.389 . . . . 0.0 109.955 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -91.78 136.93 32.77 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.398 0.618 . . . . 0.0 111.309 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -83.86 -19.8 34.24 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 168.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.7 p-80 -170.89 167.3 7.49 Favored 'General case' 0 N--CA 1.461 0.083 0 CA-C-N 115.111 -0.95 . . . . 0.0 110.442 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.7 p -65.61 -40.4 92.58 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -176.306 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.85 -32.96 59.52 Favored Glycine 0 CA--C 1.52 0.376 0 CA-C-N 116.247 -0.433 . . . . 0.0 114.172 -175.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -90.4 -1.39 57.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.251 0.525 . . . . 0.0 111.287 -177.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 48.1 t -74.69 -23.12 58.57 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.656 0.741 . . . . 0.0 110.0 -178.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -60.01 -42.57 94.61 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.211 -179.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 75.9 tttt -56.09 -61.57 6.27 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.806 -176.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -78.51 -33.52 1.77 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 121.527 1.485 . . . . 0.0 113.965 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 6.0 t -74.91 -25.26 58.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.011 0.434 . . . . 0.0 110.734 -173.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -75.07 -35.61 61.82 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.039 0.447 . . . . 0.0 110.046 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -71.74 -25.8 62.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.981 177.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.15 -52.64 53.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.173 175.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.5 3.66 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.334 -0.936 . . . . 0.0 113.532 178.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -103.53 -178.74 3.75 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.346 0.573 . . . . 0.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -100.07 -56.61 2.33 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.353 -174.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.515 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.8 OUTLIER -107.25 -159.26 0.69 Allowed 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.698 -175.895 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.401 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -175.58 136.68 3.44 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.491 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -127.29 167.0 16.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.744 0.307 . . . . 0.0 110.352 177.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.8 t -110.1 100.13 9.1 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.527 ' CD1' ' HB3' ' A' ' 33' ' ' ASP . 2.4 mp -95.78 -92.83 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.646 -172.427 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.516 ' N ' HG22 ' A' ' 28' ' ' ILE . 1.4 m120 -93.36 45.06 1.15 Allowed 'General case' 0 CA--C 1.505 -0.755 0 CA-C-O 121.88 0.848 . . . . 0.0 109.899 174.657 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.9 6.37 72.77 Favored Glycine 0 C--N 1.314 -0.654 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.282 -171.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 159.1 19.36 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 1.4 m -93.82 92.59 7.51 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.328 -176.244 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.527 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 19.3 t70 -86.92 124.24 32.91 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 167.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 7.5 m -135.11 158.47 44.27 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 121.056 -0.258 . . . . 0.0 110.846 -171.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 33.0 m -96.22 128.74 35.77 Favored Pre-proline 0 N--CA 1.446 -0.632 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 175.702 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -82.23 -160.03 0.12 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.572 2.181 . . . . 0.0 112.308 -178.016 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.206 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.863 0.363 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.482 ' HA3' ' HE2' ' A' ' 31' ' ' LYS . . . 121.14 126.35 3.29 Favored Glycine 0 N--CA 1.443 -0.891 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.226 -174.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -104.04 -178.01 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.329 0.585 . . . . 0.0 111.533 -173.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -105.3 109.07 20.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.893 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.528 HG22 ' H ' ' A' ' 6' ' ' ASP . 1.4 p -163.03 -178.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -173.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.528 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.5 m-20 -127.74 110.47 12.66 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.524 ' HA ' ' OE1' ' A' ' 12' ' ' GLN . 2.0 p -91.04 123.91 34.86 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.415 0.626 . . . . 0.0 111.702 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -74.98 -25.48 58.87 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 167.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 28.4 p-80 -177.38 163.26 1.99 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.734 177.303 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 6.4 p -63.48 -36.35 83.47 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -175.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.49 -39.32 65.48 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.176 -0.535 . . . . 0.0 113.067 -178.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.524 ' OE1' ' HA ' ' A' ' 7' ' ' CYS . 0.0 OUTLIER -90.55 -0.12 57.56 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 122.66 -0.317 . . . . 0.0 110.959 -177.718 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.626 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 32.6 t -76.02 -22.07 56.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.587 0.708 . . . . 0.0 109.625 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 10.9 mp -57.43 -43.01 83.5 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.792 -1.095 . . . . 0.0 111.065 177.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -59.51 -61.05 8.63 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 115.597 -0.728 . . . . 0.0 112.843 -174.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.68 -31.34 13.37 Favored 'Trans proline' 0 C--N 1.354 0.823 0 C-N-CA 121.453 1.435 . . . . 0.0 112.622 -175.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 8.8 t -77.63 -23.46 49.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.173 -176.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HA ' ' O ' ' A' ' 22' ' ' MET . 27.2 ttpp -68.35 -38.46 81.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 175.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -68.71 -28.25 66.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.504 176.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.0 -10.94 59.84 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.866 177.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.0 -26.12 6.56 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.501 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.593 ' O ' ' HA ' ' A' ' 18' ' ' LYS . 1.9 mpt? -83.47 175.98 9.4 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 117.261 0.531 . . . . 0.0 111.391 -174.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.7 mtm180 -94.29 -61.43 1.52 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.566 -175.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.558 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -121.81 158.57 28.58 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.044 -176.4 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.626 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -133.86 157.55 22.87 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.524 -177.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.401 ' HB3' HD11 ' A' ' 28' ' ' ILE . 52.8 tptt -127.18 157.57 39.41 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 176.146 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.4 t -104.61 97.87 7.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.602 . . . . 0.0 109.875 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.654 HG22 ' N ' ' A' ' 29' ' ' ASN . 3.5 mp -90.06 -110.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.738 -175.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.654 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.53 47.11 1.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 121.628 -0.67 . . . . 0.0 110.391 179.367 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 79.42 19.83 70.65 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -172.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.482 ' HE2' ' HA3' ' A' ' 2' ' ' GLY . 32.1 tttt -120.1 138.53 53.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.929 -0.635 . . . . 0.0 109.536 -179.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.469 ' SG ' HG11 ' A' ' 5' ' ' VAL . 1.3 m -87.56 83.02 7.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.718 173.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.57 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 16.3 t70 -79.13 124.43 28.31 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 168.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.558 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.7 m -124.11 178.17 5.45 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.105 0.479 . . . . 0.0 112.069 -167.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.446 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 95.2 m -125.12 125.53 25.28 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 170.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -82.51 -159.64 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.745 2.297 . . . . 0.0 112.199 -177.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 11.3 mptt . . . . . 0 C--O 1.247 0.949 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.322 177.713 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.435 0.16 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.598 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 97.38 138.9 10.37 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -174.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.408 HG12 ' O ' ' A' ' 32' ' ' CYS . 10.1 pt -109.51 176.76 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-O 121.362 0.601 . . . . 0.0 111.872 -170.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -100.74 100.23 10.88 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.858 178.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -162.92 179.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -174.281 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.443 ' N ' HG13 ' A' ' 5' ' ' VAL . 6.4 m-20 -128.02 112.82 15.05 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.032 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.676 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.2 p -88.8 129.76 35.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.608 0.718 . . . . 0.0 111.663 -177.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -87.15 -15.08 39.45 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 167.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . 0.472 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 26.7 p-80 178.41 158.15 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.493 178.071 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.5 p -58.32 -35.45 71.9 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 111.648 -175.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.78 -32.64 70.31 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 115.99 -0.55 . . . . 0.0 113.641 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.83 7.78 38.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.576 0.688 . . . . 0.0 111.446 -177.486 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 74.8 m -82.05 -15.6 53.02 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.143 176.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.85 -56.59 19.34 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.186 -171.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -57.12 -54.15 57.69 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.55 -27.58 39.04 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 121.265 1.31 . . . . 0.0 112.557 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.6 t -73.01 -33.95 66.09 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.26 0.552 . . . . 0.0 110.209 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -73.13 -39.16 65.97 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.914 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.2 ttmm -69.17 -28.85 66.78 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.916 176.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.06 -43.54 78.4 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.891 175.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 125.72 15.04 3.0 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.849 176.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.537 ' SD ' ' HB2' ' A' ' 34' ' ' CYS . 60.9 mtt -116.13 -179.17 3.59 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 122.649 -0.324 . . . . 0.0 110.611 -178.164 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtm180 -92.77 -79.1 0.4 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.046 -170.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -107.17 158.9 16.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -175.584 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.98 137.15 9.21 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.328 -176.015 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 26.7 ttpp -117.73 154.16 32.17 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.1 t -96.77 107.74 20.27 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.251 0.548 . . . . 0.0 110.354 -176.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.574 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 1.9 mp -94.49 -169.97 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 179.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.574 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 9.8 p30 -39.67 -43.17 1.32 Allowed 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 118.889 0.768 . . . . 0.0 112.244 -174.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 6' ' ' ASP . . . -152.41 2.63 0.33 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.201 -1.0 . . . . 0.0 112.305 172.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.25 152.01 40.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.997 0.427 . . . . 0.0 111.807 -169.548 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.676 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 65.2 m -91.59 92.91 8.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.509 176.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.598 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 22.3 t70 -80.82 135.94 36.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.605 175.228 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.537 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 81.1 m -123.84 157.51 33.99 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.268 -0.424 . . . . 0.0 112.121 -169.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.516 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.3 m -103.27 128.57 27.27 Favored Pre-proline 0 N--CA 1.442 -0.857 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 169.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -83.51 -163.63 0.22 Allowed 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.339 2.026 . . . . 0.0 112.167 -175.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm . . . . . 0 C--O 1.246 0.87 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.14 179.805 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.477 0.913 0 CA-C-O 120.928 0.394 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 111.93 106.13 2.84 Favored Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -176.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.409 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.1 pt -89.87 178.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.413 0.625 . . . . 0.0 111.639 -170.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -103.86 105.84 16.17 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.652 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -157.98 -175.91 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.364 -172.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 4.9 m-20 -132.92 106.1 7.49 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.253 0.549 . . . . 0.0 110.236 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -92.94 125.6 37.62 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.187 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 56.7 tptt -74.88 -22.14 58.82 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 167.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 13.5 p-80 -171.74 163.7 6.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 114.636 -1.165 . . . . 0.0 109.794 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 p -66.35 -33.4 75.65 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.787 0.291 . . . . 0.0 111.787 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.14 -34.38 62.39 Favored Glycine 0 CA--C 1.519 0.308 0 C-N-CA 121.273 -0.489 . . . . 0.0 113.353 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 6.5 pt20 -90.7 -1.73 57.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.836 0.351 . . . . 0.0 110.63 -177.389 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.1 t -79.86 -16.72 54.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.412 0.625 . . . . 0.0 110.258 -173.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.6 mp -64.96 -48.74 72.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.864 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 73.2 tttt -53.81 -57.52 17.26 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -174.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.478 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.7 Cg_endo -67.97 -29.57 34.03 Favored 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 121.81 1.674 . . . . 0.0 112.397 -175.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 2.2 m -78.32 -29.07 47.49 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.46 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 13.7 tmtt? -67.59 -38.4 83.96 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.9 ttmm -68.01 -35.28 78.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.747 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.24 -12.99 60.72 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.28 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 108.23 14.21 17.23 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.783 -0.723 . . . . 0.0 113.358 175.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' MET . . . . . 0.526 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -104.32 179.67 4.2 Favored 'General case' 0 C--N 1.319 -0.738 0 O-C-N 122.333 -0.51 . . . . 0.0 110.758 178.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.45 -57.11 2.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.03 0.443 . . . . 0.0 111.658 -175.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.7 OUTLIER -105.5 -159.21 0.7 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.79 -174.681 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.659 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -170.6 133.14 2.69 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.271 -0.966 . . . . 0.0 112.9 178.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.49 147.09 50.31 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.9 t -96.7 112.02 23.94 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.837 0.351 . . . . 0.0 110.508 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.43 ' HB ' ' HG2' ' A' ' 31' ' ' LYS . 7.0 mt -104.85 170.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -45.09 -34.88 2.79 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -171.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.35 -1.76 1.03 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 119.365 -1.397 . . . . 0.0 113.931 174.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.43 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 21.2 ptmt -124.02 153.7 40.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 118.184 0.992 . . . . 0.0 111.53 -172.034 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.558 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.5 OUTLIER -92.79 92.5 7.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 169.772 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -78.87 103.4 8.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.478 175.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.659 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 20.0 m -125.03 142.53 51.43 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.293 -174.422 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.519 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 41.2 m -88.42 129.83 47.87 Favored Pre-proline 0 N--CA 1.448 -0.574 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 90.2 Cg_endo -81.36 -158.73 0.1 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.798 2.332 . . . . 0.0 112.261 -177.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.498 -0.763 . . . . 0.0 110.771 -177.784 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.75 0.309 . . . . 0.0 110.769 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 114.46 130.8 5.04 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.4 pt -103.21 177.11 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-O 121.177 0.513 . . . . 0.0 111.658 -170.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -101.32 70.48 1.32 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.255 -175.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -131.44 179.53 4.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.324 -176.5 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.454 ' N ' HG13 ' A' ' 5' ' ' VAL . 7.2 p-10 -128.33 111.28 13.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.56 0.695 . . . . 0.0 109.966 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.454 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.8 p -92.9 132.07 37.36 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.969 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 mtmt -87.6 -18.45 29.64 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 163.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.463 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.2 p-80 -167.49 167.39 13.72 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.616 -1.175 . . . . 0.0 110.329 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.459 ' HB3' ' H ' ' A' ' 27' ' ' CYS . 4.9 p -72.27 -31.26 65.6 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -176.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.27 -27.87 66.04 Favored Glycine 0 CA--C 1.517 0.212 0 C-N-CA 121.11 -0.567 . . . . 0.0 113.408 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -89.0 3.65 50.94 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 122.597 -0.355 . . . . 0.0 110.721 -178.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 88.9 m -86.86 -16.12 37.04 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.829 0.347 . . . . 0.0 110.483 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 68.9 mt -62.67 -62.78 1.5 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.913 -174.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.485 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 54.5 tttm -55.23 -58.44 15.04 Favored Pre-proline 0 N--CA 1.446 -0.633 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 37.2 Cg_endo -66.5 -28.1 45.94 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 121.403 1.402 . . . . 0.0 112.922 -173.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 4.2 t -82.76 -26.65 31.69 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.19 0.519 . . . . 0.0 109.897 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -72.33 -36.31 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.8 tptm -72.14 -32.7 67.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.825 173.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.8 -48.1 80.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.586 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 144.95 8.78 0.35 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.887 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.433 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.78 178.36 4.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.71 0.255 . . . . 0.0 110.326 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 52.6 mtm180 -96.84 -54.18 3.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.864 0.364 . . . . 0.0 111.241 -173.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.456 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -112.48 -153.15 0.52 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.886 -176.633 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.35 139.06 3.18 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.725 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttpp -133.03 151.47 52.05 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 177.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.459 ' H ' ' HB3' ' A' ' 10' ' ' SER . 42.6 t -88.01 131.87 34.48 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.632 HG22 ' N ' ' A' ' 29' ' ' ASN . 6.4 mt -122.89 -112.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.207 -177.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.632 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.22 46.73 1.27 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.417 0.627 . . . . 0.0 110.586 -179.579 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.28 -5.71 65.54 Favored Glycine 0 N--CA 1.447 -0.591 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.662 -177.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -109.1 154.57 22.09 Favored 'General case' 0 CA--C 1.516 -0.349 0 CA-C-O 120.729 0.299 . . . . 0.0 110.262 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.454 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 35.9 m -96.73 90.55 5.32 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.791 -0.64 . . . . 0.0 109.807 172.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -86.0 135.13 33.77 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.857 175.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.439 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 3.2 m -135.39 178.62 6.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.893 0.378 . . . . 0.0 111.063 -170.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.456 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 57.9 m -113.64 127.42 26.84 Favored Pre-proline 0 N--CA 1.443 -0.787 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 171.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -84.87 -161.37 0.13 Allowed 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 122.894 2.396 . . . . 0.0 112.102 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.585 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.947 0 CA-C-O 118.595 -0.716 . . . . 0.0 110.035 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.9 m . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.655 0.264 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.624 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 110.96 109.51 3.14 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.903 178.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.526 HG12 ' CB ' ' A' ' 32' ' ' CYS . 1.1 pt -98.24 175.66 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.666 0.27 . . . . 0.0 110.314 -177.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -103.76 109.63 21.42 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.614 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.7 p -156.53 -175.95 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -172.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.614 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.1 m-20 -127.77 97.28 4.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.449 0.642 . . . . 0.0 111.041 -176.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 5.8 p -94.36 134.18 37.14 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.223 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -88.93 -14.64 36.24 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 166.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -171.34 161.66 6.54 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 114.643 -1.162 . . . . 0.0 110.445 174.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.5 p -58.61 -40.44 83.3 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -176.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.61 -41.69 50.24 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 114.112 0.405 . . . . 0.0 114.112 -175.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -83.52 -2.72 56.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 117.031 0.415 . . . . 0.0 111.467 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.29 -11.95 57.19 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.233 0.54 . . . . 0.0 110.159 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.8 mp -63.44 -42.88 98.67 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.55 -178.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.4 tptm -56.8 -58.33 18.17 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.339 -177.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.69 -24.04 22.16 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 121.47 1.447 . . . . 0.0 112.062 -178.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 46.3 t -69.33 -38.96 78.42 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 178.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.6 tptt -71.47 -35.18 70.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.42 178.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.3 tmtm? -61.6 -38.12 86.43 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.289 -0.868 . . . . 0.0 109.539 175.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.15 -44.1 76.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.54 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.25 8.14 0.75 Allowed Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.912 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.46 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 4.2 mpp? -108.1 -173.83 2.38 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 117.594 0.697 . . . . 0.0 111.208 -179.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 64.1 mtm180 -93.21 -60.69 1.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.553 -0.459 . . . . 0.0 111.451 -174.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.497 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -130.75 161.14 32.37 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.567 -176.279 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.501 ' HA2' ' HA ' ' A' ' 34' ' ' CYS . . . -131.22 140.02 11.43 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.846 -0.615 . . . . 0.0 112.858 -175.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -101.55 170.08 8.42 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 173.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.7 t -107.56 107.85 18.88 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.187 0.518 . . . . 0.0 111.187 -176.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.571 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.2 mt -104.56 162.27 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.19 -38.57 0.78 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.09 13.68 1.29 Allowed Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.054 175.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.9 148.82 45.01 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 120.961 0.41 . . . . 0.0 110.618 -173.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.624 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -94.55 87.92 5.27 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 167.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.571 ' HB2' HD12 ' A' ' 28' ' ' ILE . 32.1 t70 -74.52 96.73 2.98 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 122.019 0.914 . . . . 0.0 109.38 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.501 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 69.7 m -86.45 167.85 14.31 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.12 -1.4 . . . . 0.0 112.968 -171.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.497 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 30.4 m -129.23 119.92 19.83 Favored Pre-proline 0 N--CA 1.434 -1.264 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 168.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.46 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 72.0 Cg_endo -84.4 -157.98 0.09 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.303 0 C-N-CA 122.16 1.907 . . . . 0.0 111.609 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.679 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.776 -0.63 . . . . 0.0 110.601 -179.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.7 m . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.653 0.263 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 103.84 104.65 2.92 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.886 -0.674 . . . . 0.0 111.769 -179.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.7 pt -91.88 178.51 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.698 0.285 . . . . 0.0 110.452 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -104.24 110.79 23.14 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 177.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.6 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -160.82 -178.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -173.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.6 ' H ' HG22 ' A' ' 5' ' ' VAL . 26.3 m-20 -128.6 107.77 9.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.366 0.603 . . . . 0.0 110.069 -178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.5 p -91.63 135.69 33.69 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.204 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -82.8 -20.72 35.22 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 167.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.413 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 22.3 p-80 -177.93 159.06 1.32 Allowed 'General case' 0 CA--C 1.522 -0.114 0 CA-C-N 114.65 -1.159 . . . . 0.0 109.272 175.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.6 p -52.72 -44.88 66.65 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -54.49 -34.32 54.89 Favored Glycine 0 C--O 1.228 -0.273 0 CA-C-N 115.908 -0.587 . . . . 0.0 114.002 -177.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.413 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -91.48 3.12 55.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 117.744 0.772 . . . . 0.0 111.99 -177.432 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -84.09 -2.51 56.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.62 0.724 . . . . 0.0 109.543 -177.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 72.3 mt -61.09 -55.93 26.83 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.829 -1.078 . . . . 0.0 111.404 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.7 tptp -52.03 -54.86 36.24 Favored Pre-proline 0 CA--C 1.542 0.664 0 N-CA-C 113.341 0.867 . . . . 0.0 113.341 -172.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.18 -31.58 22.81 Favored 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 121.276 1.318 . . . . 0.0 112.406 -176.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.546 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 7.8 t -81.59 -22.09 37.95 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.21 0.528 . . . . 0.0 110.198 -178.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -65.41 -38.79 90.99 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 174.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -62.3 -43.94 97.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.98 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.35 -40.45 90.75 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.759 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 129.22 17.51 1.78 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.969 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.546 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -109.8 -178.02 3.42 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.748 179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.3 mtm180 -103.8 -63.58 1.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.891 0.377 . . . . 0.0 111.589 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.442 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -116.61 157.43 25.36 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 -177.411 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.9 144.47 16.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.988 -174.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttp -110.12 167.55 10.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 110.229 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 36.3 t -108.54 110.72 22.27 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.437 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.469 HG22 ' N ' ' A' ' 29' ' ' ASN . 10.1 mt -117.15 176.03 2.89 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.469 ' N ' HG22 ' A' ' 28' ' ' ILE . 9.6 p30 -38.4 -43.97 0.87 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -169.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -155.83 17.07 0.47 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.784 173.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.403 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -124.54 148.85 47.52 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.665 -175.528 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.63 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.5 t -92.83 89.17 6.49 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 173.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -77.12 107.69 9.67 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.615 0.721 . . . . 0.0 109.388 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.9 m -111.06 171.49 7.44 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.841 -171.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.44 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 75.4 m -122.18 122.9 27.39 Favored Pre-proline 0 N--CA 1.436 -1.13 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 168.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.516 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 95.8 Cg_endo -84.55 -162.95 0.17 Allowed 'Trans proline' 0 N--CA 1.445 -1.332 0 C-N-CA 122.197 1.931 . . . . 0.0 112.474 -177.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.723 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.032 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.03 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 120.624 0.249 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.87 127.24 5.85 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -174.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.4 pt -100.74 172.71 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.419 0.628 . . . . 0.0 111.732 -169.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -102.64 95.29 6.12 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.815 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -155.67 -177.39 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.948 -0.569 . . . . 0.0 109.734 -172.799 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.484 ' N ' HG13 ' A' ' 5' ' ' VAL . 16.4 m-20 -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.817 0.341 . . . . 0.0 110.42 -179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 2.4 p -92.83 128.97 38.88 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.454 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 62.5 tttm -81.73 -19.53 41.24 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 167.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.456 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 6.5 p-80 -166.28 151.19 8.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.804 -177.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 t -74.3 73.8 1.83 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.68 177.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.14 -28.84 0.03 OUTLIER Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.105 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.456 ' HB3' ' NE2' ' A' ' 9' ' ' HIS . 9.8 pt20 -87.98 3.39 48.91 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 121.142 -0.223 . . . . 0.0 111.146 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.591 ' O ' ' HB2' ' A' ' 17' ' ' CYS . 73.5 m -77.17 -11.52 59.83 Favored 'General case' 0 C--O 1.221 -0.414 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.355 -175.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 74.4 mt -62.19 -54.52 39.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.844 -0.617 . . . . 0.0 111.846 -174.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -53.51 -54.92 40.35 Favored Pre-proline 0 CA--C 1.543 0.699 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.403 -178.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.95 -23.62 25.16 Favored 'Trans proline' 0 C--N 1.354 0.822 0 C-N-CA 121.786 1.657 . . . . 0.0 112.538 178.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.591 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 19.4 t -69.72 -35.53 75.12 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.447 0.641 . . . . 0.0 109.629 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -70.47 -30.66 67.54 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.924 177.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 52.9 tttm -68.56 -41.43 79.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.705 173.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.42 -40.38 93.29 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.741 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 119.76 17.6 4.62 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.479 177.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.551 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 61.3 mtt -116.12 177.68 4.59 Favored 'General case' 0 C--N 1.32 -0.699 0 O-C-N 122.6 -0.353 . . . . 0.0 110.432 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 -91.76 -74.09 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 120.458 -0.497 . . . . 0.0 111.983 -169.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.507 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -110.23 158.95 17.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.886 -174.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.7 161.41 22.88 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.46 -175.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 0.4 OUTLIER -145.83 144.84 30.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -177.21 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 39.2 t -89.05 121.45 31.4 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.413 -178.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 6.5 mt -114.96 167.69 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.42 HD22 ' C ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -67.2 53.1 0.05 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -175.015 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 155.1 -36.77 0.65 Allowed Glycine 0 N--CA 1.438 -1.176 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.309 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -124.45 174.1 8.0 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 117.505 0.652 . . . . 0.0 111.663 -172.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -108.08 98.16 7.76 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 166.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.522 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.7 t70 -76.19 117.85 18.31 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.592 0.711 . . . . 0.0 110.367 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.421 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 48.3 m -106.83 160.68 15.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.443 -175.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.507 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 48.2 m -112.24 125.75 29.6 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 169.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -79.9 -159.83 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.722 0 C-N-CA 122.673 2.249 . . . . 0.0 111.688 -176.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.3 mptt . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.705 -0.664 . . . . 0.0 109.794 178.977 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 121.015 0.436 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 107.77 114.66 3.84 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.862 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.476 HG12 ' HB2' ' A' ' 32' ' ' CYS . 10.3 pt -100.51 -179.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.126 0.489 . . . . 0.0 111.155 -173.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -108.16 118.51 36.94 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.373 -0.83 . . . . 0.0 108.993 175.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.4 p -167.32 -174.97 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -172.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.567 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.3 p-10 -126.94 110.88 13.48 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.673 0.749 . . . . 0.0 110.395 178.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -92.84 127.45 38.36 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.476 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.8 ttmt -73.97 -25.88 60.17 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 165.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 10.6 p-80 -174.75 163.76 3.47 Favored 'General case' 0 C--O 1.226 -0.165 0 CA-C-N 114.511 -1.222 . . . . 0.0 109.459 -179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.0 p -59.21 -37.07 76.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 120.692 0.282 . . . . 0.0 111.72 -177.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.56 -33.45 66.85 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 116.269 -0.423 . . . . 0.0 114.065 -176.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 6.34 44.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.413 0.607 . . . . 0.0 111.185 -178.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.542 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 46.0 t -84.47 -15.25 46.71 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.253 0.549 . . . . 0.0 109.744 179.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 53.8 mt -58.18 -50.76 72.39 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.816 -175.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.456 ' NZ ' ' HB2' ' A' ' 15' ' ' LYS . 3.5 ttmp? -59.96 -56.25 37.46 Favored Pre-proline 0 N--CA 1.445 -0.709 0 CA-C-N 115.453 -0.794 . . . . 0.0 113.063 -175.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.8 -26.17 32.66 Favored 'Trans proline' 0 C--N 1.356 0.934 0 C-N-CA 121.024 1.149 . . . . 0.0 111.45 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 42.0 t -68.07 -37.02 80.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.783 175.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.407 ' NZ ' ' HB2' ' A' ' 18' ' ' LYS . 2.7 ttmp? -68.64 -39.94 80.51 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.733 176.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -59.16 -33.14 70.55 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.231 175.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.08 -36.85 55.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.739 177.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.06 2.18 5.18 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.354 -0.926 . . . . 0.0 114.29 172.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.558 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.0 mpp? -96.03 -169.01 1.85 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 117.705 0.753 . . . . 0.0 111.051 -177.081 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 68.0 mtm180 -99.87 -59.61 1.68 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.02 0.438 . . . . 0.0 111.45 -175.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.455 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -128.99 158.98 37.33 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.345 -175.973 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -135.27 155.02 21.89 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.813 -177.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -117.86 166.73 12.12 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 48.7 t -103.81 106.29 16.75 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.913 -178.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 29' ' ' ASN . 12.8 mt -116.03 171.71 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.463 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -58.48 65.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -173.493 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 95.94 6.41 59.22 Favored Glycine 0 N--CA 1.443 -0.856 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 31.1 ttmt -123.73 133.57 53.84 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -176.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.3 OUTLIER -97.07 87.78 4.31 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 172.434 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.86 113.08 15.4 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.49 0.662 . . . . 0.0 109.566 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.471 ' HA ' ' HA2' ' A' ' 25' ' ' GLY . 99.0 m -101.66 173.42 6.43 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.17 -172.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.455 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 87.9 m -126.09 124.97 24.7 Favored Pre-proline 0 N--CA 1.44 -0.958 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 168.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.92 -156.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 122.744 2.296 . . . . 0.0 111.868 -176.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 5.5 mptp? . . . . . 0 C--O 1.247 0.954 0 CA-C-O 118.603 -0.713 . . . . 0.0 110.672 178.265 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 34' ' ' CYS . 76.3 t . . . . . 0 N--CA 1.479 1.016 0 CA-C-O 120.813 0.34 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.564 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 102.53 97.97 2.4 Favored Glycine 0 N--CA 1.443 -0.893 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.183 179.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.559 HG12 ' CB ' ' A' ' 32' ' ' CYS . 2.1 pt -94.77 -179.55 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -106.49 106.45 16.97 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.628 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.6 p -154.0 -177.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -172.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 5' ' ' VAL . 12.0 m-20 -128.92 102.97 6.76 Favored 'General case' 0 CA--C 1.511 -0.542 0 CA-C-O 120.96 0.41 . . . . 0.0 110.787 -178.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.1 p -94.33 131.36 40.04 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.345 176.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -85.26 -18.0 35.29 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 165.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.436 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 8.6 p-80 -167.68 162.63 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.775 -176.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.3 p -66.88 -37.73 84.97 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -174.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.71 -26.28 59.92 Favored Glycine 0 CA--C 1.519 0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 113.897 -174.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.436 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 17.5 pt20 -88.39 -4.67 58.61 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 117.384 0.592 . . . . 0.0 110.908 -177.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -88.42 -2.36 58.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.534 0.683 . . . . 0.0 109.85 -175.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.3 mt -62.58 -57.16 12.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.169 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.459 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.2 tmmm? -50.76 -57.86 12.06 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 114.695 -1.138 . . . . 0.0 112.811 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.541 ' HB2' HD11 ' A' ' 3' ' ' ILE . 37.1 Cg_endo -64.94 -33.55 51.43 Favored 'Trans proline' 0 C--N 1.352 0.724 0 C-N-CA 121.628 1.552 . . . . 0.0 113.356 -173.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -83.5 -21.72 32.72 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 121.084 0.468 . . . . 0.0 110.463 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -72.78 -36.26 67.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.2 tptm -68.15 -36.32 79.49 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.783 173.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.69 -45.94 84.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.442 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.89 21.23 0.56 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.842 176.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.468 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 2.1 mpt? -109.7 -175.42 2.74 Favored 'General case' 0 C--N 1.321 -0.651 0 O-C-N 122.669 -0.312 . . . . 0.0 110.493 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.0 mtm180 -96.37 -61.44 1.43 Allowed 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.183 -0.607 . . . . 0.0 111.958 -176.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -108.06 -158.11 0.64 Allowed 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.074 -173.42 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -168.21 141.63 6.93 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.328 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -130.36 166.9 19.45 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 177.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.4 t -107.15 110.68 22.82 Favored 'General case' 0 C--N 1.317 -0.804 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.959 -175.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.432 HD12 ' HB2' ' A' ' 33' ' ' ASP . 8.3 mt -113.37 171.46 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 174.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.409 ' N ' HG22 ' A' ' 28' ' ' ILE . 12.6 m-80 -38.6 -53.71 1.59 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.908 0.483 . . . . 0.0 111.869 -171.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.71 21.82 2.17 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 173.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.413 ' O ' ' HB ' ' A' ' 28' ' ' ILE . 30.1 ttmt -122.67 132.79 54.43 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 110.305 -0.258 . . . . 0.0 110.305 -171.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.564 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.4 t -87.84 90.52 8.41 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.432 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.3 t70 -77.13 104.81 7.84 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.465 0.65 . . . . 0.0 109.753 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.44 ' O ' HG13 ' A' ' 1' ' ' VAL . 4.3 p -128.47 141.11 51.49 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.253 -173.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 38.4 m -92.91 127.87 45.86 Favored Pre-proline 0 N--CA 1.441 -0.915 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.468 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 46.4 Cg_endo -84.03 -154.09 0.05 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.073 0 C-N-CA 122.521 2.147 . . . . 0.0 111.714 -176.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.457 ' HD2' ' N ' ' A' ' 37' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.567 178.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.612 HG21 ' O ' ' A' ' 34' ' ' CYS . 27.2 m . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.847 0.356 . . . . 0.0 110.306 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 100.65 118.11 4.23 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -176.157 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.8 pt -102.55 170.61 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.43 0.634 . . . . 0.0 111.082 -174.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -104.79 92.09 4.11 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.255 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.439 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.7 OUTLIER -147.69 -179.2 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.498 -173.385 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.9 m-20 -128.4 102.69 6.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.163 0.506 . . . . 0.0 110.298 -178.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.589 ' HA ' ' NE2' ' A' ' 12' ' ' GLN . 1.9 p -92.91 133.57 35.97 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.337 -176.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -84.68 -21.84 30.03 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 164.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.464 ' NE2' ' HB3' ' A' ' 12' ' ' GLN . 14.1 p-80 -168.63 163.99 12.23 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.759 -176.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.6 p -65.09 -41.4 95.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.724 0.297 . . . . 0.0 111.577 -178.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.416 ' O ' HD23 ' A' ' 14' ' ' LEU . . . -59.85 -18.27 46.03 Favored Glycine 0 C--O 1.228 -0.275 0 CA-C-N 115.79 -0.641 . . . . 0.0 114.61 -172.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.589 ' NE2' ' HA ' ' A' ' 7' ' ' CYS . 9.7 pt20 -89.12 -17.48 29.14 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 117.73 0.765 . . . . 0.0 110.634 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 4.4 m -90.83 24.39 2.75 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-O 121.009 0.433 . . . . 0.0 111.432 -175.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 11' ' ' GLY . 4.1 mm? -82.65 -41.58 19.24 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 169.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 28.5 ttpt -62.31 -58.25 18.44 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.599 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.87 -27.05 21.65 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.318 1.345 . . . . 0.0 112.17 -177.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.547 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 40.7 t -74.12 -30.94 62.56 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.374 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 11.3 tppt? -67.86 -36.92 81.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 177.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.4 tttp -73.56 -28.86 62.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.903 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.49 -36.82 85.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.34 176.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.63 10.79 5.26 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.95 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.547 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.2 mpt? -107.88 -175.4 2.77 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.576 -0.367 . . . . 0.0 110.344 -179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 -93.61 -62.48 1.35 Allowed 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.473 -0.491 . . . . 0.0 111.268 -177.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.504 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.8 160.27 22.94 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.978 -175.961 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.87 146.22 17.61 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.402 -176.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 61.6 mtpt -134.97 167.15 21.45 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 52.1 t -104.81 121.55 43.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.867 -174.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.486 HG22 ' N ' ' A' ' 29' ' ' ASN . 8.9 mt -117.41 178.5 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.816 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.486 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -64.67 56.23 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -174.722 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 134.65 -23.03 3.62 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 121.354 -0.451 . . . . 0.0 112.661 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -123.06 169.16 11.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 116.832 0.316 . . . . 0.0 110.236 -173.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 5.2 m -114.39 100.79 8.59 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.538 0.685 . . . . 0.0 109.289 167.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.537 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 6.6 t70 -77.96 149.14 34.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 114.586 -1.188 . . . . 0.0 110.033 -178.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.612 ' O ' HG21 ' A' ' 1' ' ' VAL . 98.4 m -137.43 160.16 39.91 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -170.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 89.0 m -116.28 123.12 31.15 Favored Pre-proline 0 N--CA 1.437 -1.076 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 167.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -79.72 -163.24 0.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.555 2.17 . . . . 0.0 112.215 -174.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.425 -0.798 . . . . 0.0 110.234 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.48 1.067 0 CA-C-O 120.55 0.214 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 104.8 130.52 6.83 Favored Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.514 HG13 ' H ' ' A' ' 5' ' ' VAL . 15.5 pt -108.48 178.72 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.187 0.518 . . . . 0.0 111.486 -171.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -105.04 37.8 2.09 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.001 -175.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.64 HG12 ' SG ' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -98.43 158.33 3.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.21 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -102.84 112.52 25.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.922 0.391 . . . . 0.0 110.407 -174.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.633 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 6.0 p -91.5 131.94 36.61 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.9 mmtp -82.03 -19.58 40.09 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 164.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 -170.2 164.7 9.11 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.093 177.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 13.0 p -57.99 -38.94 77.05 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.887 0.375 . . . . 0.0 111.568 -176.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.58 -36.56 54.43 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.771 -176.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -91.71 14.6 14.8 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.265 0.533 . . . . 0.0 112.415 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.633 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 58.6 m -90.13 -21.89 22.03 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 171.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.6 -46.8 83.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.223 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.4 ttpp -62.24 -58.61 16.49 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -176.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' CG ' HG11 ' A' ' 5' ' ' VAL . 32.8 Cg_endo -69.92 -29.1 23.64 Favored 'Trans proline' 0 C--N 1.354 0.844 0 C-N-CA 121.237 1.291 . . . . 0.0 112.695 -177.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 13' ' ' CYS . 13.9 m -74.06 -27.15 60.77 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-O 120.748 0.309 . . . . 0.0 110.801 176.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -70.69 -37.66 73.61 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.8 ttpp -67.93 -32.75 73.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.577 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.66 -46.79 71.38 Favored 'General case' 0 N--CA 1.453 -0.278 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.019 176.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.85 14.15 1.9 Allowed Glycine 0 N--CA 1.447 -0.629 0 CA-C-N 115.69 -0.687 . . . . 0.0 112.914 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -99.89 173.89 6.46 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.108 0.454 . . . . 0.0 111.002 -178.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -94.78 -53.56 3.81 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.961 0.41 . . . . 0.0 111.859 -170.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.48 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.6 OUTLIER -110.19 -157.29 0.61 Allowed 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.044 -175.447 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.689 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.0 132.04 2.26 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.575 -0.822 . . . . 0.0 112.921 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.7 tttp -131.89 152.43 51.06 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 35.7 t -95.52 119.16 33.54 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.118 0.485 . . . . 0.0 110.806 -174.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.465 HD12 ' HB2' ' A' ' 33' ' ' ASP . 3.6 mt -109.49 164.0 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.171 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -40.95 -38.69 1.01 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -145.53 11.25 1.73 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.067 175.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.415 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 61.2 mttm -123.9 146.63 48.3 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 -174.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.64 ' SG ' HG12 ' A' ' 5' ' ' VAL . 5.7 m -96.8 89.66 4.98 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 163.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.465 ' HB2' HD12 ' A' ' 28' ' ' ILE . 18.5 t70 -77.99 115.19 17.54 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.747 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.689 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 35.1 m -132.86 141.27 48.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.868 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.48 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 34.9 m -91.84 132.4 33.02 Favored Pre-proline 0 N--CA 1.447 -0.588 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -176.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -81.21 -159.7 0.11 Allowed 'Trans proline' 0 N--CA 1.46 -0.444 0 C-N-CA 123.13 2.553 . . . . 0.0 112.166 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 mptt . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.352 178.502 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.479 1.004 0 CA-C-O 120.638 0.256 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.533 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 98.35 126.24 5.48 Favored Glycine 0 N--CA 1.447 -0.611 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.182 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.7 pt -106.42 177.81 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.049 0.452 . . . . 0.0 111.35 -172.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -101.17 94.91 6.21 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.284 178.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.482 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER -156.97 -179.1 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -175.773 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.482 ' N ' HG13 ' A' ' 5' ' ' VAL . 5.6 m-20 -137.15 110.99 8.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.448 0.642 . . . . 0.0 110.479 177.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 7.3 p -93.01 140.36 29.56 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.186 -178.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -85.32 -21.75 28.8 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 164.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.579 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 10.0 p-80 -164.45 162.67 22.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.893 -176.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 12.7 p -68.51 -32.17 71.95 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -175.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.05 -28.75 64.27 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.506 -176.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.579 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 21.1 pt20 -84.94 -11.08 56.32 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.894 0.347 . . . . 0.0 111.04 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 91.7 m -72.3 -23.99 61.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.816 0.341 . . . . 0.0 110.212 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.1 mp -56.44 -44.99 80.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.099 -174.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.522 ' HE3' ' HA ' ' A' ' 15' ' ' LYS . 1.1 tpmt? -65.32 -59.04 10.5 Favored Pre-proline 0 N--CA 1.444 -0.736 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -176.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.86 -24.46 46.45 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 121.629 1.552 . . . . 0.0 112.505 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.688 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 45.6 t -74.81 -33.14 62.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.27 0.557 . . . . 0.0 110.219 176.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.8 tttp -71.51 -35.75 70.85 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.671 0.748 . . . . 0.0 109.403 177.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -70.43 -27.0 63.92 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.838 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.685 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 133.62 11.16 1.73 Allowed Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.716 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.688 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -108.96 -171.14 1.79 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 117.399 0.6 . . . . 0.0 110.784 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -97.75 -66.34 0.91 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.884 0.373 . . . . 0.0 111.537 -174.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.471 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -119.19 160.33 22.36 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.902 -176.567 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.0 141.25 12.38 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.353 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 83.2 tttt -117.14 156.58 27.39 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 13.2 t -97.24 115.78 28.24 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.06 0.457 . . . . 0.0 110.714 -175.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.414 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.7 mt -114.92 163.61 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.976 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -39.61 -42.39 1.17 Allowed 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 -172.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -141.46 12.21 2.73 Favored Glycine 0 N--CA 1.445 -0.745 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.025 175.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 21.4 mttm -124.94 140.47 52.89 Favored 'General case' 0 N--CA 1.445 -0.72 0 O-C-N 122.901 -0.176 . . . . 0.0 110.836 -175.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.2 m -92.11 82.31 5.05 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 160.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.533 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.5 t70 -76.84 128.81 35.28 Favored 'General case' 0 CA--C 1.514 -0.412 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.895 -176.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 77.7 m -109.31 171.99 7.12 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.115 -169.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.471 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.2 m -120.54 124.48 27.6 Favored Pre-proline 0 N--CA 1.438 -1.07 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 166.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -81.32 -161.07 0.14 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.446 2.097 . . . . 0.0 111.786 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.477 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 119.026 -0.512 . . . . 0.0 110.809 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.8 m . . . . . 0 N--CA 1.479 0.993 0 CA-C-O 121.066 0.46 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.604 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 117.37 113.11 2.65 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.365 -176.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.54 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.7 OUTLIER -97.03 175.85 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.163 0.506 . . . . 0.0 111.076 -172.723 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.1 p-10 -99.34 113.65 26.08 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.11 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.641 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.0 p -162.34 -177.22 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.641 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.6 m-20 -132.92 100.2 4.83 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.535 0.683 . . . . 0.0 110.795 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.5 p -93.91 141.78 28.12 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 114.777 -1.101 . . . . 0.0 111.477 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -90.13 -17.93 26.76 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 164.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.55 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 11.0 p-80 -172.7 155.07 3.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.418 -1.265 . . . . 0.0 108.935 -175.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.3 p -68.51 -21.7 64.57 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -174.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.0 -34.72 88.97 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.113 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.55 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 20.3 pt20 -85.7 -4.5 59.18 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.897 0.379 . . . . 0.0 110.232 -178.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.47 -10.94 58.82 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.258 0.551 . . . . 0.0 109.734 -172.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -62.31 -53.53 53.73 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.903 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.512 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 23.5 ttpp -50.52 -55.04 29.06 Favored Pre-proline 0 CA--C 1.541 0.625 0 CA-C-N 115.139 -0.937 . . . . 0.0 113.03 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.512 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.9 Cg_endo -72.63 -26.44 16.38 Favored 'Trans proline' 0 C--N 1.357 0.999 0 C-N-CA 121.397 1.398 . . . . 0.0 112.367 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 38.8 t -70.14 -34.2 72.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.229 0.538 . . . . 0.0 110.288 178.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -72.6 -31.93 65.56 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.333 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 56.5 tptt -67.63 -30.74 70.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.808 174.247 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.28 -43.41 28.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.162 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.46 8.06 2.06 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.181 -1.009 . . . . 0.0 114.057 174.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.609 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 3.9 mpp? -106.02 -178.42 3.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 117.765 0.782 . . . . 0.0 110.914 178.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.453 ' NE ' ' HA ' ' A' ' 37' ' ' LYS . 70.6 mtm180 -91.67 -63.59 1.23 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.885 0.374 . . . . 0.0 111.686 -176.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.452 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -118.04 157.87 26.02 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.361 -175.287 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -128.12 157.68 21.27 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.112 -177.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -128.91 153.69 47.26 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 21.0 t -92.54 109.62 21.03 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.011 0.434 . . . . 0.0 110.893 -173.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.543 HD12 ' HB2' ' A' ' 33' ' ' ASP . 5.1 mt -112.24 164.23 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 174.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -43.44 -37.64 2.46 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -173.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.23 17.91 1.04 Allowed Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.002 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -123.48 147.07 47.56 Favored 'General case' 0 CA--C 1.513 -0.444 0 O-C-N 122.527 -0.396 . . . . 0.0 110.827 -176.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.604 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 6.4 t -96.77 87.45 4.32 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 166.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.543 ' HB2' HD12 ' A' ' 28' ' ' ILE . 20.5 t70 -75.62 95.42 3.37 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 122.062 0.934 . . . . 0.0 109.653 -176.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 68.7 m -92.5 175.71 6.73 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.522 -1.217 . . . . 0.0 113.129 -169.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.452 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 33.3 m -136.61 126.72 16.08 Favored Pre-proline 0 N--CA 1.439 -1.008 0 CA-C-N 114.541 -1.209 . . . . 0.0 107.89 168.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.421 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 83.0 Cg_endo -80.0 -158.44 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.301 2.001 . . . . 0.0 112.049 -179.244 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.589 ' HD3' ' H ' ' A' ' 37' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.101 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.443 177.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.479 1.012 0 CA-C-O 120.67 0.271 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 109.43 118.56 4.08 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 32' ' ' CYS . 0.6 OUTLIER -104.9 175.03 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 117.001 0.401 . . . . 0.0 110.369 -176.418 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -106.62 107.38 18.37 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 178.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.2 p -155.64 -176.86 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.408 -170.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 9.9 m-20 -122.6 105.77 10.39 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -91.93 150.06 21.22 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-O 121.39 0.614 . . . . 0.0 111.174 178.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.9 mtpt -91.29 -33.9 15.15 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 115.003 -0.999 . . . . 0.0 108.843 170.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -149.11 166.24 29.36 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.304 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 t -82.34 64.31 6.93 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.831 175.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.676 ' O ' ' HG ' ' A' ' 14' ' ' LEU . . . -177.38 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.065 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.98 9.59 5.24 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.956 0.408 . . . . 0.0 111.933 -178.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.1 t -85.45 13.65 6.49 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.9 0.857 . . . . 0.0 109.075 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.676 ' HG ' ' O ' ' A' ' 11' ' ' GLY . 80.9 mt -60.47 -48.87 79.86 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.02 -178.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -54.55 -55.68 35.07 Favored Pre-proline 0 CA--C 1.541 0.596 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -175.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -71.64 -27.61 18.28 Favored 'Trans proline' 0 C--N 1.354 0.835 0 C-N-CA 121.177 1.252 . . . . 0.0 111.767 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 44.0 t -69.6 -34.28 73.9 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.018 178.109 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -72.17 -36.07 69.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.883 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -65.3 -32.44 74.1 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.714 176.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.13 -42.12 47.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.056 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 124.2 25.21 1.69 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.672 -0.775 . . . . 0.0 113.726 172.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.59 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -114.67 178.47 4.27 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.35 0.575 . . . . 0.0 111.072 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 73.8 mtm180 -83.61 -71.73 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 111.729 -173.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -115.29 159.11 21.43 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -175.45 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -133.62 124.79 3.76 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.577 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -100.57 168.33 9.78 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.928 0.394 . . . . 0.0 110.219 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 22.4 t -108.34 116.84 32.72 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.161 0.505 . . . . 0.0 110.895 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.561 HG22 HD22 ' A' ' 29' ' ' ASN . 9.0 mt -124.14 172.75 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 176.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.561 HD22 HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -59.52 63.85 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -172.266 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.484 ' N ' ' O ' ' A' ' 28' ' ' ILE . . . 100.55 5.87 53.55 Favored Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 111.304 -0.718 . . . . 0.0 111.304 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 18.1 ttmm -122.68 129.66 52.07 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -173.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.567 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 7.1 t -89.85 89.97 7.98 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 172.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' HB2' HD12 ' A' ' 28' ' ' ILE . 7.1 t70 -77.35 105.0 8.19 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.665 0.745 . . . . 0.0 109.283 178.43 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 93.2 m -101.51 169.22 8.99 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.822 -1.081 . . . . 0.0 111.79 -175.089 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.512 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 59.6 m -115.52 125.2 29.03 Favored Pre-proline 0 N--CA 1.441 -0.906 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 167.445 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -81.55 -160.66 0.13 Allowed 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.555 2.17 . . . . 0.0 111.813 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.297 -0.859 . . . . 0.0 110.166 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.645 0.259 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.581 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 113.66 110.89 2.96 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.489 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.6 pt -87.22 178.05 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.082 0.468 . . . . 0.0 110.896 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -103.27 92.75 4.64 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.031 -177.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.555 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.1 p -145.4 -178.17 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.555 ' H ' HG22 ' A' ' 5' ' ' VAL . 7.0 m-20 -131.48 101.52 5.55 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.339 0.59 . . . . 0.0 110.541 -176.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.427 ' HB2' ' O ' ' A' ' 9' ' ' HIS . 2.2 p -93.07 132.49 37.13 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.641 -178.358 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -90.13 -18.37 25.95 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 166.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 7.2 m80 -151.05 167.72 26.81 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.8 179.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 22.2 p -80.93 -21.6 40.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.876 0.369 . . . . 0.0 110.764 177.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.18 -39.55 72.17 Favored Glycine 0 C--N 1.33 0.22 0 C-N-CA 121.203 -0.523 . . . . 0.0 112.746 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -79.62 2.9 20.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.995 0.426 . . . . 0.0 110.54 178.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 10' ' ' SER . 42.6 t -85.04 -16.33 41.07 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.583 0.706 . . . . 0.0 109.566 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.7 mt -65.04 -57.78 7.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.209 -178.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.7 tppp? -49.42 -53.97 34.99 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.129 -0.941 . . . . 0.0 113.493 -174.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.96 -27.87 20.21 Favored 'Trans proline' 0 C--N 1.355 0.911 0 C-N-CA 121.374 1.383 . . . . 0.0 112.873 -177.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 3.3 m -78.45 -25.78 46.0 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 120.819 0.343 . . . . 0.0 110.903 178.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.03 -23.65 55.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 173.27 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -72.83 -36.81 67.57 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.245 -0.888 . . . . 0.0 109.14 172.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.61 -49.96 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.789 178.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.36 20.22 0.57 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.1 177.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.498 ' HG3' ' HB3' ' A' ' 36' ' ' PRO . 1.8 mpt? -103.18 178.23 4.61 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 122.737 -0.272 . . . . 0.0 111.367 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.5 mtm180 -97.39 -57.87 2.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.206 0.526 . . . . 0.0 111.805 -175.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.5 OUTLIER -105.88 -161.44 0.8 Allowed 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.819 -174.195 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.746 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -160.41 138.21 5.41 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.481 178.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -132.23 143.97 50.3 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 25.6 t -95.78 112.59 24.28 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-O 120.929 0.395 . . . . 0.0 110.672 -174.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.478 HD12 ' HB2' ' A' ' 33' ' ' ASP . 4.9 mt -110.01 163.22 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 176.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -44.73 -36.99 3.44 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -172.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -142.73 12.25 2.42 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.855 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.429 ' HB2' ' HB ' ' A' ' 28' ' ' ILE . 97.9 mttt -123.84 158.21 32.38 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 117.231 0.516 . . . . 0.0 111.55 -175.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.581 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -105.6 88.47 2.84 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 162.786 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.478 ' HB2' HD12 ' A' ' 28' ' ' ILE . 21.2 t70 -77.64 90.28 3.96 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.739 0.781 . . . . 0.0 110.032 -178.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.746 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 34.9 m -111.28 142.54 43.37 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.75 -174.253 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.408 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 87.5 m -96.34 128.67 35.81 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.498 ' HB3' ' HG3' ' A' ' 22' ' ' MET . 88.1 Cg_endo -83.81 -162.06 0.16 Allowed 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.55 2.167 . . . . 0.0 112.581 -177.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.919 0 CA-C-O 118.411 -0.805 . . . . 0.0 110.367 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.629 0.252 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.78 124.87 5.41 Favored Glycine 0 N--CA 1.445 -0.751 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -178.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.2 pt -103.5 -174.37 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -177.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.438 ' O ' HG12 ' A' ' 5' ' ' VAL . 24.2 t-20 -87.68 -87.2 0.15 Allowed 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.508 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.4 OUTLIER 50.78 -172.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 124.05 0.844 . . . . 0.0 112.078 175.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.508 ' H ' HG22 ' A' ' 5' ' ' VAL . 3.6 p30 -141.07 115.55 9.48 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 174.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 13.1 p -93.53 130.54 39.36 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.373 0.606 . . . . 0.0 112.036 177.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.586 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 64.5 tttm -84.66 -21.43 30.22 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 163.286 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.451 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 12.7 p-80 -175.96 159.34 2.17 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.135 -177.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.9 p -67.5 -26.81 66.54 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -174.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.02 -34.49 79.31 Favored Glycine 0 CA--C 1.517 0.184 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.812 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.586 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 10.3 pt20 -90.66 5.56 47.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.029 0.443 . . . . 0.0 110.393 -178.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.582 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 42.2 t -88.11 -14.45 38.76 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.193 0.521 . . . . 0.0 110.316 -175.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 59.2 mt -64.79 -51.72 60.68 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.033 -177.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.486 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 59.7 tttp -50.88 -56.89 15.9 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -177.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.486 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 58.7 Cg_endo -71.27 -26.79 20.48 Favored 'Trans proline' 0 C--N 1.355 0.913 0 C-N-CA 121.335 1.357 . . . . 0.0 111.702 -177.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.1 t -74.15 -30.49 62.3 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.053 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 tppt? -74.16 -30.83 62.45 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.83 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -70.95 -28.32 64.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.454 174.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.5 -36.0 65.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.845 174.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.05 19.95 5.78 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.294 173.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.619 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.0 mpt? -103.88 -174.61 2.58 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 122.714 -0.286 . . . . 0.0 111.0 -178.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -90.87 -57.95 2.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.885 0.374 . . . . 0.0 110.719 -175.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.495 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -136.11 161.09 36.69 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.186 -176.893 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.582 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -122.56 163.86 15.79 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.386 178.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 35.4 tptt -138.01 145.41 41.85 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 47.5 t -91.27 106.16 18.31 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.14 0.495 . . . . 0.0 110.057 -177.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.802 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.1 mt -96.3 -161.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.802 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.1 OUTLIER -65.19 44.87 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.857 0 CA-C-N 120.294 1.407 . . . . 0.0 113.267 -179.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 118.59 -2.4 15.6 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.111 -0.566 . . . . 0.0 113.39 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -120.89 159.72 24.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 117.555 0.678 . . . . 0.0 111.121 -175.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 1.2 m -100.51 87.87 3.49 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.042 174.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.467 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.2 t70 -78.98 124.43 28.24 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 171.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 89.0 m -107.58 168.12 9.47 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.112 -0.495 . . . . 0.0 112.183 -171.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.495 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 92.9 m -119.9 122.53 28.99 Favored Pre-proline 0 N--CA 1.441 -0.905 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 168.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -85.64 -159.27 0.1 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.009 0 C-N-CA 122.704 2.269 . . . . 0.0 111.431 -177.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.812 -0.613 . . . . 0.0 110.194 178.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 N--CA 1.479 0.996 0 CA-C-O 120.781 0.324 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.599 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 108.77 125.9 5.26 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.376 -0.69 . . . . 0.0 111.376 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.523 HG12 ' HB3' ' A' ' 32' ' ' CYS . 1.4 pt -110.21 176.32 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.0 0.428 . . . . 0.0 110.827 -175.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -107.72 97.24 6.99 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -178.162 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.681 HG22 ' H ' ' A' ' 6' ' ' ASP . 3.7 p -141.87 -177.73 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.927 -171.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.681 ' H ' HG22 ' A' ' 5' ' ' VAL . 11.8 m-20 -126.35 92.57 3.59 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-O 121.609 0.718 . . . . 0.0 110.964 -177.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.9 p -94.55 135.16 36.32 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.473 -1.24 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.0 tptp -85.42 -17.57 36.23 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 166.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.49 ' O ' ' HG2' ' A' ' 12' ' ' GLN . 7.9 p-80 -169.17 155.1 6.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.801 -176.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.704 ' OG ' ' HA ' ' A' ' 26' ' ' LYS . 39.2 t -60.91 -30.23 70.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.852 -175.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.08 -33.23 68.78 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.187 -0.53 . . . . 0.0 113.447 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.49 ' HG2' ' O ' ' A' ' 9' ' ' HIS . 19.1 pt20 -90.78 1.8 56.6 Favored 'General case' 0 C--N 1.326 -0.425 0 O-C-N 122.488 -0.419 . . . . 0.0 110.959 -177.106 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.28 -11.03 57.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.193 0.52 . . . . 0.0 110.011 -175.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 64.0 mt -63.88 -53.39 51.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.454 -176.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.464 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 8.6 tmtt? -51.61 -57.12 15.64 Favored Pre-proline 0 CA--C 1.541 0.62 0 CA-C-N 115.817 -0.628 . . . . 0.0 112.368 -177.163 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.464 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 54.7 Cg_endo -68.86 -26.02 32.41 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 121.477 1.451 . . . . 0.0 111.948 -178.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.707 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.7 t -70.27 -35.76 73.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.928 177.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 28.8 mmmt -72.71 -32.01 65.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.183 177.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 29.5 ttpp -70.98 -31.74 68.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.701 176.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.56 -52.3 16.13 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.483 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 143.77 12.43 0.33 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.128 -1.034 . . . . 0.0 113.536 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.707 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 4.3 mpp? -106.26 -174.72 2.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 117.316 0.558 . . . . 0.0 110.511 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 76.6 mtm180 -98.98 -58.5 1.93 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 111.004 -176.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.468 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -123.45 156.41 35.6 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.022 -176.801 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -134.7 150.82 20.2 Favored Glycine 0 N--CA 1.448 -0.562 0 O-C-N 123.615 0.572 . . . . 0.0 111.969 -176.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.704 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 59.1 tttm -130.24 149.74 51.8 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.3 t -94.21 116.82 29.27 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.687 -178.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.697 HG22 ' H ' ' A' ' 29' ' ' ASN . 6.8 mt -120.07 -122.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.061 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.697 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -91.37 49.55 1.62 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 118.862 0.755 . . . . 0.0 111.243 -175.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 89.44 10.81 65.16 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.893 -0.67 . . . . 0.0 111.515 -177.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 22.8 ptmt -120.14 150.02 41.28 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.599 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 4.3 t -93.53 83.93 4.6 Favored 'General case' 0 C--N 1.315 -0.919 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 172.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.424 ' CB ' HD12 ' A' ' 28' ' ' ILE . 16.0 t70 -76.39 107.38 8.61 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 63.6 m -105.99 173.44 6.31 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.999 -1.001 . . . . 0.0 112.351 -170.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.468 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 90.0 m -122.29 124.6 26.81 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 167.557 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -82.07 -157.9 0.09 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.978 2.452 . . . . 0.0 112.122 -175.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.6 mppt? . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.491 -0.766 . . . . 0.0 109.747 178.195 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.481 1.095 0 CA-C-O 120.986 0.422 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 105.74 113.89 3.87 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.1 pt -87.98 175.66 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.166 0.508 . . . . 0.0 111.693 -166.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -106.68 89.68 3.09 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.024 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.482 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -146.81 -175.48 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.492 -171.288 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.482 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.2 p-10 -129.9 107.6 9.5 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.749 0.785 . . . . 0.0 110.408 176.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 4.2 p -92.45 135.18 34.26 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.805 -177.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -83.52 -23.99 31.87 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 164.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.412 ' CD2' ' HG2' ' A' ' 12' ' ' GLN . 10.6 p-80 -173.17 167.42 4.87 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 115.045 -0.98 . . . . 0.0 109.624 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' CYS . 25.6 p -65.7 -30.07 70.7 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.67 0.272 . . . . 0.0 111.682 -175.756 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.58 -39.52 66.74 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 121.175 -0.536 . . . . 0.0 112.495 178.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.412 ' HG2' ' CD2' ' A' ' 9' ' ' HIS . 3.9 pt20 -91.67 14.82 14.07 Favored 'General case' 0 C--N 1.33 -0.277 0 O-C-N 122.577 -0.367 . . . . 0.0 111.905 178.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 10' ' ' SER . 35.0 m -90.26 -21.46 22.09 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.876 0.369 . . . . 0.0 110.156 173.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 72.5 mt -61.12 -56.29 22.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.831 -173.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -56.6 31.9 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.491 -177.113 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -66.63 -23.77 48.95 Favored 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 121.328 1.352 . . . . 0.0 112.31 -178.597 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 49.5 t -72.13 -37.25 69.5 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.234 0.54 . . . . 0.0 110.109 176.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -78.41 -26.81 46.5 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.857 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -71.0 -29.48 65.45 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.32 172.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.92 -51.76 17.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.433 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.53 9.93 0.62 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.113 177.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.607 ' HB2' ' SG ' ' A' ' 17' ' ' CYS . 2.1 mpt? -107.65 -174.4 2.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.975 0.388 . . . . 0.0 110.242 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -99.93 -75.5 0.57 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.999 0.428 . . . . 0.0 111.504 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.444 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -101.68 157.95 16.45 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.92 -175.144 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.01 141.73 11.54 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.391 -175.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 87.6 tttt -126.85 152.94 46.33 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.6 t -97.84 118.49 34.51 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.675 HG22 ' H ' ' A' ' 29' ' ' ASN . 8.8 mt -118.36 -119.24 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.55 -172.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.675 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.77 45.77 1.28 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.313 0.578 . . . . 0.0 110.824 -175.693 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.96 1.95 58.37 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.519 -177.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -117.32 143.76 45.6 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 23.1 m -86.68 86.43 7.33 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 167.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.528 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 28.7 t70 -77.24 135.7 38.48 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.16 -178.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 85.7 m -126.49 168.11 14.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.33 -168.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.444 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 97.7 m -119.75 127.58 26.33 Favored Pre-proline 0 N--CA 1.444 -0.734 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 165.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.51 -159.88 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.601 2.201 . . . . 0.0 112.22 -175.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.928 0 CA-C-O 118.546 -0.74 . . . . 0.0 110.195 -178.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 m . . . . . 0 N--CA 1.477 0.877 0 CA-C-O 120.768 0.318 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 113.9 127.46 4.53 Favored Glycine 0 N--CA 1.443 -0.89 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -175.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.513 ' CD1' ' HB ' ' A' ' 5' ' ' VAL . 19.1 pt -103.77 -178.53 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.006 0.431 . . . . 0.0 111.249 -172.215 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -99.51 2.55 44.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.565 0.697 . . . . 0.0 110.292 -173.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.527 HG12 ' SG ' ' A' ' 32' ' ' CYS . 1.2 t -69.36 152.51 9.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.418 176.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -106.52 128.41 54.08 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.386 -176.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.727 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 2.7 p -91.43 139.64 30.52 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -177.07 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.408 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 35.1 ttpt -88.16 -22.68 23.93 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 163.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.562 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 16.1 p-80 -172.47 164.1 5.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.35 179.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.5 p -61.39 -42.89 99.44 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -174.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.63 -30.6 59.46 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 116.079 -0.51 . . . . 0.0 113.805 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.562 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.73 6.0 45.88 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 117.099 0.449 . . . . 0.0 111.554 -177.306 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.727 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 54.7 m -84.79 -21.52 29.91 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.077 0.465 . . . . 0.0 109.882 175.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.49 -49.26 76.88 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.492 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.609 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 2.3 tmtp? -53.48 -59.47 9.33 Favored Pre-proline 0 CA--C 1.546 0.802 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.316 -175.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.609 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 47.5 Cg_endo -73.13 -29.16 11.99 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 121.25 1.3 . . . . 0.0 113.309 -178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 11.9 m -71.7 -29.73 64.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 120.635 0.255 . . . . 0.0 111.129 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.33 -27.99 62.77 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.242 0.544 . . . . 0.0 109.955 175.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -73.51 -37.87 65.51 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.567 172.693 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.77 -44.15 86.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.883 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.05 18.5 0.84 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.766 178.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.546 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -107.61 -173.16 2.22 Favored 'General case' 0 C--N 1.322 -0.622 0 O-C-N 122.588 -0.36 . . . . 0.0 110.85 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 63.9 mtm180 -108.29 -58.29 2.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.067 0.46 . . . . 0.0 111.745 -175.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.466 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.4 OUTLIER -105.02 -153.83 0.5 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.77 -174.655 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.75 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -173.02 136.28 3.65 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.703 179.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -134.81 150.6 50.53 Favored 'General case' 0 N--CA 1.45 -0.427 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 43.9 t -102.55 111.32 23.57 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -177.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.678 HG22 ' H ' ' A' ' 29' ' ' ASN . 9.4 mt -105.41 -115.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.22 -174.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.678 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -90.99 43.23 1.14 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 118.709 0.686 . . . . 0.0 110.588 -177.29 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 96.39 2.39 60.35 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.761 -176.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.531 ' HG2' ' ND2' ' A' ' 29' ' ' ASN . 16.8 ptpt -114.49 150.9 34.12 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.527 ' SG ' HG12 ' A' ' 5' ' ' VAL . 59.0 m -91.16 90.17 7.68 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.334 173.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.511 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 15.5 t70 -79.22 118.98 21.67 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 172.055 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.75 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 33.9 m -133.85 139.97 46.57 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 -173.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.466 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 88.3 m -86.32 131.93 44.69 Favored Pre-proline 0 N--CA 1.447 -0.595 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 67.5 Cg_endo -82.22 -161.57 0.15 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.657 2.238 . . . . 0.0 112.547 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.3 mptp? . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.297 -0.859 . . . . 0.0 109.875 -179.158 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.482 1.138 0 CA-C-O 120.794 0.331 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 101.81 112.81 3.62 Favored Glycine 0 N--CA 1.443 -0.851 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -175.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.452 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.4 pt -92.12 177.48 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.328 0.585 . . . . 0.0 111.314 -171.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -103.08 86.63 2.73 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.304 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.494 HG22 ' H ' ' A' ' 6' ' ' ASP . 0.9 OUTLIER -145.0 -179.87 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.674 -173.41 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.494 ' H ' HG22 ' A' ' 5' ' ' VAL . 19.7 m-20 -132.58 106.74 8.0 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.916 0.389 . . . . 0.0 109.955 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.1 p -91.78 136.93 32.77 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.398 0.618 . . . . 0.0 111.309 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -83.86 -19.8 34.24 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 168.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.7 p-80 -170.89 167.3 7.49 Favored 'General case' 0 N--CA 1.461 0.083 0 CA-C-N 115.111 -0.95 . . . . 0.0 110.442 178.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 5.7 p -65.61 -40.4 92.58 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.023 0.379 . . . . 0.0 112.023 -176.306 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.85 -32.96 59.52 Favored Glycine 0 CA--C 1.52 0.376 0 CA-C-N 116.247 -0.433 . . . . 0.0 114.172 -175.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -90.4 -1.39 57.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.251 0.525 . . . . 0.0 111.287 -177.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 48.1 t -74.69 -23.12 58.57 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.656 0.741 . . . . 0.0 110.0 -178.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -60.01 -42.57 94.61 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.815 -1.084 . . . . 0.0 111.211 -179.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 75.9 tttt -56.09 -61.57 6.27 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.806 -176.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -78.51 -33.52 1.77 Allowed 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 121.527 1.485 . . . . 0.0 113.965 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 6.0 t -74.91 -25.26 58.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.011 0.434 . . . . 0.0 110.734 -173.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -75.07 -35.61 61.82 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.039 0.447 . . . . 0.0 110.046 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -71.74 -25.8 62.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.981 177.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.15 -52.64 53.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.173 175.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.5 3.66 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.334 -0.936 . . . . 0.0 113.532 178.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -103.53 -178.74 3.75 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.346 0.573 . . . . 0.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -100.07 -56.61 2.33 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.353 -174.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.515 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.8 OUTLIER -107.25 -159.26 0.69 Allowed 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.698 -175.895 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.401 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -175.58 136.68 3.44 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.491 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -127.29 167.0 16.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.744 0.307 . . . . 0.0 110.352 177.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 7.8 t -110.1 100.13 9.1 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.527 ' CD1' ' HB3' ' A' ' 33' ' ' ASP . 2.4 mp -95.78 -92.83 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.646 -172.427 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.516 ' N ' HG22 ' A' ' 28' ' ' ILE . 1.4 m120 -93.36 45.06 1.15 Allowed 'General case' 0 CA--C 1.505 -0.755 0 CA-C-O 121.88 0.848 . . . . 0.0 109.899 174.657 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.9 6.37 72.77 Favored Glycine 0 C--N 1.314 -0.654 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.282 -171.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 159.1 19.36 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA2' ' A' ' 2' ' ' GLY . 1.4 m -93.82 92.59 7.51 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.328 -176.244 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.527 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 19.3 t70 -86.92 124.24 32.91 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 167.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 7.5 m -135.11 158.47 44.27 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 121.056 -0.258 . . . . 0.0 110.846 -171.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 33.0 m -96.22 128.74 35.77 Favored Pre-proline 0 N--CA 1.446 -0.632 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 175.702 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -82.23 -160.03 0.12 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.572 2.181 . . . . 0.0 112.308 -178.016 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.31 -0.853 . . . . 0.0 111.206 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.479 1.011 0 CA-C-O 120.863 0.363 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.482 ' HA3' ' HE2' ' A' ' 31' ' ' LYS . . . 121.14 126.35 3.29 Favored Glycine 0 N--CA 1.443 -0.891 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.226 -174.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -104.04 -178.01 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.329 0.585 . . . . 0.0 111.533 -173.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -105.3 109.07 20.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.893 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.528 HG22 ' H ' ' A' ' 6' ' ' ASP . 1.4 p -163.03 -178.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -173.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.528 ' H ' HG22 ' A' ' 5' ' ' VAL . 10.5 m-20 -127.74 110.47 12.66 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.524 ' HA ' ' OE1' ' A' ' 12' ' ' GLN . 2.0 p -91.04 123.91 34.86 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.415 0.626 . . . . 0.0 111.702 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -74.98 -25.48 58.87 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 167.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 28.4 p-80 -177.38 163.26 1.99 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.734 177.303 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 6.4 p -63.48 -36.35 83.47 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -175.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -54.49 -39.32 65.48 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.176 -0.535 . . . . 0.0 113.067 -178.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.524 ' OE1' ' HA ' ' A' ' 7' ' ' CYS . 0.0 OUTLIER -90.55 -0.12 57.56 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 122.66 -0.317 . . . . 0.0 110.959 -177.718 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.626 ' SG ' ' HA3' ' A' ' 25' ' ' GLY . 32.6 t -76.02 -22.07 56.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.587 0.708 . . . . 0.0 109.625 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 10.9 mp -57.43 -43.01 83.5 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.792 -1.095 . . . . 0.0 111.065 177.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -59.51 -61.05 8.63 Favored Pre-proline 0 CA--C 1.543 0.688 0 CA-C-N 115.597 -0.728 . . . . 0.0 112.843 -174.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.68 -31.34 13.37 Favored 'Trans proline' 0 C--N 1.354 0.823 0 C-N-CA 121.453 1.435 . . . . 0.0 112.622 -175.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 8.8 t -77.63 -23.46 49.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.173 -176.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HA ' ' O ' ' A' ' 22' ' ' MET . 27.2 ttpp -68.35 -38.46 81.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 175.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -68.71 -28.25 66.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.504 176.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.0 -10.94 59.84 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.866 177.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 122.0 -26.12 6.56 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.501 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.593 ' O ' ' HA ' ' A' ' 18' ' ' LYS . 1.9 mpt? -83.47 175.98 9.4 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 117.261 0.531 . . . . 0.0 111.391 -174.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 65.7 mtm180 -94.29 -61.43 1.52 Allowed 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.566 -175.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.558 ' O ' ' HB3' ' A' ' 34' ' ' CYS . 0.0 OUTLIER -121.81 158.57 28.58 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.044 -176.4 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.626 ' HA3' ' SG ' ' A' ' 13' ' ' CYS . . . -133.86 157.55 22.87 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.051 -0.595 . . . . 0.0 112.524 -177.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.401 ' HB3' HD11 ' A' ' 28' ' ' ILE . 52.8 tptt -127.18 157.57 39.41 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 176.146 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.4 t -104.61 97.87 7.71 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.602 . . . . 0.0 109.875 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.654 HG22 ' N ' ' A' ' 29' ' ' ASN . 3.5 mp -90.06 -110.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.738 -175.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.654 ' N ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -92.53 47.11 1.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 O-C-N 121.628 -0.67 . . . . 0.0 110.391 179.367 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 79.42 19.83 70.65 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -172.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.482 ' HE2' ' HA3' ' A' ' 2' ' ' GLY . 32.1 tttt -120.1 138.53 53.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.929 -0.635 . . . . 0.0 109.536 -179.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.469 ' SG ' HG11 ' A' ' 5' ' ' VAL . 1.3 m -87.56 83.02 7.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.718 173.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.57 ' HB3' ' CD1' ' A' ' 28' ' ' ILE . 16.3 t70 -79.13 124.43 28.31 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 168.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.558 ' HB3' ' O ' ' A' ' 24' ' ' PHE . 57.7 m -124.11 178.17 5.45 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.105 0.479 . . . . 0.0 112.069 -167.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.446 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 95.2 m -125.12 125.53 25.28 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 170.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -82.51 -159.64 0.11 Allowed 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.745 2.297 . . . . 0.0 112.199 -177.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 11.3 mptt . . . . . 0 C--O 1.247 0.949 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.322 177.713 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.435 0.16 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.598 ' HA2' ' HA ' ' A' ' 33' ' ' ASP . . . 97.38 138.9 10.37 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -174.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.408 HG12 ' O ' ' A' ' 32' ' ' CYS . 10.1 pt -109.51 176.76 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-O 121.362 0.601 . . . . 0.0 111.872 -170.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -100.74 100.23 10.88 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.858 178.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.443 HG13 ' N ' ' A' ' 6' ' ' ASP . 0.5 OUTLIER -162.92 179.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -174.281 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.443 ' N ' HG13 ' A' ' 5' ' ' VAL . 6.4 m-20 -128.02 112.82 15.05 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.032 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.676 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.2 p -88.8 129.76 35.5 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.608 0.718 . . . . 0.0 111.663 -177.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -87.15 -15.08 39.45 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 167.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.472 ' O ' ' HG3' ' A' ' 12' ' ' GLN . 26.7 p-80 178.41 158.15 0.48 Allowed 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.833 -1.076 . . . . 0.0 109.493 178.071 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.5 p -58.32 -35.45 71.9 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.952 0.406 . . . . 0.0 111.648 -175.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.78 -32.64 70.31 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 115.99 -0.55 . . . . 0.0 113.641 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 9' ' ' HIS . 0.0 OUTLIER -90.83 7.78 38.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 117.576 0.688 . . . . 0.0 111.446 -177.486 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 74.8 m -82.05 -15.6 53.02 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.143 176.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.7 mt -60.85 -56.59 19.34 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.186 -171.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -57.12 -54.15 57.69 Favored Pre-proline 0 CA--C 1.54 0.563 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -176.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.55 -27.58 39.04 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 121.265 1.31 . . . . 0.0 112.557 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 22' ' ' MET . 43.6 t -73.01 -33.95 66.09 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.26 0.552 . . . . 0.0 110.209 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 23.7 ttmm -73.13 -39.16 65.97 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.914 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.2 ttmm -69.17 -28.85 66.78 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.916 176.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.06 -43.54 78.4 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.891 175.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 125.72 15.04 3.0 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.849 176.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.537 ' SD ' ' HB2' ' A' ' 34' ' ' CYS . 60.9 mtt -116.13 -179.17 3.59 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 122.649 -0.324 . . . . 0.0 110.611 -178.164 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 53.4 mtm180 -92.77 -79.1 0.4 Allowed 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 120.284 -0.566 . . . . 0.0 112.046 -170.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 35' ' ' THR . 0.0 OUTLIER -107.17 158.9 16.73 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -175.584 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.98 137.15 9.21 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.328 -176.015 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 32' ' ' CYS . 26.7 ttpp -117.73 154.16 32.17 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 49.1 t -96.77 107.74 20.27 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.251 0.548 . . . . 0.0 110.354 -176.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.574 ' CG2' ' H ' ' A' ' 29' ' ' ASN . 1.9 mp -94.49 -169.97 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 179.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.574 ' H ' ' CG2' ' A' ' 28' ' ' ILE . 9.8 p30 -39.67 -43.17 1.32 Allowed 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 118.889 0.768 . . . . 0.0 112.244 -174.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 6' ' ' ASP . . . -152.41 2.63 0.33 Allowed Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.201 -1.0 . . . . 0.0 112.305 172.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.25 152.01 40.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.997 0.427 . . . . 0.0 111.807 -169.548 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.676 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 65.2 m -91.59 92.91 8.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.509 176.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.598 ' HA ' ' HA2' ' A' ' 2' ' ' GLY . 22.3 t70 -80.82 135.94 36.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.605 175.228 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.537 ' HB2' ' SD ' ' A' ' 22' ' ' MET . 81.1 m -123.84 157.51 33.99 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.268 -0.424 . . . . 0.0 112.121 -169.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.516 ' HB ' ' CD1' ' A' ' 24' ' ' PHE . 85.3 m -103.27 128.57 27.27 Favored Pre-proline 0 N--CA 1.442 -0.857 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 169.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -83.51 -163.63 0.22 Allowed 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.339 2.026 . . . . 0.0 112.167 -175.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm . . . . . 0 C--O 1.246 0.87 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.14 179.805 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.477 0.913 0 CA-C-O 120.928 0.394 . . . . 0.0 110.588 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 32' ' ' CYS . . . 111.93 106.13 2.84 Favored Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -176.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.409 HG12 ' HB2' ' A' ' 32' ' ' CYS . 16.1 pt -89.87 178.6 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.413 0.625 . . . . 0.0 111.639 -170.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -103.86 105.84 16.17 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.652 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.62 HG22 ' H ' ' A' ' 6' ' ' ASP . 2.3 p -157.98 -175.91 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.364 -172.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.62 ' H ' HG22 ' A' ' 5' ' ' VAL . 4.9 m-20 -132.92 106.1 7.49 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.253 0.549 . . . . 0.0 110.236 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 1.8 p -92.94 125.6 37.62 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.187 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' A' ' 12' ' ' GLN . 56.7 tptt -74.88 -22.14 58.82 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 167.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 13.5 p-80 -171.74 163.7 6.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 114.636 -1.165 . . . . 0.0 109.794 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 6.1 p -66.35 -33.4 75.65 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 111.787 0.291 . . . . 0.0 111.787 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.14 -34.38 62.39 Favored Glycine 0 CA--C 1.519 0.308 0 C-N-CA 121.273 -0.489 . . . . 0.0 113.353 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' A' ' 8' ' ' LYS . 6.5 pt20 -90.7 -1.73 57.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.836 0.351 . . . . 0.0 110.63 -177.389 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 52.1 t -79.86 -16.72 54.84 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.412 0.625 . . . . 0.0 110.258 -173.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 9.6 mp -64.96 -48.74 72.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.864 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HB3' ' HD3' ' A' ' 16' ' ' PRO . 73.2 tttt -53.81 -57.52 17.26 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 113.145 0.794 . . . . 0.0 113.145 -174.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.478 ' HD3' ' HB3' ' A' ' 15' ' ' LYS . 56.7 Cg_endo -67.97 -29.57 34.03 Favored 'Trans proline' 0 C--N 1.354 0.827 0 C-N-CA 121.81 1.674 . . . . 0.0 112.397 -175.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.558 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 2.2 m -78.32 -29.07 47.49 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.46 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 13.7 tmtt? -67.59 -38.4 83.96 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.116 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.9 ttmm -68.01 -35.28 78.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.747 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.24 -12.99 60.72 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.28 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 108.23 14.21 17.23 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.783 -0.723 . . . . 0.0 113.358 175.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' MET . . . . . 0.526 ' HA ' ' HA ' ' A' ' 36' ' ' PRO . 2.1 mpt? -104.32 179.67 4.2 Favored 'General case' 0 C--N 1.319 -0.738 0 O-C-N 122.333 -0.51 . . . . 0.0 110.758 178.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.45 -57.11 2.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.03 0.443 . . . . 0.0 111.658 -175.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CD2' ' HB ' ' A' ' 35' ' ' THR . 0.7 OUTLIER -105.5 -159.21 0.7 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.79 -174.681 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.659 ' HA2' ' SG ' ' A' ' 34' ' ' CYS . . . -170.6 133.14 2.69 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.271 -0.966 . . . . 0.0 112.9 178.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.49 147.09 50.31 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 34.9 t -96.7 112.02 23.94 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.837 0.351 . . . . 0.0 110.508 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.43 ' HB ' ' HG2' ' A' ' 31' ' ' LYS . 7.0 mt -104.85 170.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -45.09 -34.88 2.79 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -171.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -143.35 -1.76 1.03 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 119.365 -1.397 . . . . 0.0 113.931 174.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.43 ' HG2' ' HB ' ' A' ' 28' ' ' ILE . 21.2 ptmt -124.02 153.7 40.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 118.184 0.992 . . . . 0.0 111.53 -172.034 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.558 ' HB3' ' SG ' ' A' ' 17' ' ' CYS . 0.5 OUTLIER -92.79 92.5 7.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 169.772 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -78.87 103.4 8.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.478 175.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.659 ' SG ' ' HA2' ' A' ' 25' ' ' GLY . 20.0 m -125.03 142.53 51.43 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.293 -174.422 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.519 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 41.2 m -88.42 129.83 47.87 Favored Pre-proline 0 N--CA 1.448 -0.574 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 22' ' ' MET . 90.2 Cg_endo -81.36 -158.73 0.1 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.798 2.332 . . . . 0.0 112.261 -177.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.498 -0.763 . . . . 0.0 110.771 -177.784 . . . . . . . . 0 0 . 1 stop_ save_